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Given a global online sample of Black men (n=194) who responded to a social 
media campaign and completed the study, the convenience sample of Black males 
(N=194) was mostly married (N=147, 75.85%), had a mean age of 49.53 years (min 40, 
max 76, SD=8.73), and was well educated; 24.7% (n=48) had an Associate Degree, 
20.6% (n=40) had a Bachelor’s, 18% (n=35) had a Master’s, and 5.2% (n=10) had a 
Doctorate. The mean annual income was 4.21 for category 4 of $40,000-$49,999 (min 1, 
max 9, SD=1.64). Most of the participants were employed (n=188, 96.9%) and born in 
the United States (n=152, 78.4%).  
As a reflection of a global sample, if not a sample of men born in Ghana (77.3%, 
n=194) who were now dispersed across the globe, over two-thirds (77.3%) were born in 
 
 
Ghana while 78.4% (n=152) were currently living in the United States; 15.5% (n=30) 
were currently living in Ghana, followed by 5.1 (n=10) currently living in other countries.  
Key findings showed that, as a brief intervention of taking the PC-S-KT-39, as 
per results of four paired t-tests (Bonferroni Adjustment Significance, .05/4, p=.013), this 
was associated with a significant increase from pre-knowledge test to post-knowledge 
test (p<.000; Bonferroni Adjustment Significance, .05/4, p=.013) for (a) knowledge of 
prostate cancer and screening (t=-8.475, df=193, p=.000); (b) self-efficacy for talking to 
doctor about prostate cancer and screening (t=-9.098, df=193, p=.000); (c) knowledge of 
Vitamin D screening and supplementation (t=-9.748, df=193, p=.000); and (d) self-
efficacy for talking about Vitamin D screening and supplementation (t=-9.384, df=193, 
p=.000). 
The study demonstrated how there is great value in contemporary times in using 
an online social media campaign, posting and distributing flyers in community venues 
(barber shops, churches), snowballing, and using smart phones to conduct global online 
research.  
Given these findings, wide dissemination via the Internet of a link to the new 
Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) is justified. If men such as 
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This dissertation is dedicated to the memory of my father, Mr. Twene Kwadwo 
Aduasare (October 13, 1940 to November 19, 2015), Suma Ahenkro who died from 
prostate cancer. 
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undertook this investigation which will help educate other men to talk to their medical 
providers about prostate cancer, get early screening, and get early treatment. 
We cannot hold mortality’s strong hand. 
(William Shakespeare, King John, Act IV, scene 2) 
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Strikingly, “Black men in America have the highest death rates” from prostate 
cancer” in the world (Ogunsanya et al., 2017, p. 1009). Wang et al. (2015) reported that 
prostate cancer was the “second most frequently diagnosed cancer among men 
worldwide” and of all racial/ethnic groups (p. 733). Ogunsanya et al. (2017) reported that 
one “in seven American men will be diagnosed with prostate cancer” (PCa) during his 
lifetime (p. 1009). However, both the “mortality and morbidity rates are significantly 
elevated in Black men, compared with men of other racial and ethnic groups” (p. 1009). 
Batai et al. (2017) indicated that prostate cancer is “the most common cancer among men 
in the U.S., and African American” men have both “higher incidence and mortality rates 
compared to European American” men and men from “other racial/ethnic groups” (p. 2). 
The American Cancer Society (ACS, 2016) estimated that 1 in 6 Black men will be 
diagnosed with “prostate cancer in his lifetime, compared to 1 in 8” White men (p. 15). 
Richards et al. (2017) emphasized how African American men “not only present with 
PCa at a younger age, but they also have 50% higher incidence and twice the mortality 
compared with European American (EA) men” (p. 1). 
Nelson, Batai, Ahaghotu, Agurs-Collins, and Kittles (2016) noted that even 







shown African American” men to develop prostate cancer “at a rate 1.5-1.9 times higher 
than their European American” counterparts (p. 1). Also, “racial differences are further 
emphasized by the increased diagnosis of aggressive prostate cancer” in African 
American men (p. 2). Nelson et al. offered details, as follows: 
     For the year 2016, about 29,530 cases of newly diagnosed prostate cancer 
were expected for Black men (ACS, 2016). This would account for 31% of all 
cancers diagnosed for Black men. (ACS, 2016)  
 
Ashorobi et al. (2017) emphasized how African American men not only have the 
highest incidence and mortality from prostate cancer in the United States, but also have 
held this status as a persistent trend for more than three decades. Moreover, it was found 
that men from “low socioeconomic backgrounds are at a higher risk” for having an 
increased prostate cancer burden, including a lower utilization of prostate cancer 
screening services (p. 82). Ashorobi et al. found that in Texas, “two racial and ethnic 
minorities,” specifically African American and Hispanic men, “had a lower incidence of 
digital rectal examination (DRE) performed” (p. 82). Thus, not surprisingly, these groups 
had a “lower likelihood of being diagnosed with early stage” prostate cancer, yet a 
“higher likelihood of being diagnosed with late-stage” prostate cancer—in comparison to 
White men. They concluded that, in order to “address this health disparity among 
medically underserved racial and ethnic groups, there must be increased education and 
awareness” on the topic of prostate cancer (p. 82). 
Prostate Cancer Screening 
Prostate cancer screening with the use of the prostate-specific antigen (PSA) test 







also commonly performed by physicians (Ashorobi et al., 2017, p. 82). The ACS has 
recommended that men start screening for prostate cancer at age 45, “with the interval for 
further screening based on initial and subsequent PSA levels” (Smith et al., 2018, p. 297). 
Baptista, Sampaio, Heleno, Azevedo, and Martins (2018) indicated that “screening for 
prostate cancer is a controversial issue” (p. 1). While the “United States Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial found no benefits from using prostate-
specific antigen (PSA) screening for prostate cancer diagnoses,” the “results from the 
European Randomised Study of Screening for Prostate Cancer concluded that one 
prostate cancer death would be avoided and 27 excess cases detected per 781 men invited 
for screening with PSA” (p. 3). It was emphasized that a “decision about whether to be 
screened should be an individual one based on conversations with the physician about the 
benefits and adverse effects of screening, in order to help men make a decision based on 
personal values and preferences” (p. 4). However, the majority of experts justified “a 
shared decision-making process involving doctor and patient, using validated decision 
aids” (p. 4). Further, it was reported that “many guidelines issued by medical 
organizations such as the European Association of Urology, the American Cancer 
Society, and the American College of Physicians supported a shared decision-making 
process for prostate cancer screening,” with decision aids to help ensure the quality of the 
decision, instead of relying solely on individualized decision making (p. 4). 
Ogunsanya et al. (2017) discussed the debate over the importance of prostate 
cancer screening, noting how “there are controversies associated with routine prostate 
cancer screening and its specificity”; meanwhile, “screening is beneficial in men with 







(pp. 1009-1010). Notwithstanding the controversies surrounding screening, “the 
American Cancer Society endorses prostate cancer screening annually”—but, only after 
the “benefits and limitations of prostate cancer screening have been outlined to patients” 
(p. 1010).  
According to Ogunsanya et al. (2017), for “effective decision making to take 
place, it is also important for patients to understand the risks and benefits associated with 
the decision (prostate cancer screening) to be made” (p. 1010). Consider how screening 
may also lead to treatment, and while “prostate cancer treatment may be lifesaving, 
studies suggest that this benefit is not applicable in all cases” (Wang et al., 2015, p. 733). 
For example, a “large randomized study revealed that in comparison with watchful 
waiting, 15 men must be treated with radical prostatectomy to save 1 life” (p. 733).  
Mahal et al. (2014) expressed doubt as to whether “African Americans (AAs) 
with intermediate- to high-risk prostate cancer” are given equal treatment as compared to 
White patients (p. 386). For “patients with intermediate to high-risk” prostate cancer, 
“definitive treatments have been shown to decrease prostate cancer-specific mortality” 
and “improve overall survival” (p. 386). African American men with “intermediate- to 
high-risk” prostate cancer “are less likely” to receive treatment with “curative intent” 
than are White men—such that the “disparity is worse in high-risk disease and is not 
improving over time” (p. 386). Given racial disparities in the treatment of prostate cancer, 
African American men “have a significantly higher risk of dying from” prostate cancer 
than White men (p. 386).   
Mahal et al. (2014) indicated a number of possible causes for the glut of prostate 







aggressive disease,” poorer access to care, treatment delays, and the receipt of care from 
lower volume and lower quality centers—all of which contribute to “worse survival”  
(p. 389). Most noteworthy, the “disparity in the receipt of appropriate treatment, 
particularly for high-risk disease” has contributed to the excess deaths from prostate 
cancer (p. 389).  
The “American Cancer Society, the National Comprehensive Cancer Network, 
and the American Society of Clinical Oncology” have all emphasized the “importance of 
shared and informed decision making in the screening and treatment of prostate cancer” 
(Wang et al., 2015, p. 733). Also, the study reiterated that “informed decision making is 
the ability of patients to fully comprehend the risks and benefits of particular treatment 
options” and to “accomplish this task, health care providers often use medical 
terminology,” while “patients—especially those in underserved areas—are prone to 
misunderstanding such terminology” (p. 733). Therefore, there is a role for “assessing 
patients’ knowledge level regarding prostate cancer and screening” (Ogunsanya et al., 
2017, p. 1010). Of note, “knowledge of prostate cancer and screening has been reported 
to play an important role in participation in screening practices” (p. 1010).  
Consider a relevant study with regard to the role of knowledge level, as per Wang 
et al. (2015). Research indicated that “less than 50% of men understood the term 
impotence, and only 5% understood the term incontinence” (p. 734). Further, the study 
showed that the absence of “comprehension has important implications for the counseling 
of prostate cancer patients” (p. 734). Also, in a study on the “educational needs of 
prostate cancer patients, nearly one-fifth of patients felt that they had not received enough 







knowledge regarding prostate cancer has also been associated with decisional regret 
among men treated for localized disease” (p. 734). They concluded that the “ability of 
patients to fully comprehend the language used” in any such efforts is “essential to the 
informed decision-making process” (p. 736). Also, a “review has demonstrated that 
decisional aids improve patient knowledge and enhance patient involvement in the 
decision-making process for prostate cancer screening” (p. 736). The study concluded 
that “a videobased educational tool could serve as an effective method for combating the 
severe lack of comprehension of prostate health terminology” (p. 740). 
Regardless, it is recommended that men in higher risk groups (i.e., with positive 
family histories) receive information on prostate screening “between age 40 and 50 
years” (Ogunsanya et al., 2017, p. 1010). Both the “American Urologic Association and 
the National Medical Association” emphasized the role of “screening in early detection of 
prostate cancer as a means to support health promotion, especially in Black men”  
(p. 1010). While the controversy surrounding prostate cancer screening continues, Black 
men “remain at high risk” and in need of screening (p. 1010). 
Screening issues vary by age and life expectancy. In 2017, the United States 
Preventive Services Task Force (USPSTF) made available draft recommendations that 
assigned a “C” grade for the recommendation for prostate cancer screening “in men  
55-69 years old, stating that the potential benefits and adverse effects of PSA-based 
screening are closely balanced in that age group” (Baptista et al., 2018, p. 4). According 
to Smith et al. (2017), “men who have at least a 10-year life expectancy” should have an 







to be screened for prostate cancer, after receiving information about “the benefits, risks, 
and uncertainties associated with prostate cancer screening” (p. 110).  
Baptista et al. (2018) examined “the impact of using Web-based decision aids to 
support men’s prostate cancer screening decisions in comparison with usual care and 
other formats of decision aids” (p. 2). Findings indicated that the use of Web-based 
“decision aids can increase patient knowledge, make people feel clearer about their 
values, reduce decisional conflict, and promote an active patient role in decision making” 
(p. 5). Also, it was found that Web-based decision aids significantly reduced the 
practitioner-controlled role in the decision-making process, in comparison with usual 
care. Further, as there is an “increasing use and ease of access to the internet, the Web has 
been proposed as a promising way of delivering decision aids” (p. 6). It is therefore 
“important to assess the impact of Web-based decision aids in the prostate cancer 
screening decision-making process, but the number of studies addressing this subject to 
date have been scarce and showed mixed results” (p. 6). 
Screening for Vitamin D Levels 
Meanwhile, other research has suggested value in men potentially at risk for 
prostate cancer, such as African American men, also screening for Vitamin D levels 
(Richards et al., 2017; Xie et al., 2017; Young & Xiong, 2018). For example, Francis 
(2017) emphasized the importance of regular testing of Vitamin D levels by health care 
providers. In this regard, Nelson et al. (2016) offered details on the higher incidence of 
prostate cancer and aggressive prostate cancer in African American men, as follows, 







     Demographic characteristics, such as family history, socioeconomic status, 
access to medical care, other comorbidities, and diet and lifestyle have been 
shown to contribute to the increased burden of prostate cancer in AA men. 
Recently, however, studies have focused on differences in serum 25-
hydroxyVitamin D (25(OH)D) concentrations as a source of the disparate trends 
seen in this disease. Critical to overall health, 25(OH)D plays a role in bone 
mineralization, diabetes mellitus, and multiple sclerosis. The main source of 
25(OH)D is derived from sunlight ultraviolet (UV)-B rays, accounting for over 
90% of circulating levels. High melanin, commonly seen in ethnic groups with 
dark skin, such as AA men, reduces the amount of UVB radiation absorbed in the 
skin, thus decreasing the concentration of 25(OH)D and increasing susceptibility 
to developing Vitamin D deficiencies. In the Health, Aging and Body 
Composition Study, comparison between AAs and EAs showed only 16% of 
older AA participants had serum 25(OH)D levels over 30 ng/mL, compared to 
44% in EAs. Data from the Prostate Cancer Prevention Trial determined AA men 
with higher Vitamin D levels see a reduced risk in high-grade disease, while 
results in Afro-Caribbean men residing in the Caribbean indicate Vitamin D 
insufficiency may contribute to increased prostate cancer risk. Moreover, 
molecular studies suggest deficiencies in Vitamin D overtime may lead to 
progression from pre-clinical to clinically aggressive forms of prostate cancer.  
(p. 2) 
 
Forrest and Stuhldreher (2010) explained how Vitamin D “can be synthesized by 
the skin through exposure to ultraviolet light of wavelength 290 to 315 nm that stimulates 
the conversion of 7-dehydrocholesterol to preVitamin D” (p. 49). In addition, the “other 
source of Vitamin D is from the diet” (p. 49).  
Consequently, American men are increasingly looking to dietary supplements to 
reduce their risk of developing prostate cancer, and to delay progression after diagnosis 
(Paller et al., 2015). Paller et al. (2015) explained how Vitamin D “supplementation has 
been promoted for prostate cancer prevention based in part on a 2007 Harvard University 
study of nearly 15,000 men initially free of prostate cancer” (p. 2). The study found that 
those men “whose plasma levels of Vitamin D were below (versus above) the median had 
a significantly increased risk of developing aggressive prostate cancer (OR = 2.1, 95%CI: 







prostate biopsy outcomes in 667 men found that Vitamin D deficiency was associated 
with higher Gleason grade and tumor stage in both European-American and African 
American men and with increased odds of prostate cancer diagnosis on biopsy” (p. 2).  
Also, the findings of a 2012 study based in the United Kingdom confirmed a 
relationship between Vitamin D levels and aggressive prostate cancer, such that lower 
Vitamin D levels correlated with more aggressive cancers; however, the study “found no 
evidence of a link between Vitamin D levels and overall prostate cancer risk” (Paller  
et al., 2015, p. 2). The finding of “no association between Vitamin D levels and overall 
prostate cancer risk is consistent with a retrospective study of 479 prostate cancer patients 
with age-matched controls that showed no causal relationship between Vitamin D levels 
and risk of prostate cancer” (p. 2). Also, another population-based cohort study of “1,476 
prostate cancer patients” found “no evidence that serum Vitamin D levels measured after 
diagnosis affect prostate cancer prognosis” (p. 2). Yet another study that matched “1,000 
prostate cancer patients with 1,000 controls found men with higher levels of Vitamin D” 
had an “increased risk of prostate cancer” (p. 2). Given this body of “conflicting data,” 
the National Cancer Institute has not offered a recommendation “for or against the use of 
Vitamin D supplements to reduce the risk” of prostate cancer (p. 2). 
Murphy et al. (2012) discussed how darker skin “pigmentation resulting from 
increased melanin production in the skin melanocytes can reduce the efficacy of UV-B 
radiation–induced Vitamin D3 synthesis” (p. 422). Skin with high melanin content can 
reduce Vitamin D3 synthesis by up to 99%, much in the way as SPF15 (sun protection 
factor-15) sunscreen (p. 422). According to Murphy et al., African Americans “have been 







Furthermore, it was found that “many of the diseases thought to be associated with 
Vitamin D deficiency are more prevalent” among African Americans (p. 421). Using the 
Institute of Medicine (IOM) definition of deficiency being <20 ng/mL, 18% of the EA 
men were deficient versus 63% of African American men (Murphy et al., 2012). 
Murphy et al. (2012) determined that Vitamin D level is estimable by season, 
African American race, “income, BMI, and Vitamin D supplemental intake” (p. 423). 
Overall, findings underscored how Vitamin D “supplementation currently remains the 
most appropriate mode for preventing Vitamin D deficiency in high-risk groups such as” 
African Americans and “individuals living in UV-poor environments” (p. 425). It was 
concluded that “more than 90%” of African American men have a deficiency of Vitamin 
D (p. 423).  
Francis (2017) reported that Vitamin D deficiency is a predictor of aggressive 
prostate cancer, or cancer that has spread outside the prostate. Most people are Vitamin D 
deficient, especially in the winter, as it is difficult to maintain normal levels of Vitamin D 
without a lot of sunlight exposure. Further, men with dark skin (e.g., African Americans 
and others) are far more likely to be Vitamin D-deficient because they need more sunlight 
to get the Vitamin D. Also, it is important to have one’s health care provider test 
regularly for level of Vitamin D (e.g., during annual physical exam, or more often). If 
one’s health care provider tests for Vitamin D level and identifies a deficiency, then it is 
important to take a daily supplement of high-quality Vitamin D. One’s Vitamin D level 
should be kept in the upper half of the normal range—with the optimal level of Vitamin 
D being about 50 to 70 nanograms per milliliter year around. Francis (2017) asserted that 







sound approach to Vitamin D supplementation is to take 5,000 i.u. of a high-quality 
Vitamin D supplement every day. Francis (2017) stressed how one must be careful in 
choosing any supplement, such as a daily supplement of Vitamin D, because if the 
supplement is not high quality, then it may contain toxins and be ineffective.  
Batai et al. (2017) found among African Americans “the highest quartile of total 
Vitamin D intake was associated with 47% lower odds” of PCa diagnosis “(95% 
C.I.:0.30-0.94)” (p. 6). Betai et al. reported that a larger consumption of Vitamin D 
indicated a pattern of reduction in PCa. Also, it was found that in leaner men, “high total 
Vitamin D intake reduced odds of PCa diagnosis” (p. 6). Further, “the interaction 
between total Vitamin D intake and BMI on high risk and high grade PCa was also 
statistically significant” (p. 6).  
Gao et al. (2018) indicated that the role of Vitamin D in human disease has been 
given greater attention. It has been perceived as a crucial hormone playing an important 
role in maintaining the normal functions of various organs and systems in the human 
body. Research has shown that Vitamin D “has some extraskeletal biological functions 
including inhibiting the progression of cancer cells” (p. 96). Also, prior research has 
shown that “Vitamin D can exert a key role in decreasing cancer risk. Meta-analyses of 
epidemiological studies have suggested that higher circulating 25-hydroxyVitamin D 
concentration is correlated with decreased risks of several common cancers, such as 
colorectal cancer and bladder cancer” (p. 96). 
Xie et al. (2017) highlighted the association among prostate cancer, Vitamin D 
status, and inflammation. It was conjectured that Vitamin D inhibits the incidence and 







“numerous in vitro experiments demonstrated that 1,25-(OH)2D3, the active form of 
Vitamin D, inhibited the growth and differentiation of human prostate cancer cells”  
(p. 22076). Furthermore, “men with Vitamin D” deficiency “had a higher risk of prostate 
cancer compared to men with Vitamin D” sufficiency (p. 22076). Xie et al. indicated that 
their data provided “evidence for the first time that low Vitamin D status is associated 
with inflammation in patients with prostate cancer” (p. 22080). They found low levels of 
Vitamin D in patients with acute prostate cancer as compared to patients with mild and 
moderate prostate cancer. Also, “low Vitamin D status” was associated with 
inflammation and the progression of prostate cancer” (p. 22080). They asserted that their 
data added to the body of increasing evidence, indicating that Vitamin D has an anti-
inflammatory activity. They indicated that their “results suggest that inflammation may 
be a key mediator for prostate cancer progression in patients with low Vitamin D status” 
(p. 22080).  
The research of Young and Xiong (2018) added to “the association between 
Vitamin D and cancer risk,” as well as to the results of “clinical trials involving Vitamin 
D” (p. 1). Vitamin D in circulation was discussed as being “sufficient (i.e., 30-100 
ng/ml), insufficient (i.e., 21-29 ng/ml), or deficient (i.e., <20 ng/ml)” (p. 2). Findings 
showed that Vitamin D “can also indirectly prevent cancer” (p. 2). The indirect “anti-
cancer effects of Vitamin D can also be due to its anti-inflammatory properties” (p. 2). 
Findings showed that men “with prostate cancer had reduced 25(OH)D and increased 
inflammatory mediator levels compared to controls” (p. 2). They found a relationship 
“between circulating 25(OH)D levels and cancer risk” (p. 2). In clinical trials involving 







inflammation and, thus, has been examined for efficacy in inflammation-associated 
disorders” (p. 5).  
In addition, Young and Xiong (2018) found that “analysis of the prostate 
transcriptome showed that Vitamin D supplementation (4,000 IU/day) for 2 months prior 
to undergoing prostatectomy altered expression of inflammatory genes” (p. 5). Body 
Mass Index (BMI) counterbalanced the effects of Vitamin D. Specifically, a “greater 
BMI” tempers the “capacity of Vitamin D supplementation to increase 25(OH)D levels” 
(p. 7). Recommendations included providing “higher doses” for those who were 
overweight (7,000 IU/day) and obese (8,000 IU/day), in comparison to doses for those of 
normal weight (6,000 IU/day) (p. 7). 
As per Richards et al. (2017), Vitamin D is viewed as “an essential regulatory 
hormone for normal human physiology,” and the “canonical role for Vitamin D is 
calcium homeostasis; however, Vitamin D deficiency has been associated with both 
calcium-related conditions, including rickets and osteoporosis” (p. 1). Research has 
demonstrated that there is a higher risk of prostate cancer as a result of Vitamin D 
deficiency among African Americans when compared to European Americans. 
According to Richards et al. (2017), skin pigmentation “is the largest predictor of 
Vitamin D deficiency in the USA, as UV-induced cutaneous synthesis of Vitamin D is 
the primary source of the Vitamin D prohormone and is inhibited by melanin” (p. 1). 
Thus, as a consequence, greater than 90% of African American men “are Vitamin D 
insufficient by current standards, and 65% are deficient with serum levels below 20 
ng/ml” (p. 1). Also, “Vitamin D deficiency affects a greater segment of various world 







PCa and risk of Vitamin D deficiency” (p. 1). Further, even though “epidemiologic 
studies on the relationship between PCa incidence and Vitamin D serum concentration 
have produced mixed results, analyses restricted to aggressive or lethal cases have more 
consistently shown inverse associations” (p. 2). Indeed, interventional studies “with 
Vitamin D supplements” have “reported lower prostate-specific antigen levels (20), 
reduced number of positive biopsies” as well as “decreased prostate proliferation 
markers” (p. 2).  
Of note, the USPSTF (2014) has acknowledged that some studies have 
demonstrated how low levels of Vitamin D are associated with an increased risk of 
cancer. The USPSTF concluded from its review of research that the benefits and harms of 
screening for a Vitamin D deficiency and early intervention cannot be determined. This 
was based on their finding insufficient evidence to support screening for Vitamin D 
deficiency in asymptomatic adults, in order to improve health outcomes. The USPSTF 
acknowledged how the Endocrine Society recommended screening for Vitamin D 
deficiency only in individuals considered to have an “at-risk” status. 
The work of Richards et al. (2017) suggested that African American men have an 
“at-risk” status, given that greater than 90% of African American men are Vitamin D 
insufficient. Further, African American men are disproportionately affected by both 
prostate cancer and Vitamin D deficiency (p. 1). Also, interventional studies “with 
Vitamin D supplements” have “reported lower prostate-specific antigen levels and a 
reduced number of positive biopsies” as well as “decreased prostate proliferation 
markers” (p. 2). With African American men having the highest death rates from prostate 







Statement of the Problem 
The problem that this study addressed is the need to educate Black men globally 
about prostate cancer and screening—and, also about the potential value in screening for 
Vitamin D level—toward the goal of increasing their level of knowledge and self-
efficacy to engage in discussions about screening with their medical providers. This 
follows from how “knowledge of prostate cancer and screening has been reported to play 
an important role in participation in screening practices” (Ogunsanya et al., 2017,  
p. 1010).  
Purpose of the Study 
The purpose of the study was to identify significant predictors of the two study 
outcome variables/dependent variables, as follows: 
1. Study outcome variable/dependent variable #1—a higher self-rating for Self-
Efficacy to Talk to a Medical Provider about prostate cancer and prostate 
cancer (PC) screening, after they took the Prostate Cancer and Screening 
Knowledge Test (PC-S-KT-39)—as item #4 in survey Part VII (i.e., POST PC 
Self-efficacy). 
2. Study outcome variable/dependent variable #2—a higher self-rating for Self-
Efficacy to Talk to a Medical Provider about Vitamin D (VD) screening and 
supplementation, after they took the Prostate Cancer and Screening 









Research Questions, Survey Parts, and Data Analysis Plan 
Given a global online sample of Black men (n=194) who responded to a social 
media campaign (i.e., “Go to https://tinyurl.com/Black-Men-Age-40-PLUS to take the 
Prostate Cancer & Screening—& Vitamin D Survey for Black Men age 40 and above for 
a chance to win 1 of 3 $100 Amazon gift cards”) and completed the study, the following 
research questions were answered: 
1-What are the men’s demographic and background characteristics (e.g. age, skin color, 
partner status, born in the United States—yes/no, living in United States or other country, 
annual household income, level of education, employment status.)? 
Part I: Basic Demographics (BD-9) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-How do the men rate their health status, and what is their Body Mass Index, rating of 
their weight status, and rating of the overall quality of care received for their health? 
Part II: Brief Health Survey (BHS-5) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-What is the men’s prevalence of a diagnosis of prostate cancer, being told they were at 
risk for prostate cancer, history of screening for prostate cancer by a Digital Rectal 
Examination (DRE) or Prostate-Specific Antigen (PSA) Test, as well as the prevalence in 
their family of prostate cancer diagnoses and deaths from prostate cancer? 
Part III: Prostate Cancer Scale (PCS-6) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-What is the men’s history of having a Vitamin D screening, being told they were 
Vitamin D deficient, being advised to take a Vitamin D supplement, and taking a Vitamin 
D supplement? 
Part IV: Vitamin D Scale (VDS-4) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
5- What is the men’s level of knowledge for Prostate cancer and screening, and for Vitamin 
D and taking a Vitamin D supplement? 
Part V: Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 







6-After the men are told that the researchers created the Prostate Cancer Knowledge Test 
(PC-S-KT-39)—with all TRUE answers (i.e., as a way to prepare African American men 
to talk with their medical providers about taking important screening tests that may help 
protect them from dying from prostate cancer at a rate higher than for any other men in 
the entire world), do the men recommend the PC-S-KT-39 to other African American 
men as an online intervention (i.e., diffusion of the innovation)? 
 
Part VI: Diffusion of the Innovation of the Prostate Cancer Knowledge Test (DOI-
PCKT-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
7-After the men are told that the researchers created the Prostate Cancer Knowledge Test 
(PC-S-KT-39)—with all TRUE answers (i.e., as a way to prepare African American men 
to talk with their medical providers about taking important screening tests that may help 
protect them from dying from prostate cancer at a rate higher than for any other men in 
the entire world), how do the men rate their self-efficacy—or item #4 after rating for 
confidence to talk to a medical provider about prostate cancer and screening, and item 
#8 after rating confidence to talk to a medical provider about Vitamin D screening and 
taking a Vitamin D supplement? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
Part VII: Pre- and Post-Knowledge Test—Ratings for Knowledge and Self-Efficacy 
to Talk to a Medical Provider (PRE-A-POST-KT-RF-K-SETMP-8), specifically, the 
mean for the: 
After Took PC-S-KT-39 Global Self-Efficacy Subscale #4 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
NOTE: item #4 and item #8 after ratings are the two study outcome 
variables/dependent variables 
 
8-After taking the Prostate Cancer Knowledge Test (PC-S-KT-39)—with all TRUE 
answers—in order to determine if taking the PC-S-KT-39 may serve as a potential online 
intervention that may significantly increase knowledge and self-efficacy levels, how do 
the men rate themselves for before taking the PC-S-KT-39 versus after taking the 
PC-S-KT-39 for (1) what they knew about prostate cancer and screening, (2) what they 
knew about Vitamin D screening and taking a Vitamin D, (3) confidence to talk to a 
medical provider about prostate cancer and screening, and (4) confidence to talk to a 
medical provider about Vitamin D screening and taking a Vitamin D supplement—and 
was there a significant difference in mean scores from before to after taking the  
PC-S-KT-39?  
Data Analysis Plan: Paired t-tests (before v. after ratings) 
 
9-Are there any significant relationships between selected demographics and (1) study 
outcome variable/dependent variable #1—a higher self-rating for Self-Efficacy to Talk 







after they took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—
as item #4 in survey Part VII, i.e., POST PC Self-efficacy), and (2) study outcome 
variable/dependent variable #2—a higher self-rating for Self-Efficacy to Talk to a 
Medical Provider about Vitamin D (VD) screening and supplementation, after they 
took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—as item #8 
in survey Part VII, i.e., POST VD Self-efficacy)? 
Data Analysis Plan: Inferential statistics, specifically, independent t-tests and 
Pearson correlations 
 
10-What are the significant predictors of (1) study outcome variable/dependent variable 
#1—a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
prostate cancer and prostate cancer (PC) screening, after they took the Prostate 
Cancer and Screening Knowledge Test (PC-S-KT-39—as item #4 in survey Part 
VII, i.e., POST PC Self-efficacy), and (2) study outcome variable/dependent variable 
#2—a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
Vitamin D (VD) screening and supplementation, after they took the Prostate Cancer 
and Screening Knowledge Test (PC-S-KT-39—as item #8 in survey Part VII, i.e., 
POST VD Self-efficacy)? 
Data Analysis Plan: Backward stepwise regression 
Rationale for Study 
There is a strong rationale for the present study, as it is framed by Health 
Disparities Theory (Institute of Medicine [IOM], 2012); Self-Efficacy in the Social 
Cognitive Theory of Bandura (1997), and Diffusion of Innovation Theory (Rogers, 
1995).  
A strong rationale for this global study and the anticipated findings follows from 
key research findings. Among men from all racial/ethnic groups, prostate cancer was the 
“second most frequently diagnosed cancer among men worldwide” (Wang et al., 2015,  
p. 733). Black men have the highest death rates of prostate cancer in the world 
(Ogunsanya et al., 2017). African American men present with prostate cancer at a 
younger age have a 50% higher incidence and twice the mortality of White American 







African American men compared to White men (Nelson et al., 2016), and African 
American men have lower rates of prostate cancer screening, including a lower incidence 
of having a digital rectal examination (DRE) performed, a lower likelihood of being 
diagnosed with prostate cancer, and a higher likelihood of being diagnosed with late stage 
prostate cancer—compared to White men (Ashorobi et al., 2017).  
It is recommended that the way to address these health disparities is via increased 
prostate cancer education for Black men (Ashorobi et al., 2017). Therefore, there is a role 
for assessing patients’ level of knowledge for prostate cancer and screening—while such 
knowledge has been found to play an important role in participation in screening for 
prostate cancer (Ogunsanya et al., 2017, p. 1010). It is therefore important to provide 
education on prostate cancer screening with the prostate-specific antigen (PSA) test 
(Schenk et al., 2014), and/or the digital rectal examination (DRE) performed by 
physicians (Ashorobi et al., 2017). 
Emphasis has been placed on informed decision making about prostate screening 
and prostate cancer treatment—as a process that includes the physician and the patient, 
and requires that patients have adequate knowledge and understanding of key 
terminology (Wang et al., 2015). Baptista et al. (2018) emphasized that the decision 
about whether or not to be screened for prostate cancer should be “an individual one 
based on conversations with the physician about the benefits and adverse effects of 
screening, in order to help men make a decision based on personal values and 
preferences” (p. 4).  
In order to increase men’s knowledge of prostate cancer, prostate cancer 







medical provider about these issues—so as to enable men to participate in decision 
making and make an informed decision about screening and treatment, this study had a 
strong rationale for creating a new Prostate Cancer and Screening Knowledge Test  
(PC-S-KT-39). The new PC-S-KT-39—with all TRUE answers—was designed as an 
online intervention to prepare African American men to talk with their medical providers 
about taking important screening tests that may help protect them from dying from 
prostate cancer at a rate higher than for any other men in the entire world.   
There is a rationale for this study creating and evaluating the potential for the new 
Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) to serve as an online 
intervention that may increase men’s knowledge of prostate cancer and screening—with 
all TRUE answers—and potentially increase self-efficacy for talking to a medical 
provider about these issues. This follows from the work of Baptista et al. (2018) who 
found that Internet or Web-based decision aids have great value; they can “increase 
patient knowledge, make people feel clearer about their values, reduce decisional 
conflict, and promote an active patient role in decision making” about prostate cancer 
screening and treatment (p. 5).  
Hence, at the conclusion of the study, the intent is to widely disseminate via the 
Internet a link to the new PC-S-KT-39 in order to potentially replicate the promise that 
Baptista et al. (2018) found in Web-based decision aids.  
The Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) is considered 
a new innovation in providing online education, and study participants also have an 
opportunity to indicate if they would recommend the test to other African American men, 







Further, given evidence that supports African American men, in particular, also 
screening for their levels of Vitamin D, and taking Vitamin D supplements if they are 
found to be Vitamin D-deficient, the new PC-S-KT-39 also seeks to increase knowledge 
in this area (Francis, 2017; Richards et al., 2017; Xie et al., 2017; Young & Xiong, 2018). 
In addition, the new test seeks to increase self-efficacy to discuss these issues with a 
physician. 
Delimitations 
The study was delimited to Black men from the global community who are age 40 
and above, indicating the ability to read and understand English on the 12th grade level, 
and who completed the entire survey. 
Limitations 
Study limitations included the following: being an online study which requires 
access to the Internet and a computer, potentially creating a sample biased toward those 
who enjoy such access; the use of an online sample of convenience of volunteers who 
were able to devote the requisite time for completing the survey, including the use of 
snowballing; the lack of a measure of social desirability, which could have permitted 
controlling for socially desirable answers in the regression analysis, but would have 
added to the limitation of the burden of time to participate in the study; and the fact that 
the new Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) has 39 True-False 
items, with a potential burden of time, given the length of this key test. To reduce the 








first pilot indicated it took 30 minutes to complete the entire survey; other parts of the 
survey were also reduced by 1-3 items, where possible (e.g., eliminating questions about 
prevalence of prostate cancer among friends and associates). The result of the attempt to 
reduce the burden of time on study participants was a survey that took about 20-30 
minutes to complete.  
Also, another study limitation involved the use of a study methodology where the 
study men are asked at the same time (i.e., after taking the new PC-S-KT-39 to rate both 
their before taking the PC-S-KT-39 and their after taking the PC-S-KT-39 levels of 
knowledge [on prostate cancer and screening, and on Vitamin D screening and 
supplementation]) and self-efficacy (for talking to a medical provider about prostate 
cancer and screening, and about Vitamin D screening and supplementation).  
An alternative methodology that might be perceived as more desirable would be 
to assess knowledge and self-efficacy before taking the PC-S-KT-39 and, then again, 
after taking the PC-S-KT-39; however, the method chosen was also deemed a way to 
shorten the length of the survey and reduce the burden of time on subjects. Also, after 
reading 39 true facts within the PC-S-KT-39, it was likely that the men could more 
accurately rate both their before taking the PC-S-KT-39 and their after taking the  
PC-S-KT-39 levels of knowledge (on prostate cancer and screening, and on Vitamin D 
screening and supplementation) and self-efficacy (for talking to a medical provider about 








Definition of Terms 
The following terms are defined to assist the reader. 
 
• Aggressive prostate cancer. This describes a type of prostate cancer tumor or 
disease that forms, grows, or spreads quickly (National Institutes of Health 
[NIH], 2019). 
• Benign prostatic hyperplasia (BPH). BPH, benign prostatic hyperplasia, is a 
condition in which the prostate is enlarged. With BPH, there is an overgrowth 
of prostate tissue that pushes against the urethra and the bladder, blocking the 
flow of urine (NIH, 2019). 
• Biopsy/Prostate biopsy. The removal of cells or tissues for examination by a 
pathologist. The pathologist may study the tissue under a microscope or 
perform other tests on the cells or tissue. There are many different types of 
biopsy procedures. The most common types include: (a) incisional biopsy, in 
which only a sample of tissue is removed; (b) excisional biopsy, in which an 
entire lump or suspicious area is removed; and (c) needle biopsy, in which a 
sample of tissue or fluid is removed with a needle. When a wide needle is 
used, the procedure is called a core biopsy. When a thin needle is used, the 
procedure is called a fine-needle aspiration biopsy (NIH, 2019). 
• Body Mass Index (BMI). A measure that relates body weight to height. BMI 
is sometimes used to measure total body fat and whether a person is a healthy 
weight. Excess body fat is linked to an increased risk of some diseases, 








• Digital Rectal Examination (DRE). An examination in which a doctor 
inserts a lubricated, gloved finger into the rectum to feel for abnormalities. 
Also called DRE (NIH, 2019). 
• Health disparities. According to the Department of Health and Human 
Services (HHS), health disparities are “differences in health outcomes that are 
closely linked with social, economic, and environmental disadvantage and are 
often driven by the social conditions in which individuals live, learn, work, 
and play” (NIH, 2019). 
• Impotence. This refers to the inability to have an erection of the penis 
adequate for sexual intercourse, while also referred to as erectile dysfunction 
(NIH, 2019). 
• Incontinence. Inability to control the flow of urine from the bladder (urinary 
incontinence), or the escape of stool from the rectum (fecal incontinence) 
(NIH, 2019). 
• Metastasize. This is when cancer cells spread from one part of the body to 
another—or metastasize and form secondary tumors; of note, the cells in the 
metastatic tumor are like those in the original (primary) tumor (NIH, 2019). 
• Prostate. A gland in the male reproductive system. The prostate surrounds the 
part of the urethra (the tube that empties the bladder) just below the bladder 
and produces a fluid that forms part of the semen (NIH, 2019). Some studies 
have used the abbreviation PCa and some PC; both are used interchangeably 







• Prostate cancer. Cancer that forms in tissues of the prostate (a gland in the 
male reproductive system found below the bladder and in front of the rectum). 
Prostate cancer usually occurs in older men (NIH, 2019). 
• Prostate-Specific Antigen (PSA) Test. This blood test measures the level of 
prostate-specific antigen (PSA), a substance produced by the prostate and 
some other tissues in the body. Increased levels of PSA may be a sign of 
prostate cancer (NIH, 2019). 
• Prostatitis. Prostatitis is a painful condition in which the prostate is inflamed, 
swollen, and tender. Inflammation of the prostate gland (NIH, 2019). 
• Radical prostatectomy and a radical treatment. This involves the use of 
surgery to remove part or all of the prostate and some of the tissue around it. 
Nearby lymph nodes may also be removed. It may be done through an open 
prostatectomy, in which an incision (cut) is made in the wall of the lower 
abdomen or the perineum, or by using a laparoscope (a thin, tube-like 
instrument with a light and lens for viewing) (NIH, 2019). 
• Self-efficacy. This involves an individual’s level of confidence to perform 
specific behaviors in specific situations (Bandura, 1997).  
• Serum 25-hydroxyVitamin D (25(OH)D) concentrations and circulating 
25-hydroxyVitamin D. This refers to two major forms of Vitamin D that are 
important to humans: Vitamin D2, or ergocalciferol, and Vitamin D3, or 
cholecalciferol. Vitamin D2 is made naturally by plants, and Vitamin D3 is 







sunlight. Both forms are converted to 25-hydroxyVitamin D in the liver (NIH, 
2019). 
• Sunlight ultraviolet (UV)-B rays, ultraviolet light, and UVB radiation. 
This refers to invisible rays that are part of the energy that comes from the 
sun, can burn the skin, and cause skin cancer (NIH, 2019). 
• Vitamin D deficiency. This occurs when usual Vitamin D intake is lower 
than recommended levels over time, exposure to sunlight is limited, the 
kidneys cannot convert 25(OH)D to its active form, or absorption of Vitamin 
D from the digestive tract is inadequate (NIH, 2019). 
• Vitamin D supplementation. This is a cost-effective method of correcting 
Vitamin D deficiency and maintaining adequate levels of Vitamin D (NIH 
2019). 
• Watchful waiting. This involves closely watching a patient’s condition, but 
not giving treatment unless signs or symptoms appear or change. Treatment is 
given to relieve symptoms and improve quality of life. It is also used when the 
risks of treatment are greater than the possible benefits. During watchful 
waiting, patients may be given certain tests and exams. Watchful waiting is 
sometimes used in prostate cancer (NIH, 2019). 
Conclusion 
This chapter introduced the topic and provided an overview of Black men’s 
knowledge of prostate cancer and prostate cancer screening, screening for Vitamin D 







questions, and rationale of this study. Chapter II provides a review of the literature 
relevant to this dissertation.  
Chapter III includes the methods of this study. Chapter IV includes the results of 
data analysis for this study. The dissertation concludes with Chapter V, which provides a 













REVIEW OF LITERATURE 
 
A review of the literature supporting this study is presented in this chapter. This 
literature review covers the following topics: (a) prevalence of prostate cancer morbidity 
and mortality globally; (b) health disparities and prostate cancer morbidity/mortality in 
the United States; (c) factors related to prostate cancer morbidity/mortality for U.S. 
Blacks; (d) screening tests for prostate cancer; (e) racial disparities in the United States in 
prostate cancer treatment research; (f) increasing prostate cancer screening to decrease 
morbidity and mortality; (g) research on the importance of screening for Vitamin D;  
(h) research to increase knowledge on Vitamin D deficiency; and (i) the theoretical 
framework guiding this study.  
Prevalence of Prostate Cancer (PCa) Morbidity and Mortality Globally 
Farhad et al. (2017) indicated that “PCa metrics among different locations and 
changing trends are valuable to determine how various health policies and screening 
protocols might affect the outcome of PCa” (p. 1226). In addition, “precise and reliable 
reports on patterns and trends of diseases in different geographical areas provide policy 
makers with the evidence needed to allocate resources appropriately” (p. 1226). Farhad et 







and 70 years or older by 4.5-fold and 3.2-fold, respectively. Incidence rates in these age 
groups also showed a 2.4-fold and a 1.5-fold increase, respectively” (p. 1227). They 
explained the global trend in detail, as follows: 
     The highest number of newly diagnosed prostate cancers were recorded in 
Western European countries in 2015 while the Australasian region had the highest 
ASIR in 2015. The high income Asia Pacific region had the largest increase in the 
PCa incidence with a 4.4-fold and 11.2-fold increase in ASIR and incident cases, 
respectively, during the study period. United States, France and Japan were the 
countries with the highest incident cases in 2015. Moreover, the highest ASIR 
was observed in Dominica, France and Virgin Islands. (p. 1227) 
 
Further, prostate cancer “caused 365,933 deaths (95% uncertainty interval 
303,492-459,614) around the world in 2015, a 91% increase from 191,896 deaths (95% 
uncertainty interval 154,039-236,473) in 1990” and the “highest number of PCa deaths at 
the global level was recorded in men 70 years old or older in all study years” (Farhad et 
al., 2017, p. 1227). They concluded that “incidence of PCa is increasing globally, and is 
expected to increase further as screening is becoming more popular in less developed 
regions and life expectancy continues to rise” (p. 1232). 
Rebbeck et al. (2013) reported that “Prostate cancer (CaP) is the leading cancer 
among men of African descent in the USA, Caribbean, and Sub-Saharan Africa (SSA)” 
(p. 2). Also, “The International Agency for Research on Cancer (IARC) estimates that 
CaP is the leading cancer in terms of incidence and mortality in men from Africa and the 
Caribbean” (p. 2). It is estimated “that CaP is a growing problem in Africa with 
approximately 28,006 deaths from CaP in 2010, and approximately 57,048 deaths in 
2030,” representing an “104% increase in the number of CaP deaths in Africa over the 
next two decades” (p. 2). The study indicated that “CaP is a major cancer in men of 







mortality rates may represent an underestimate of the actual CaP incidence and mortality 
rates in SSA and the Caribbean” (p. 6). Rebbek et al. explained in detail, as follows: 
     Possible explanations for the wide range in CaP incidence and mortality by 
geography observed here fall into several categories: (1) differences in health care 
access, diagnosis, and screening; (2) differences in the methodology used to 
generate rates including completeness of ascertainment and (3) underlying 
differences in risk due to demographic differences, genetics/biology, lifestyle, or 
environmental exposures. (p. 6) 
 
Taitt (2018) also added that the literature on prevalence of prostate cancer 
morbidity and mortality related to “geography, race, and ethnicity has yielded 
inconsistent and, in some cases, unreliable information” (p. 1807). Taitt emphasized, 
despite evidence that “prostate cancer (PCa) incidence and mortality rates are among the 
highest for African Americans,” there is no significant data “regarding PCa rates in native 
African men, Black men residing in other countries, and men in Asia, Europe, and the 
Americas” (p. 1807). Taitt reported that “PCa mortality rates have been declining in most 
Western countries as well as in some European countries” without clear rationale, but 
suggested that it may be due to “early detection and improved treatment” (p. 1808). 
However, it is suspected that “variations in incidence and mortality rates reported for 
many countries may possibly be due to underdiagnosis, underreporting, differences in 
screening practices, differences in health-care access, gaps in knowledge and awareness, 
and attitudes toward PCa and associated screening” (p. 1808).  
Taitt (2018) investigated the differences in “PCa detection methods, incidence, 
and mortality rates between races and ethnicities in various regions of the world,” and 
found that “men of African descent outside of the African continent are at a higher risk of 
developing PCa” (p. 1808). The situation is different with Black men in Africa, as the 







mortality to incidence ratio (MR/IR) is quite striking between developed and less 
developed countries” (p. 1810).  
Ogunsanya et al. (2017) also found that “mortality and morbidity rates are 
significantly elevated in Black men, compared with men of other racial and ethnic 
groups” (p. 1009). In addition, they showed “survival rates comparing Black men with 
Caucasian men report clear disparity” (p. 1009). Likewise, Taitt (2018) stated that “in 
developed countries such as the United States and New Zealand, the mortality trend has 
been declining or stable,” and “PSA testing has declined based on the 2012 USPSTF 
recommendations” (p. 1811). However, “many developing countries have seen a trend of 
increasing mortality rates, while their incidence rates have increased due to increased 
testing” (p. 1811). 
According to Jemal, Center, DeSantis, and Ward (2010):  
incidence and mortality rates for most cancers (including lung, colorectum, 
female breast, and prostate) are decreasing in the United States and many other 
western countries, they are increasing in several less developed and economically 
transitioning countries because of adoption of unhealthy western lifestyles such as 
smoking and physical inactivity and consumption of calorie-dense food. (p. 1893) 
 
They further submitted that “the international variations in cancer rates for most cancers 
largely reflect differences in environmental risk factors (including lifestyle and culture) 
rather than genetic differences” (p. 1893). Furthermore, “the future burden of cancer in 
the developing world is likely to be exasperated by the expected increases in life 
expectancy and aging and growth of the population” (p. 1893).  
Jemal et al. (2010) found that “the international variations in prostate cancer 
incidence rates reflect differences in the use of prostate-specific antigen (PSA) testing, 







one’s lifetime” (p. 1897). They suspected that “the high prostate cancer incidence and 
mortality rates among black populations in the United States and other parts of the world 
including Jamaica and Trinidad and Tobago may reflect differences in genetic 
susceptibility” (p.1897). 
Health Disparities and Prostate Cancer Morbidity/Mortality  
in the United States 
There is a reality that in America, the prostate cancer “death rate for African-
American men in 2000 was 66.9 per 100,000 males and for white men 27.7 per 100,000 
males” (Odedina et al., 2004, p. 780). Scher, Solo, Valant, Todd, and Mehra (2015) also 
noted that “Prostate cancer is a significant cause of morbidity and mortality in the United 
States” (p. 1). They reported “an estimated incidence of 233,000 new cases and 29,480 
deaths in 2014,” which makes it “the most frequently diagnosed cancer and second most 
frequent cause of cancer deaths in US males” (p. 8).  
Per Scher et al. (2015), in the United States, “the point prevalence of prostate 
cancer was 2.2 million in 2009, which will increase to 3.07 million in 2020”; of that, 
“2,121,650 (95.6%) presented with localized or locally advanced disease while 97,630 
(4.4%) had metastatic prostate cancer (corresponding to non-castrate and mCRPC 
states)” (p. 8). They found that the “prevalence for 2009 was lower than that reported by 
SEER, in part because it did not account for prostate cancer incident cases diagnosed 
prior to 1990” (p. 8). Also, “model estimates for the year 2020 are based on 
existing/current (2009) disease incidence, diagnosis, and treatment patterns, and reflect 
demographic changes in the US population over time (e.g., the impact of the baby 







obesity have long been considered as possible risk factors for PC. Several lines of 
research have shown the association between animal fat such as red meat consumption 
and diagnosis of PC especially among AA men” (p. 4). 
Kelly et al. (2016) indicated that prostate cancer “is the most frequently diagnosed 
cancer among men in the United States (US), with 180,890 estimated new cases for 
2016” (p. 2).They reported that despite evidence of “notable improvements in prostate 
cancer mortality rates in the US over the last few decades, it is estimated that 26,120 men 
(8% of male cancer deaths) will die from this disease in 2016,” and that racial disparities 
“in prostate cancer are higher than for any other malignancy, with black men exhibiting a 
2.5 fold greater risk of death from prostate cancer compared with white men” (p. 2). The 
study found that “black men had substantially greater risk of fatal prostate cancer than 
white men in every period and cohort examined, and this racial disparity was magnified 
amongst younger men” (p. 5). Further, Kelly et at. (2016) reported that recent studies of 
“prostate cancer mortality in the US have shown the black-to-white disparity beginning to 
narrow over the last decade, yet studies prior to 2007 had reported that the racial disparity 
was rising,” adding that their study found “no improvement in the black-to-white 
disparity over the 28-year period examined” (p. 6). Also, “evidence has found that black 
race and low-income are associated with lower rates of aggressive treatment of prostate 
cancer among men with localized/regional disease” (p. 7).  
Kelly et al. (2017) further reported that “Metastatic prostate cancer (PCA) 
remains a highly lethal malignancy in the USA” (p. 1). Also, there is “an urgent need to 
accurately assess recent incidence trends of metastatic PCA, particularly by age and 







their “main models” projected that “the burden of metastatic PCA will increase 
considerably by 2025 and that incidence rates will steadily rise, particularly among men 
aged ≤69 yr.,” the “black-to-white racial disparity in metastatic PCA continued to persist” 
(p. 6). Specifically, Black men currently exhibit prostate cancer “rates two times greater 
than those of white men, which is heightened to almost five times greater among men 
younger than age 50” (p. 6). 
The American Cancer Society’s (ACS, 2018) age‐adjusted incidence rates of 
prostate cancer among Black men remain 75% higher than those among non‐Hispanic 
White men, and mortality rates among Black men are more than double. Further, the 
study showed “stark and significant geographic differences in prostate cancer incidence 
rates between black and white men” (p. 4). Cook et al. (2015) indicated that “it is not just 
blacks in the U.S. who have a relative high prostate cancer incidence; blacks in Brazil are 
1.7-fold (12), and in the UK are 3-fold (13) more likely than whites to be diagnosed with 
prostate cancer” (p. 5). They concluded that within the United States, there is significant 
“geographical variability of racial differences in prostate cancer incidence” rates (p. 5). 
Factors Related to Prostate Cancer Morbidity/Mortality for U.S. Blacks 
According to Taitt (2018), “prostate cancer (PCa) incidence and mortality rates 
are among the highest for African Americans,” even though “the data is inconclusive 
regarding PCa rates in native African men, Black men residing in other countries, and 
men in Asia, Europe, and the Americas” (p. 1807). Taitt further noted that “African 







likely to develop PCa at any age, and develop the disease earlier in life than men from all 
other racial and ethnic groups” (p. 1811).  
Cook et al. (2015) also noted that “Black men have a higher incidence of prostate 
cancer than white men in the U.S., but little is known whether incidence or racial 
differences vary geographically” (p. 1). He and Mullins (2017) indicated that “Prostate 
cancer mortality rates have decreased over recent decades, but racial disparities in 
prostate cancer survival still present as a serious challenge,” explaining that “disparities 
may be impacted by age; in fact, African American men younger than age 65 have 
prostate cancer mortality rates nearly three times greater than that of White men” (p. 1). 
They added that “African American men are two and a half times as likely to die of 
prostate cancer as any other race” (p. 2). Also, He and Mullins stipulated that “prostate 
cancer may become distant metastatic disease at a rate of 4:1 starting at age 40 to 49 
years,” and concluded that “prostate cancer may grow more rapidly or transform into an 
aggressive form earlier in African American men compared with White men” (p. 2). 
Further, the “majority of the articles (68%) indicated the gap in survival and mortality 
between African Americans and Whites lessened with increasing age,” with “a greater 
mortality difference between African American and White men younger than age 65 than 
of men older than age 65” (p. 5). Also, “as prostate cancer patients age, African 
American patients may have increased competing causes of death, which may narrow the 
disparity gap between the races” (p. 5). He and Mullins offered a detailed explanation, as 
follows: 
     The first explanation to the survival and mortality gap decreasing with age 
may be that among younger prostate cancer patients, more aggressive disease is 
seen in African American men than White men. Within the literature collected, 







Americans present with higher grade and/or higher staged tumors when compared 
to Whites, while in patients older than 60–70 years the difference is less 
pronounced. (p. 5) 
 
Furthermore, He and Mullins (2017) indicated that “African American patients younger 
than age 65 have reduced access to medical care when compared to White patients,” 
while “the percent of African Americans under age 65 with no health insurance was 
almost twice that of Whites” (p. 5). For the majority of African Americans, “insurance 
status and employment status were associated with the presentation of advanced disease 
of prostate cancer,” such that “Medicare could provide health care coverage to the 
patients over age 65 who could otherwise not afford adequate treatment, and create equal 
health care access to patients regardless of race” (p. 6). 
Yedjou et al. (2019) found that “Prostate cancer (PC) is one of the most common 
cancers in men,” while “global burden of this disease is rising” (p. 1). The study noted 
that “PC causes nearly 30,000 deaths and 230,300 new cases in the United States with the 
highest incidence and mortality rates among African-American (AA) men” (p. 2). The 
study indicated that vegetables and fruits “are the best known anti-cancer agents that 
contain a wide variety of different micronutrients with properties that could make it more 
difficult for cancer to develop” (p. 2). While consuming “vegetables and fruits containing 
high levels of polyphenols and flavonoids” promotes the PC arresting, “several studies 
and a report from our lab” showed that “a poor diet may contribute to approximately 10% 
to 75% of various cancer-related deaths” (p. 2). Further, “if a man is eating a healthy diet 
rich in vegetables and fruits, he can reduce his risk of getting PC by 75%” (p. 2). They 








     A study reported that Asian populations have a relatively low incidence rate of 
PC compared to whites and black Americans because they use the extract of 
medicinal plants against cancer [19]. In general, scientific evidence from 
epidemiological studies suggests that consumption of high fiber, lean protein, and 
low fat together with high vegetables and fruits significantly reduces the overall 
cancer risks. (p. 2) 
 
According to Yedjou et al. (2019), the “Asian population living in Asia and the United 
States exhibit the lowest frequencies of PC because they commonly consume soybeans,” 
and the “organic compounds (isoflavones) that are present in soybeans are thought to 
have a potential protective effect against PC” (p. 4). The study found that “the 
biochemical properties and medicinal values of curcumin, garlic, and Vernonia 
amygdalina for their use in PC prevention and/or treatment” may be beneficial, as 
“phytochemicals in these natural products are more likely to not only prevent PC 
development, but also reduce its incidence and mortality rates, improve the survival rate, 
and reduce racial disparity in PC” (p. 10). 
Screening Tests for Prostate Cancer 
Globally, there is lack of unanimous opinion in favor of screening for prostate 
cancer. Sacher et al. (2015) noted that “Prostate-specific antigen (PSA)-based detection 
strategies are now widely used in the United States, with the result that most men are 
diagnosed with the disease clinically confined to the gland” (p. 1). This has resulted in 
“earlier intervention and, in parallel, declining mortality, although the overall impact of 
early detection is controversial” (p. 1). Sacher et al. indicated that “for many men 
diagnosed with prostate cancer, the risk of cancer-related symptoms, metastases, and 







Taitt (2018) noted that “PCa screening can detect early disease and it offers the 
potential to decrease morbidity and mortality,” but was also skeptical about “potential 
and expected better outcomes from early detection” due to the fact that “benefits from 
PCa screening remained unproven prior to 2018” (p. 1810) He explained further, below: 
     Recent data from the U.S. Preventive Services Task Force (USPSTF) report 
documented that PSA screening offers a potential benefit of reducing the chance 
of death from PCa in some men aged 55-69 years. The Task Force now 
recommends that men should discuss the benefits and harms of screening with 
their doctor, so they can make the best choice for themselves based on their 
individual circumstances. (p. 1809) 
 
Taitt (2018) further reported there was “decline in PSA use,” which resulted in 
“increase in the incidence of distant-stage disease from 2008 to 2014” (p. 1911). He 
added that “when there is an increase in screening, several distant cases may be caught in 
the earlier stages, but with the lowered use of screening, such cases may be missed”  
(p. 1811). Additionally, as of 2018, “there is adequate evidence from randomized clinical 
trials documenting that PSA-based screening in men aged 55-69 years might prevent 
approximately 1.3 deaths from PCa over approximately 13 years per 1,000 men 
screened” (p. 1811). Per Taitt, “evidence illustrated that screening programs might also 
prevent approximately 3 cases of metastatic PCa per 1,000 men screened’ (p. 1811).  
Obana and O’Lawrence (2015) further noted that “prostate-specific antigen (PSA) 
is discovered in a blood test to find cancerous cells associated with the prostate gland”  
(p. 17). The “discussion about PSA tests between health care providers and patients 
usually happens at age 50 years old, but prostate cancer screenings are available as early 
as 40 years old for those who have family history of cancer” (p. 18). Obana and 
O’Lawrence noted that men were ignorant of their prostate health, despite nearly 10,000 







United States to become aware of PSA tests to help detect and diagnose early prostate 
cancer” (p. 18). They indicated that “adult males avoided screening because of the 
perception that they were at low risk due to lack of family history and the belief that that 
they are living a healthy lifestyle,” and further showed that “80% of primary care 
physicians (PCPs) in the United States informed adult males about the process of prostate 
cancer screening and 64% of PCPs recommended their patients to follow up with a PSA 
test” (p. 18). Obana and O’Lawrence emphasized that “Prostate cancer is one of the 
leading cancers among male adults 40 years of age and older and it is essential for this 
intended population to understand the benefits PSA testing” (p. 18). They explained, 
below: 
     With routine doctor visits, adult males would also discuss with their PCP about 
being a candidate for prostate cancer screening. It is important for physicians to 
effectively communicate with their patients about the importance of PSA testing 
and the advantages of early screenings. (p. 18) 
 
Obana and O’Lawrence (2015) showed that public awareness about PSA “testing 
may also influence patients to follow through with the screening,” as “education and 
income level of adult males are both important to make an informed decision for PSA 
testing” (pp. 18-19). It is crucial for “adult males to understand the impact that PSA 
testing has in order to treat prostate cancer at an early stage,” which would “prevent 
further harm to their bodies and improve their quality of life” (p. 19). Obana and 
O’Lawrence observed that communication “between men and their primary care 
physicians was critical in improving their awareness of PSA tests, their overall health, 
and ensuring that they received the proper screening” (p. 20). According to Obana and 







control of screening for prostate cancer, with the majority of participants desiring a 
shared decisional process with, and recommendations from, their health care provider.  
Similarly, Reynolds (2008) indicated that “African American men have the 
highest rate of incidence for prostate cancer in the world and are more likely to die from 
the disease than other ethnic groups” (p. 172). Regular “screening for prostate cancer can 
lead to early detection of the disease, thereby reducing negative outcomes” (p. 172). 
However, “African American men are less likely than Caucasian men to engage in 
screening practices,” due to a number of possible causes such as absence of “access to 
health care, socioeconomic status, inadequate knowledge, fear, patient-provider 
communication, distrust of the medical profession, and aversion to digital rectal exam” 
(p.172). As Reynolds explained: 
     American Cancer Society, American Urological Association, and the 
American Medical Association all endorse PSA testing and DRE as screening 
recommendations. The American College of Physicians suggests that physicians 
describe the potential benefits and disadvantages of screening then individualize 
the decision to screen. The American Academy of Physicians has stated that they 
believe there is insufficient evidence to make a recommendation for or against 
routine screening for prostate cancer using PSA testing or DRE. Furthermore, the 
U.S. Preventive Services Task Force agrees that there is inconclusive evidence 
that early detection improves health outcomes. (p. 173)  
 
Reynolds (2008) recommended that “men 50 and over be tested for prostate 
cancer annually through the use of PSA and DRE,” and emphasized “men at risk for 
developing prostate cancer (African American men and men with a family history of 
prostate cancer) should be tested earlier” (p. 173). Results indicated that “Black men are 
substantially less likely than White men to undergo PSA screening” (p. 173). The study 
“supports previous research that suggests African American men have less knowledge 







“lack of knowledge creates fear, which increases the likelihood that an individual will not 
access information on prevention” (p. 174). Per Reynolds, providers are “not getting the 
message out about the increased risk of African American men and prostate cancer,” 
while physicians “must provide information about the advantages and disadvantages of 
the options, and the opportunity to integrate this information with the patient’s personal 
values”; communication between patient and provider was found to be a valuable link in 
putting knowledge into practice (p. 174). Further, distrust of “medical professionals and 
the government were predisposing factors identified in both qualitative and quantitative 
studies that limited the participation of African American men in routine screening for 
prostate cancer” (p. 174). Reynolds (2008) offered details, as follows: 
     Participants in focus groups conducted in the South Bronx voiced a distrust 
and fear of the health care system and felt that because of their race or ethnicity 
they received second-class care. One participant said, “Going to the doctor is 
traumatic. I don’t trust any of them…. They don’t care; they really don’t care…. 
You’re a person of color…your existence is unimportant.” (p. 174) 
 
Bergstralh et al. (2007) used “medical records to estimate the effectiveness of 
screening by PSA testing and/or DRE in reducing PC mortality” (p. 2). The study found 
that “screening with either DRE or PSA was generally associated with over a 50% 
reduction in PC mortality,” and urged “a potential benefit of PSA and DRE screening on 
PC mortality” (pp. 5-6). Agalliu, Weis, Lin, and Stanford (2007) examined the 
“associations between screening by PSA and/or DRE during middle age” and “in relation 
to death from prostate cancer and other causes” (p. 934). The study found “a 62% 
reduction in prostate cancer-specific mortality associated with one or more PSA and/or 
DRE screening tests done within the five-year period preceding prostate cancer 







between screening by PSA and/or DRE and prostate cancer mortality,” such as “a 
population-based case control study in Olmsted County, Minnesota…reported a 50% 
reduction in prostate cancer mortality associated with DRE tests performed in the ten 
year period before diagnosis” (p. 934). Bergstralh et al. (2007) stated that “studies have 
reported a 20-30% prostate cancer mortality associated with screening,” and concluded 
that there is “a reduction in prostate cancer-specific mortality associated with PSA DRE 
screening in middle-aged men” (p. 936). 
Racial Disparities in the United States in  
Prostate Cancer Treatment and Research 
Recall from above that according to Reynolds (2008), racial differences are 
“contributing factors to screening behaviors and possible causes of the striking disparity 
between prostate cancer incidence and mortality in African American men” (p. 172). 
Often, “African American men present at a later stage of prostate cancer than do other 
ethnic groups,” with “a plausible explanation for that fact” being lack of health insurance 
(p. 173). Indeed, “men report that they do not get screened for prostate cancer because the 
tests are expensive and they do not have health insurance coverage” (p. 173). Reynolds 
showed that “Not knowing that screening was needed was cited as the Number 1 barrier 
of being screened for prostate cancer” among African American men, while “lower 
income men had significantly lower total knowledge scores using a revised Knowledge of 
Prostate Cancer Questionnaire than did men with higher incomes” (p. 174). Reynolds 
explained, below: 
     There may also be inadequate knowledge on the part of the physician as well 
as the patient. In a 2005 survey conducted by Miles, only three quarters of 







risk group. Where does that leave African American men, if 25% of their health 
care providers are unaware of the cancer risks facing this group? (p. 174) 
 
According to Reynolds (2008), the fear of “developing prostate cancer and being 
worried that having an early detection exam would result in a diagnosis…were found to 
have a significantly negative association with intention to be tested for prostate cancer 
susceptibility” (p. 174). Further, there is “a culturally linked aversion to part of the 
screening process, namely, the DRE” (p. 174). Per Reynolds:  
     A 1995 study conducted by Gelfand and colleagues indicated that older, more 
educated, and higher income men were more positive toward digital rectal exam 
than younger, less educated, and lower income men. Additionally, attitudes 
toward DRE became more negative when fear of cancer increased. In a qualitative 
study conducted by Forrester-Anderson in 2005, African American men reported 
that “men shy away because of the finger test.” Embarrassment was cited as a 
barrier for participation in prostate cancer screening among African American 
men, in a 2005 study conducted by Shelton, Weinrich, and Reynolds. It is not 
known, however, how the men defined “embarrassment” in the study, or if there 
is a relationship between the embarrassment of a DRE performed by a personal 
physician versus an unknown physician. (p. 174) 
 
Recall from Chapter I how Kang et al. (2018) reported that “PCa has risen to the 
first place among new cancer cases, and become the second leading cause of cancer-
related deaths in males” (p. 2377). Further, “the global prevalence rate of PCa is rising 
rapidly” (p. 2377). The study “forecasted that by 2030, the number of newly diagnosed 
PCa cases and deaths will rise up to more than 1.8 million and 0.5 million, respectively,” 
indicating that “PCa risk might increase due to multiple factors, including aging, genetic 
factors, pathological changes, diet, hormonal level, as well as ethnicity and environment” 
(p. 2377). 
Scher et al. (2015) noted that understanding “the prognosis for patient populations 
at different points in the prostate cancer disease continuum” should be a required step in 







doubt as to whether “African Americans (AAs) with intermediate- to high-risk prostate 
cancer” are given equal treatment as compared to White patients (p. 386). For “patients 
with intermediate to high-risk” prostate cancer, “definitive treatments have been shown to 
decrease prostate cancer-specific mortality” and “improve overall survival” (p. 386). 
African American men with “intermediate- to high-risk” prostate cancer “are less likely” 
to receive treatment with “curative intent” than are White men—such that the “disparity 
is worse in high-risk disease and is not improving over time” (p. 386). Given racial 
disparities in the treatment of prostate cancer, African American men “have a 
significantly higher risk of dying from” prostate cancer than White men (p. 386).   
Increasing Prostate Cancer Screening to Decrease Morbidity and Mortality 
Prostate cancer screening with the use of the prostate-specific antigen (PSA) test 
“is common” (Schenk et al., 2014, p. 2), while the digital rectal examination (DRE) is 
also commonly performed by physicians (Ashorobi et al., 2017, p. 82). The ACS 
recommends commencement of prostate cancer screening at age 45; PSA levels should 
guide further testing (Smith et al., 2018, p. 297). Scher et al. (2015) also “proposed a 
dynamic progression model that partitioned both the untreated natural history and post-
treatment history of the prostate cancer disease continuum from diagnosis to death into 
distinct clinical states,” where “each state represents a clinically significant milestone and 
key decision point that is easily recognized by patients, physicians, and researchers”  
(p. 1). 
Recall from Chapter I how Baptista et al. (2018) stipulated that “screening for 







Colorectal, and Ovarian Cancer Screening Trial found no benefits from using prostate-
specific antigen (PSA) screening for prostate cancer diagnoses,” the “results from the 
European Randomised Study of Screening for Prostate Cancer concluded that one 
prostate cancer death would be avoided and 27 excess cases detected per 781 men invited 
for screening with PSA” (p. 3). It was highlighted that a “decision about whether to be 
screened should be an individual one based on conversations with the physician about the 
benefits and adverse effects of screening, in order to help men make a decision based on 
personal values and preferences” (p. 4). 
Taitt (2018) identified the “primary goal of screening for PCa is to detect the 
disease early with the expectation that it can be managed with better outcomes before it 
reaches the later metastatic stages,” and added that “data from the USPSTF reported 
evidence that PSA screening offers a potential benefit of reducing the chance of death 
from PCa in some men aged 55-69 years” (p. 1813). Of note, “African American men 
were significantly less likely than Caucasian men to correctly identify early symptoms of 
PCa and the basic components of a prostate checkup,” and “were also more likely to 
believe that ‘pain’ was the first symptom of PCa and were less likely to undergo 
screening and other early diagnostic procedures such as PSA testing and digital rectal 
examinations (DRE) compared to Caucasian men” (p. 1813). Taitt also showed how 
before the revised 2018 USPSTF report, “researchers have questioned whether the high 
mortality in African American men can actually be reduced by increasing awareness, 
screening, and treatment,” and indicated “several limitations to PCa screening, including 
potential adverse health effects associated with false positives, overdiagnosis, and 







Obu (2014) reported that “screening is important for all men at the age when 
prostate cancer becomes more likely. But for black men, routine prostate cancer 
screening should start at an even younger age” (p. 041). Mahal et al. (2017) found that 
“several major cancer organizations in the United States recommend shared decision-
making for PSA screening, with specific attention to race,” adding that “the American 
Urological Association (AUA) recommends shared decision making to undergo PSA 
screening for men age 55-69 years (with individualized plans for Black men younger than 
age 55 years)” (p. 1098). Also, “the American Society of Clinical Oncology (ASCO) 
recommends shared decision-making in men with a life expectancy >10 years,” while 
“the American Cancer Society (ACS) recommends the discussion of PSA screening to 
begin at age 50 years for men at average risk (and age 45 years for Black men) who are 
expected to live at least 10 years” (p. 1098). Rebbeck et al. (2013) noted that there is lack 
of data on the prevalence of PSA testing “among men in Sub-Saharan Africa (SSA)”  
(p. 2).  
Taitt (2018) showed that “there is adequate evidence from randomized clinical 
trials documenting that PSA-based screening in men aged 55-69 years might prevent 
approximately 1.3 deaths from PCa over approximately 13 years per 1,000 men 
screened” (p. 1811). Taitt explained, as follows: 
     The evidence illustrated that screening programs might also prevent 
approximately 3 cases of metastatic PCa per 1,000 men screened. The USPSTF 
therefore revised its 2012 PSA screening rating and concluded that although the 
net benefit of PSA-based screening in men aged 55-69 years is small, screening 
offers a potential benefit of reducing the chance of death from PCa in some men. 
Consequently, for men aged 55-69 years, the decision to undergo periodic PSA 









Hoffman (2011) also noted that in the United States, “approximately 90% of 
prostate cancers are detected by means of screening” (p. 2013). The “rationale for 
screening is that early detection and treatment of asymptomatic cancers could extend life, 
as compared with treatment at the time of clinical diagnosis” (p. 2014). Such screening 
should be “accurate, reliable, and easy-to-administer…detects clinically important 
cancers at a preclinical stage,” while there should be “availability of effective treatment 
that results in better outcomes when administered early, rather than after signs or 
symptoms of disease have developed” (p. 2014). Hoffman urged that “experts 
recommend that men receive support in making informed decisions,” rather than the 
usual way where “PSA testing is often performed without discussion of the benefits and 
harms of screening” (p. 2016). The aforementioned AUA and ACS guidelines 
“encourage shared decision making between patients and clinicians and periodic PSA 
testing when the patient’s life expectancy is at least 10 years,” including “informing him 
of his cancer risk…and educating him about the often indolent natural history of prostate 
cancer, the limited accuracy of screening and diagnostic tests, and the potential benefits 
and harms of screening and treatment” (pp. 2017-2018).  
Rahal, Badgett, and Hoffman (2016) “found significant benefit from screening 
among trials with sufficiently long duration of PSA screening compared to control 
groups” (p. 5). However, the report suggested that “benefit is gained without requiring 
annual screening, which is consistent with studies that have modeled data from non-
randomized cohorts of men and suggested benefit is affected by the interscreening 
interval” (p. 5). Accordingly, less frequent “screening is recommended for High Value 







Ogunsanya et al. (2017) evaluated “the knowledge of prostate cancer and 
screening and its associated factors in young Black men aged 18 to 40 years” (p. 1009). 
They supported the ACS guidelines that “men in higher risk groups (with positive family 
histories) should receive this information between age 40 and 50 years” (p. 1010). They 
observed that “questions regarding risk factors, screening age guidelines, limitations, and 
diet, were mostly answered incorrectly which are consistent with findings in older Black 
men,” and that those “knowledge deficiencies can be used as a framework to enlighten 
young Black men about prostate cancer issues” (p. 1013). Ogunsanya et al. indicated that 
“participants who had positive health screening experiences, were more highly educated, 
and majored in health care and natural sciences, had higher PC knowledge, compared 
with their counterparts”; “rural residents also scored significantly lower on their 
knowledge scores,” explained by the “significant geographical, economic, and cultural 
limitations” (pp. 1013-1014).  
According to Tuong, Larson, and Armstrong (2014), modification of health 
behaviors is crucial in preventing “many diseases that are associated with significant 
morbidity and mortality in the United States” (p. 219). Health information involves 
“written pamphlets, videos, face to-face counseling, and web-based applications,” but the 
“use of video as an educational medium offers several potential advantages” (p. 219). 
Research on the Importance of Screening for Vitamin D 
Recall from Chapter I how Batai et al. (2017) found that “African American men 
have higher incidence rates of aggressive prostate cancer, where high levels of calcium 







(p. 1). They indicated that demographic features, such as “family history, socioeconomic 
status, access to medical care, other comorbidities, and diet and lifestyle have been shown 
to contribute to the increased burden of prostate cancer in AA men,” and added that 
recent “studies have focused on differences in serum 25-hydroxyVitamin D (25(OH)D) 
concentrations as a source of the disparate trends seen in this disease” (p. 2).  
Batai et al. (2017) noted that the “main source of 25(OH)D is derived from 
sunlight ultraviolet (UV)-B rays, accounting for over 90% of circulating levels,” but high 
melanin, “commonly seen in ethnic groups with dark skin, such as AA men, reduces the 
amount of UVB radiation absorbed…decreasing the concentration of 25(OH)D and 
increasing susceptibility to developing Vitamin D deficiencies” (p. 2). Also, “AA men 
with higher Vitamin D levels see a reduced risk in high-grade disease, while results in 
Afro-Caribbean men residing in the Caribbean indicate Vitamin D insufficiency may 
contribute to increased prostate cancer risk” (p. 2). In addition, “molecular studies 
suggest deficiencies in Vitamin D overtime may lead to progression from pre-clinical to 
clinically aggressive forms of prostate cancer” (p. 2). Batai et al. established that in 
studies on “cancer aggressiveness, a large percentage of both aggressive and non-
aggressive cases had mean levels of serum 25(OH)D below deficient levels, as defined by 
the Institute of Medicine (IOM)” (p .6).  
Lenz (2009) found that “from 40% to 100% of community-living elderly men  
and women in both the United States and Europe have deficient levels of Vitamin D”  
(p. 365). Likely “1 billion people worldwide have Vitamin D deficiency or 
insufficiency,” while an “estimated cost to our society of Vitamin D deficiency is 







D researchers generally agree that 32 ng/mL is considered sufficient, and Vitamin D 
intoxication is observed at levels of 150 ng/mL or higher” (p. 366).   
Lenz (2009) identified “the amount of solar ultraviolet B (UVB) radiation 
(determined by the time of day, season, latitude, skin pigmentation, use of sunscreen, and 
age), dietary habits, obesity, and many others” as key determinants of a person’s Vitamin 
D levels (p. 366). The study reported that “emerging evidence showing the relationship 
between decreased cancer risk and Vitamin D intake may be relatively new or even 
unheard of for many health care professionals,” yet research demonstrating a 
“relationship between solar radiation and cancer mortality in North America was actually 
published in 1941” (p. 366). Lenz concluded that obtaining “adequate amounts of 
Vitamin D is important not only for bone health but also for decreasing the risk for 
several other diseases and conditions, including cancer” (p. 368). 
Forrest and Stuhldreher (2010) investigated “the prevalence of Vitamin D 
deficiency and its correlates to test the hypothesis that Vitamin D deficiency was 
common in the US population, especially in certain minority groups,” and found that 
mounting “evidence suggests that Vitamin D deficiency could be linked to several 
chronic diseases, including cardiovascular disease and cancer”; Vitamin D helps “prevent 
cancer progression” (pp. 48-49). They noted that the “overall prevalence rate of Vitamin 
D deficiency was 41.6%, with the highest rate seen in blacks (82.1%), followed by 
Hispanics (69.2%)” (p. 49). The USPSTF (2014) concluded that the benefits and harms 
of screening for a Vitamin D deficiency cannot be determined based on a review of the 







screening for Vitamin D deficiency only in individuals considered to have an “at-risk” 
status. 
Forrest and Stuhldreher (2010) “found that over 80% of black adults, both men 
and women, would be categorized as Vitamin D deficient,” and “other minorities were 
also at a higher risk for Vitamin D deficiency, especially Hispanic men” (p. 52). They 
also found that as a result of “the skin pigment melanin absorbs sunlight, an important 
source of erethymal Vitamin D, people of color are at particularly high risk for Vitamin D 
deficiency” (p. 52). They explained that sun exposure is the “primary determinant of 
Vitamin D status and non-whites require more sunlight exposure to obtain adequate 
Vitamin D levels because of skin pigmentation” (p. 52). Richards et al. (2017) also noted 
that skin pigmentation is the “largest predictor of Vitamin D deficiency in the USA, as 
UV-induced cutaneous synthesis of Vitamin D is the primary source of the Vitamin D 
prohormone and is inhibited by melanin” (p. 1). 
Lappe (2011) reported that Vitamin D deficiency is “pandemic, spanning many 
continents and including all ages, genders and racial/ethnic groups,” and recently, 
“world-wide attention is focused on the importance of Vitamin D in optimizing health 
and preventing disease” (p. 58). The study reported an “optimal level of at least 30 to 32 
ng/mL (75-80 nmol/L) is also suggested by the relationship between 25(OH)D and both 
bone mineral density and lower extremity neuromuscular function in National Health and 
Nutrition Examination Survey III (NHANES III),” also finding that low Vitamin D status 
“is prevalent across all age-groups, geographic regions, and seasons” (p .60). Lappe 
indicated how it is “very difficult to achieve and maintain optimal levels of serum 







foods contain limited amounts” (p. 61). Thus, “Vitamin D dietary supplements, which are 
safe and inexpensive, are becoming widely available” (p. 61). The IOM had, during that 
era, “raised the tolerable upper intake level of Vitamin D from 2000 IU/day to 4000 
IU/day” (p. 62).  
Two Vitamin D findings were considered highly noteworthy: “(a) Vitamin D 
receptors are present in nearly every tissue and cell in the body and (b) 25(OH)D-1a-
hydroxylase…has been identified in a multitude of cells outside the kidney” (Lappe, 
2011, p. 63). Further, “preclinical research has advanced the field by elucidating 
mechanisms underlying the preventive effects of Vitamin D” (p. 63). Lappe indicated that 
an “impressive body of evidence suggests that Vitamin D decreases the risk of cancer,” 
while it has “long been recognized that there is an inverse association between sunlight 
exposure and malignancy” (p. 63). The study concluded that there is even “stronger 
evidence for the anticancer effect of Vitamin D”—as provided by “numerous cohort and 
case–control studies that show an inverse association between serum 25(OH)D and 
cancer incidence/mortality” (p. 63). 
Yao et al. (2017) also found “(AA) individuals…have notably lower 25-
hydroxyVitamin D [25(OH)D] concentrations…possibly because of the high content of 
skin melanin coupled with the relatively low UV-radiation exposure of AAs in North 
American” (p. 1362). The study suggested that Vitamin D deficiency “has been 
implicated in a number of chronic diseases including cancer,” and the “high prevalence of 
Vitamin D deficiency in AA populations may put them at high risk of these diseases and 







found that Vitamin D deficiency “is also more common in AAs than EAs, and the 
difference in serum Vitamin D levels may help explain the PCa disparities” (p. 1).  
Batai et al. (2017) further “demonstrated that the active form of Vitamin D, 1,25-
dihydroxyVitamin D, has anti-inflammatory effects by mediating immune-related gene 
expression in prostate tissue” (p. 1). Kang et al. (2018) added that in “a laboratory 
investigation, prostate cell division and growth was reported to be affected by Vitamin 
D,” and reported that “low plasma levels of Vitamin D were hypothesized to be one of 
the important contributors to PCa” (p. 2378). They disclosed that “clinical trial also found 
that pre-diagnostic serum levels of Vitamin D >85 nmol/L may improve survival in men 
with PCa” (p. 2378).  
Research to Increase Knowledge of Vitamin D Deficiency 
Trump et al. (2009) reported that Vitamin D “deficiency and insufficiency were 
common among men with prostate cancer,” and indicated that “25-OH Vitamin D is the 
accepted measure of the adequacy of Vitamin D body stores” (p. 2). The study “reported 
that 57% of patients admitted to the Massachusetts General Hospital were Vitamin D-
deficient and Vitamin D deficiency was still common (42%) after individuals with factors 
known to lead to Vitamin D deficiency were excluded” (pp. 2-3). Trump et al. explained 
that “epidemiological data indicate that Vitamin D deficiency is associated with an 
increased risk of many types of cancer,” and reported that increasing data “link Vitamin 
D deficiency and cancer prognosis, and numerous studies suggest that Vitamin D 
deficiency is associated with an increased risk of medical complications to which patients 







25(OH) D levels have been associated with increased cardiovascular and all-cause 
mortality and other adverse outcomes,” and that “Vitamin D supplementation is safe and 
low cost” (p. 1444). 
Cashman and Kiely (2011) offered an “overview of the approach used by the 
IOM committee to revise the DRI for Vitamin D and to collate from a number of 
authoritative sources,” while identifying “key knowledge gaps in Vitamin D nutrition 
from the public health perspective” (p. 1617). They found that in “2010, when [IOM] 
revised the DRI for Ca and Vitamin D, the research output in the field of Vitamin D 
increased exponentially, yielding a considerable body of data” (p. 1617). This “DRI 
report is the most comprehensive document on Vitamin D nutrition to date” (p. 1617). 
Ever since the “amount of research data generated since 1997 advanced the knowledge 
base in Vitamin D to the extent that for the first time, the DRI committee had sufficient 
evidence on which to base estimated average requirements (EAR)” (p. 1617). Cashman 
and Kiely (2011) reported that “the committee proposed a serum 25-hydroxyVitamin D 
(25(OH)D) level of…50 nmol/l as its estimate of the…level that would meet the 
requirement of nearly all (i.e. 97·5 %) ‘normal healthy persons’” (p. 1617). They 
explained problems associated with lack of information, however, below: 
     The scarcity of information in some life stages, particularly pregnancy, infancy 
and adolescence, as well as insufficient experimental data in human volunteers for 
non-skeletal health indicators, were all identified by the DRI committee as 
obstacles to defining Vitamin D requirements using any but the indices of bone 
health listed above. Experimental data in appropriately designed studies are 
required to progress the debate and enable consideration of data appropriate to 
potentially vulnerable life stages as well as clarify the putative role for Vitamin D 
in non-skeletal health outcomes. (p. 1618) 
 
Felcher, Gold, Mosen, and Stoneburner (2017) evaluated “the impact of clinical 







that screening for “Vitamin D deficiency has increased in recent years, spurred by studies 
suggesting Vitamin D’s clinical benefits” (p. 776). Further, the “rate of outpatient visits 
in the United States associated with Vitamin D deficiency tripled from 2008 to 2010, 
rising to 1,177 visits per 100,000 people; half of clinical laboratories surveyed reported 
that testing for serum 25-hydroxy Vitamin D rose by at least 50% between 2008 and 
2009” (p. 776). The UPSTF and the American Board of Internal Medicine Foundation 
both “found insufficient evidence to support screening for Vitamin D deficiency in the 
general population,” given “an initiative to reduce overuse of tests and procedures, 
recommends avoiding screening for patients at low risk of Vitamin D deficiency”  
(p. 777). Felcher et al. reported “significantly reduced overall rates of Vitamin D 
screening and a significant increase in the proportion of ordered Vitamin D screening 
tests that were clinically appropriate,” which “support the Institute for Healthcare 
Improvement’s triple aim of increasing quality, increasing patient-centered care, and 
decreasing cost” (p. 778). The study concluded that “a set of inexpensive, easily 
implemented CDS changes greatly reduced rates of inappropriate Vitamin D testing in an 
integrated health plan” (p. 779). 
Murphy et al. (2012) “found that season of blood draw and lack of Vitamin D 
supplement use was significant for EA men; lack of Vitamin D supplement use predicted 
deficiency among AAs” (p. 424). They explained that because “season is not an easily 
modifiable risk factor, supplementation may be the easiest way to overcome this issue,” 
and indicated that “more than 90% of the AA men have deficiency” in Vitamin D (p. 
424). Further, “AA people are at increased risk for many of these diseases. It is essential, 







deficiency, such as “increased skin exposure to sunlight, increased fortification of food 
items with Vitamin D, and Vitamin D supplementation” (pp. 424-425). The study offered 
that in the “absence of adequate exposure to sunlight, there is mounting evidence that at 
least 1,000 IU of dietary or supplemental Vitamin D intake is required daily to prevent 
Vitamin D deficiency” (p. 426). 
Goodman, Morrongiello, and Meckling (2016) promoted an intervention to 
increase Vitamin D knowledge and intake. They indicated that Vitamin D is “crucial for 
bone health, including the prevention of rickets in children and osteomalacia in adults,” 
while sufficient serum Vitamin D concentrations “also may be protective against a range 
of disease states, including cancer, cardiovascular disease, diabetes and multiple 
sclerosis, and may enhance the immune system” (p. 2). As “individuals with darker skin 
pigmentations have a higher concentration of melanin in their skin, placing them at 
higher risk for Vitamin D insufficiency; this makes Vitamin D particularly important for 
non-Caucasian individuals, including immigrants to Canada” (p. 2). The study reported 
that “after adjusting for gender and education, study group had a significant effect on the 
change in Vitamin D intake from pre- to post-intervention” (p. 9). Goodman et al. offered 
details, as follows: 
     Specifically, the mean Vitamin D intake of intervention participants increased 
more than that of control participants. Mean Vitamin D intake from supplements 
increased significantly by 267 IU/day among intervention participants, while a 
nonsignificant increase was observed in the control group. The increase in total 
daily Vitamin D intake (food + supplements) was thus approximately 43% greater 
in the intervention (+308 IU) than the control group (+131 IU). The additional 
177 IU/day Vitamin D consumed by intervention participants is roughly 
equivalent to an extra 1¾ cups of milk or ½ to 1 serving of oily fish per day, an 








In addition, “blood Vitamin D concentrations in our sample improved 
significantly from pre-test (27 nmol/L) to post test (43 nmol/), but did not differ 
significantly between groups” (pp. 9-10). Also, “an analysis of survey measures indicates 
that participation in the intervention led to improved perceptions and knowledge of 
Vitamin D,” and “the intervention group agreed more strongly with the importance of 
taking Vitamin D supplements…suggesting that the intervention had the intended effect. 
Vitamin D knowledge increased significantly only in the intervention group” (p. 10). The 
study found that “higher education was associated with more frequent app use, similar to 
previous research indicating that individuals with higher education levels were more 
likely to adhere to a dietary intervention” (p. 10). 
Theoretical Framework Guiding the Study 
Three theories were the basis for the theoretical framework guiding the present 
study: Health Disparities Theory (Institute of Medicine [IOM], 2012), Self-Efficacy in 
the Social Cognitive Theory of Bandura (1997), and Diffusion of Innovation Theory 
(Rogers, 1995). This section briefly reviews these theories. 
Health Disparities Theory 
Health disparities theory is also relevant (IOM, 2012). Numerous works, such as 
the IOM (2012) report, have focused on health disparities as a major public health 
problem. This includes the 2003 report by the IOM on Unequal Treatment: Confronting 
Racial and Ethnic Disparities in Healthcare, which documented that racial and ethnic 
minorities have less access to health care and often receive poor quality care. Also, 







outcomes” (p. 4). What emerges is a theory of health disparities that encompasses key 
themes, including: the persistence of health disparities; impact of the economy and 
increasing poverty; role of race and racism; importance of place, as in residential 
segregation and impact of low-income communities; the need to increase awareness 
about them, given its low level in the public at large; the need for health in all policies; 
and the role of the community in creating a health disparities agenda (p. 4). 
The National Academies of Sciences, Engineering, and Medicine (NASEM, 
2017) have continued the effort to address health disparities and foster equity in health, 
while focusing on taking action on the level of communities via coalitions, collaboration, 
and partnerships. Others have also contributed to these efforts (Betancourt, Green, 
Carrillo, & Ananeh-Firempong, 2003; LaVeist, Gaskin, & Richard, 2009; Rose, 2018; 
Wallace, 2008). 
As per NASEM (2017), health disparities are or reflect differences between racial 
or ethnic groups in their health status, but disparities can exist across many other 
dimensions as well, such as gender, sexual orientation, age, disability status, 
socioeconomic status, and geographic location. According to Healthy People 2020, all of 
these factors, in addition to race and ethnicity, shape an individual’s ability to achieve 
optimal health (NASEM, 2017).  
At the same time, the National Standards for Culturally and Linguistically 
Appropriate Services in Health and Health Care (USDHHS, 2013) explained how health 
disparities “adversely affect neighborhoods, communities, and the broader society, thus 
making the issue not only an individual concern but also a public health concern” (p. 9). 







Health and Health Care “align with the” the actions plans of other government agencies 
(e.g., Health and Human Services) to reduce racial and ethnic health disparities (p. 9).  
An analysis by LaVeist et al. (2009) and the Joint Center for Political and 
Economic Studies found that eliminating health disparities for minorities would have 
reduced direct medical care expenditures by $229.4 billion for the years 2003-2006. In 
addition, for the year 2016, about 29,530 cases of newly diagnosed prostate cancer were 
expected for Black men (ACS, 2016). This would represent 31% of all cancers diagnosed 
for Black men (ACS, 2016). Hence, the emergent theory of health disparities presented as 
themes by the IOM (2012), as described above, was important for framing the current 
research.  
Social Cognitive Theory: Self-Efficacy  
Bandura’s (1997) concept of self-efficacy was advanced as a key component of 
the social cognitive theory (SCT). According to Bandura, self-efficacy “is based on the 
principal assumption that psychological procedures, whatever their form, serve as a 
means of creating and strengthening expectations of personal efficacy” (p. 193). The 
theory advocates a theme of “triadic reciprocity,” which asserts that a person’s behavior 
is constantly under the reciprocal influence of the environment and personal cognitions 
(Tsang et al., 2012, p. 1). According to Tsang et al., self-efficacy “refers to one’s beliefs 
in one’s capability to organize and execute the courses of action required to achieve given 
results” (p. 1). Further, Bandura emphasized that “self-efficacy beliefs determine how 
people feel, think, motivate themselves and behave” (p. 1). Tsang et al. emphasized that 







level, strength, and generativity,” where self-efficacy “assessment is needed for 
understanding the nature and strength of beliefs that influence performance” (p. 2). 
Self-efficacy theory assumes that confidence, or perception of a task as doable, is 
the most important precondition for performing a desired behavior or for changing an 
ineradicable behavior, while “different modes of efficacy induction, diverse populations, 
using both inter-individual and intra-individual verification, in all sorts of domains of 
functioning, and with micro level and macro level relations” may impact self-efficacy 
(Bandura, 1997, p. 18). 
Thus, the study tools used self-efficacy theory for good reason in assessing 
confidence to talk to a medical provider about key issues of focus: i.e., about prostate 
cancer and screening as well as about Vitamin D screening and supplementation.  
Diffusion of Innovations Theory 
Rogers (1995) invented the diffusion of innovations theory to illustrate the 
adoption and spread of innovations by individuals in a social network. According to 
Rogers, diffusion is “the process by which an innovation is communicated through 
certain channels over time among the members of a social system” (p. 5). Greenhalgh, 
Robert, Macfarlane, Bate, and Kyriakidou (2004) broadened the theory to address the 
assimilation and implementation of service-level innovations in health care organizations. 
They defined it as “a novel set of behaviors, routines, and ways of working that are 
directed at improving health outcomes, administrative efficiency, cost effectiveness, or 
users’ experience and that are implemented by planned and coordinated actions” (p. 582).  
The diffusion of innovations theory was pertinent to the present study because it 







Screening Knowledge Test (PC-S-KT-39)—and learning about Vitamin D screening and 
supplementation to other Black males. 
The new Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) is 
considered a new innovation in providing online education, and the study participants had 
an opportunity to indicate if they would recommend the test to other African American 
men, as an indicator of the value placed on diffusing this new innovation online. 
Conclusion 
This chapter provided a review of the literature, including the following topics: 
(a) prevalence of prostate cancer morbidity and mortality globally; (b) health disparities 
and prostate cancer morbidity/mortality in the United States; (c) factors related to prostate 
cancer morbidity/mortality for U.S. Blacks; (d) screening tests for prostate cancer;  
(e) racial disparities in the United States in prostate cancer treatment research;  
(f) increasing prostate cancer screening to decrease morbidity and mortality; (g) research 
on the importance of screening for Vitamin D; (h) research to increase knowledge on 
Vitamin D deficiency; and (i) the theoretical framework guiding this study.  
Chapter III next describes in detail the methods used in this study. This includes a 
description of the study procedures, study participants, and research instrumentation. 














This chapter provides a description of the methods and procedures followed in 
this study. This includes the following: the study design and procedures, description of 
the study participants, and description of the research instruments. Finally, the chapter 
provides the treatment of the data and data analysis plan. 
Study Design and Procedures 
The cross-sectional study used an online survey. Qualtrics provided the platform 
and secure technology to support the online survey—as the only platform deemed 
sufficiently secure for research use by Teachers College, Columbia University. This 
section provides an overview of all relevant study procedures. 
IRB Approval  
First, before any data collection began, this study received approval from the 
Teachers College, Columbia University Institutional Review Board (IRB) as Protocol 
#19-134—with an “exempt status” (see Appendix A, IRB Approval Letter). It was not 








Recruitment of Study Participants  
This study recruited 194 Black men between the ages of 40 and 76 who were 
potentially at risk for prostate cancer. Participants were recruited to this study via a social 
media campaign, globally, wherein the main study recruitment message, shown below, 
was disseminated via Facebook, emails, text messages, and twitter:  
“Go to https://tinyurl.com/Black-Men-Age-40-PLUS to take the Prostate Cancer & 
Screening—& Vitamin D Survey for Black Men age 40 & above for a chance to win 1 of 
3 $100 Amazon gift cards” (see Appendices B and C).  
In addition, flyers (see Appendix D, Study Flyer) were distributed in venues 
frequented by African American men, including barber shops and churches, featuring the 
same message shown above. 
In addition, members of my extended social network were asked to help recruit 
Black males to the study using three different ways: (a) by posting the study flyer 
physically in their building, (b) by distributing the flyer to their clientele (many copies 
were provided to that effect), or (c) by sending an email out on any listserv that they may 
have had (not all entities had listservs). This flyer outlined the tasks involved in the study, 
including taking a 20-minute online survey. The flyer may have motivated potential 
participants to join the study by having photographs of Black men and inviting interested 
parties to take part in the study for a 3 in 250 chance of winning one of three $100 
Amazon gift cards by providing their email addresses.  
Also, the study’s IRB approved email message (see Appendix B, IRB Approval 
Email) was also distributed widely. Finally, the Principal Investigator texted an invite to 







The Screening Tool Questions: Inclusion-Exclusion Criteria 
The study Screening Tool embodies the study inclusion-exclusion criteria, as 
shown in Appendix A and below: 
1) Are you a Black man who is age 40 or older? 
Yes ___ No___ 
 
2) Are you able to read and understand English on a high school level? 
Yes ___ No___ 
 
3) Are you able to spend about 20 minutes answering a survey—for a chance to 
win one of three $100 Amazon gift cards? 
Yes___ No____ 
Meeting additional study inclusion criteria: Survey completion with data on 
a study outcome variable. After a period of 2 weeks, 390 participants had completed the 
Informed Consent and proceeded to start the survey. However, data analysis could only 
proceed with 194 who completed the survey to the point of providing data for at least one 
of this study’s two outcome variables. Another 132 were eligible for study participation, 
but did not complete the survey to the point of providing data for a study outcome 
variable. When comparing the group of survey completers (n=194) to the group of survey 
non-completers (n=132), using independent t-tests, there were no significant differences 
between the groups on dichotomous variables (i.e., if married, if lives in U.S., if 
employed), and not for continuous variables (i.e., age, skin tone, annual household 
income, level of education). 
Some men contacted the Principal Investigator to share a problem that contributed 
to survey non-completion: i.e., if taking the survey using their cell phones and a new call 
came through, the system took them away from the survey online on the Qualtrics 







created some duplicate IP addresses, as some attempted survey completion a second time. 
Some 37 instances of duplicate IP addresses were examined and deemed to be non-
suspicious and benign—and not strategic attempts to increase one’s chances of winning a 
prize. Instead of eliminating these 37 and reducing the sample size further from 194 to 
157, the decision was made to retain these non-suspicious and benign duplicate IP 
address cases. Hence, the final sample was N=194. 
Although the intent was to collect up to 250 responses, only 194 respondents met 
the additional study inclusion criteria of providing sufficient data as survey completers on 
at least one of the study’s outcome variables. 
Study Completion and Entering Email Address for Chance to Win a Prize 
Once the survey was completed, participants were routed to a “thank you” page 
where they were thanked for study participation and invited to enter their email address, 
thereby formally entering the lottery for a 1 in 3 chance to win one of three $100 gift 
cards for use on www.Amazon.com. As a final step, the webmaster of the Research 
Group on Disparities in Health (RGDH), Dr. Rupananda Misra, had responsibility for the 
program to select the three winners. The winners received an email with the bar-coded 
gift certificate information. The Principal Investigator did not have access to the email 
addresses. Also, of note, study participants were made aware that their study information 
was not linked to their email addresses, thereby ensuring their confidentiality.   
Other Study Procedures  
Completion of the survey took an estimated 20 minutes of time. Those 







the survey. Immediately after clicking on the study link, potential participants read and 
electronically signed informed consent documents and read their participants rights (see 
Appendix E). After giving consent, participants completed a short screening 
questionnaire to assess study eligibility (see Appendix G).   
If they were not eligible, they were routed to a disqualification page explaining 
that they were ineligible and could market the website online to their peers. If they were 
eligible, participants were able to begin the survey.   
Description of the Research Instrumentation 
The study measure is entitled “The Prostate Cancer & Screening—& Vitamin D 
Survey for African American Men” (see Appendix G). This survey has many parts, as 
described in this section.  
Most of the survey parts are standard tools used by the RGDH, directed by 
Professor Barbara Wallace at Teachers College, Columbia University. The RGDH is part 
of the Center for Health Equity and Urban Science Education (CHEUSE), Teachers 
College, Columbia University; Professor Barbara Wallace is Co-Director of CHEUSE. 
Numerous studies are conducted annually by the RGDH, with Dr. Barbara Wallace 
serving as the research sponsor; this doctoral dissertation was one of those studies. Thus, 
a good number of the subscales in this study were utilized in previous research studies of 
the RGDH. Other survey parts are new, having been created for first-time use in the 
present study by the Principal Investigator and the dissertation sponsor, Professor Barbara 







This section describes all of the survey parts, or scales and subscales, in detail 
(see Appendix G). 
Part I: Basic Demographics (BD-9) 
The BD-9 is a standard tool used by the RGDH. Here, this scale has nine items to 
capture basic demographics of the sample (e.g., age, race/ethnicity, education level, 
household income, and employment status). The tool permits descriptive statistics, 
including obtaining mean, SD, minimum, maximum, as well as percentage and frequency 
data.  
Part II: Brief Health Survey (BHS-5) 
The BHS-5 is another standard tool used by the RGDH. In this study, the tool has 
five items, reduced from a typical eight items, and eliminating type of insurance, for 
example, to lessen the burden of time on study participants. The tool permits descriptive 
statistics, including obtaining mean, SD, minimum, maximum, as well as percentage and 
frequency data.  
Part III: Prostate Cancer Scale (PCS-6) 
Professor Barbara Wallace developed the PCS-6 as a tool used by the RGDH that 
was first used by Hall (2018). Questions permit obtaining data on any diagnosis of 
prostate cancer or being told one is at risk of prostate cancer, as well as history of prostate 
cancer screening, and family history of prostate cancer diagnoses and deaths. It was 
reduced by about three items (e.g., prostate cancer diagnoses and deaths for friends and 







descriptive statistics, including obtaining mean, SD, minimum, maximum, as well as 
percentage and frequency data.  
Part IV: Vitamin D Scale (VDS-4) 
Professor Barbara Wallace developed the VDS-4 as a new tool used by the 
RGDH that was created for first-time use in this study. The tool permits determining if 
participants were ever screened for Vitamin D, or told they were Vitamin D-deficient, or 
given a recommendation to take Vitamin D supplements, and any history of taking 
Vitamin D supplements. The tool permits descriptive statistics, including obtaining mean, 
SD, minimum, maximum, as well as percentage and frequency data.  
Part V: Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) 
Professor Barbara Wallace and the Principal Investigator developed the  
PC-S-KT-39 as a new tool used by the RGDH that was created for first-time use in this 
study. All 39 statements in this True-False test are TRUE, allowing the test to serve as a 
brief online intervention designed to support men in their decision making about prostate 
cancer screening and treatment by aspiring to increase their knowledge and self-efficacy 
to talk to a medical provider. The tool permits ascertaining the men’s level of knowledge 
for (a) prostate cancer and screening, and (b) Vitamin D screening and supplementation. 
The tool permits descriptive statistics, including obtaining mean, SD, minimum, 
maximum, as well as percentage and frequency data.  
Part VI: Diffusion of the Innovation of the  
Prostate Cancer Knowledge Test (DOI-PCKT-1) 
The DOI-PCKT-1 is a standard tool of the RGDH, being widely used, typically 







response to a single question about whether the participant would recommend to others 
the online intervention of taking the new PC-S-KT-39 and, specifically, for this study, 
recommend it to other African American men. The tool permits descriptive statistics, 
including obtaining mean, SD, minimum, maximum, as well as percentage and frequency 
data.  
Part VII: Pre- and Post-Knowledge Test—Ratings for Knowledge and Self-Efficacy 
to Talk to a Medical Provider (PRE-A-POST-KT-RF-K-SETMP-8) 
Professor Barbara Wallace and the Principal Investigator developed the PRE-A-
POST-KT-RF-K-SETMP-8 as a new tool for use by the RGDH that was created for first-
time use in this study—while following a standard format commonly used for RGDH 
measure. Specifically, this tool obtains self-ratings for knowledge of prostate cancer and 
screening, and knowledge on Vitamin D screening and supplementation, as well as self-
ratings for self-efficacy to talk to a medical provider about prostate cancer and screening, 
and about Vitamin D screening and supplementation. Specifically, these ratings are 
ascertained in succession for before taking the new Prostate Cancer and Screening 
Knowledge Test (PC-S-KT-39) and for after taking the new test.  
The PRE-A-POST-KT-RF-K-SETMP-8 tool has the following subscales of 
special note, requiring special calculation (e.g., item #1 and item #5):  
• Before Took PC-SKT-39 Global Knowledge Subscale #1 = based on item 
#1 before rating of what knew about prostate cancer and screening, and item 
#5 before rating of what knew about Vitamin D and taking a Vitamin D 
supplement. 
• After Took PC-SKT-39 Global Knowledge Subscale #2 = based on item #2 
after rating of what knew about prostate cancer and screening, and item #6 
after rating of what knew about Vitamin D screening and taking a Vitamin D 
supplement. 
• Before Took PC-SKT-39 Global Self-Efficacy Subscale #3 = based on item 







cancer and screening, and item #7 before rating for confidence to talk to a 
medical provider about Vitamin D screening and taking a Vitamin D 
supplement. 
• After Took PC-SKT-39 Global Self-Efficacy Subscale #4 = based on item 
#4 after rating for confidence to talk to a medical provider about prostate 
cancer and screening, and item #8 after rating for confidence to talk to a 
medical provider about Vitamin D screening and taking a Vitamin D 
supplement. 
Finally, the new tool permits descriptive statistics, including obtaining mean, SD, 
minimum, maximum, as well as percentage and frequency data. 
Treatment of the Data 
The data were transferred from the online Qualtrics platform to the latest version 
of SPSS, i.e., 25.0. Data analysis proceeded using SPSS 25.0. 
Data Analysis Plan 
Given a global online sample of Black men (n=194) who responded to a social 
media campaign (i.e., “Go to https://tinyurl.com/Black-Men-Age-40-PLUS to take the 
Prostate Cancer & Screening—& Vitamin D Survey for Black Men age 40 and above for 
a chance to win 1 of 3 $100 Amazon gift cards”) and completed the study, the following 
research questions were answered, using the data analysis plan indicated. 
1-What are the men’s demographic and background characteristics (e.g., age, skin color, 
partner status, born in the United States—yes/no, living in United States or other country, 
annual household income, level of education, employment status.)? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-How do the men rate their health status, and what is their Body Mass Index, rating of 
their weight status, and rating of the overall quality of care received for their health? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-What is the men’s prevalence of a diagnosis of prostate cancer, being told they were at 







Examination (DRE) or Prostate-Specific Antigen (PSA) Test, as well as the prevalence in 
their family of prostate cancer diagnoses and deaths from prostate cancer? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-What is the men’s history of having a Vitamin D screening, being told they were 
Vitamin D-deficient, being advised to take a Vitamin D supplement, and taking a 
Vitamin D supplement? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
5- What is the men’s level of knowledge for prostate cancer and screening, and for Vitamin 
D and taking a Vitamin D supplement? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
6-After the men are told that the researchers created the Prostate Cancer Knowledge Test 
(PC-S-KT-39)—with all TRUE answers (i.e., as a way to prepare African American men 
to talk with their medical providers about taking important screening tests that may help 
protect them from dying from prostate cancer at a rate higher than for any other men in 
the entire world), do the men recommend the PC-S-KT-39 to other African American 
men as an online intervention (i.e., diffusion of the innovation)? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
7-After the men are told that the researchers created the Prostate Cancer Knowledge Test 
(PC-S-KT-39)—with all TRUE answers (i.e., as a way to prepare African American men 
to talk with their medical providers about taking important screening tests that may help 
protect them from dying from prostate cancer at a rate higher than for any other men in 
the entire world), how do the men rate their self-efficacy—or item #4 after rating for 
confidence to talk to a medical provider about prostate cancer and screening, and item 
#8 after rating for confidence to talk to a medical provider about Vitamin D screening 
and taking a Vitamin D supplement? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
NOTE: item #4 and item #8 after ratings are the two study outcome 
variables/dependent variables 
 
8-After taking the Prostate Cancer Knowledge Test (PC-S-KT-39)—with all TRUE 
answers—in order to determine if taking the PC-S-KT-39 may serve as a potential online 
intervention that may significantly increase knowledge and self-efficacy levels, how do 
the men rate themselves for before taking the PC-S-KT-39 versus after taking the 
PC-S-KT-39 for (a) what they knew about prostate cancer and screening, (b) what they 
knew about Vitamin D screening and taking a Vitamin D, (c) confidence to talk to a 
medical provider about prostate cancer and screening, and (d) confidence to talk to a 







was there a significant difference in mean scores from before to after taking the PC-S-
KT-39?  
Data Analysis Plan: Paired t-tests (before v. after ratings) 
 
9-Are there any significant relationships between selected demographics and (a) study 
outcome variable/dependent variable #1—a higher self-rating for Self-Efficacy to Talk 
to a Medical Provider about prostate cancer and prostate cancer (PC) screening, 
after they took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—
as item #4 in survey Part VII, i.e., POST PC Self-efficacy), and (b) study outcome 
variable/dependent variable #2—a higher self-rating for Self-Efficacy to Talk to a 
Medical Provider about Vitamin D (VD) screening and supplementation, after they 
took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—as item #8 
in survey Part VII, i.e., POST VD Self-efficacy)?? 
Data Analysis Plan: Inferential statistics, specifically, independent t-tests and 
Pearson correlations 
 
10-What are the significant predictors of (a) study outcome variable/dependent variable 
#1—a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
prostate cancer and prostate cancer (PC) screening, after they took the Prostate 
Cancer and Screening Knowledge Test (PC-S-KT-39—as item #4 in survey Part 
VII, i.e., POST PC Self-efficacy), and (b) study outcome variable/dependent variable 
#2—a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
Vitamin D (VD) screening and supplementation, after they took the Prostate Cancer 
and Screening Knowledge Test (PC-S-KT-39—as item #8 in survey Part VII, i.e., 
POST VD Self-efficacy)? 
Data Analysis Plan: Backward stepwise regression 
 
Conclusion 
Chapter III provided the methods used in the present study. This included an 
overview of the study design, study procedures, recruitment of participants, description of 
the study participants, and a description of the research instrumentation. The chapter 
concluded with the data analysis plan.   














This chapter provides the results of the data analysis. The results are organized by 
research question, including presentation of data in tables, to summarize the findings. 
Data Analysis Results by Study Question 
Results for Research Question #1 
 
What were the demographic characteristics of the sample? (Survey Part 1-BD-10) 
The study sample included 194 Black males. While 393 gave informed consent to 
engage in the study, 194 finished the entire survey. There were 132 who were eligible for 
study participation, but did not complete the survey to the point of providing a primary 
outcome; t-tests showed there were no differences between completers (n=194) versus 
non-completers (n=132) on several variables (age, skin color, annual household income, 
level of education, and if married, if born in the U.S., and if employed)—finding no 
significant group differences.  
The study’s convenience sample of Black males (N=194) was mostly married 
(75.85, N=147) and had a mean age of 49.53 years (min 40, max 76, SD =8.73). For 
example, those ages 51 to 70 made up 34.2% (n=66). The sample was well educated with 







18% (n=35) having a Master’s Degree, and 5.2% (n=10) having a Doctoral Degree. The 
mean annual income was 4.21. for category 4 of $40,000-$49,999 (min 1, max 9, 
SD=1.64); for example, 17.3% (n=30) reported having annual household incomes of 
$40,000 to $49,000. Most of the participants were employed (n=188, 96.9%) and born in 
the United States (n=152, 78.4%).  
As a reflection of being a global sample, if not a sample of men born in Ghana 
(77.3%, n=194) who are now dispersed across the globe, over two-thirds (77.3%) were 
born in Ghana, while 78.4% (n=152) were currently living in the United States and 
15.5% (n=30) were currently living in Ghana—followed by another 5.1 (n=10) currently 
living in other countries (e.g., 2 [1.0%] each in United Kingdom, Canada, Jamaica, Spain; 
and 1 [.05%] each in Netherlands, Armenia, Germany, Italy). [Note that data for n=1 at 
05% do not appear in the table, being combined for other countries]. 
If not born in Ghana, another 10.8% (n=21) were born in the United States,  
while 4.1% (n=8) were born in Jamaica, 2.1% (n=4) in Nigeria, followed by lower 
representation of other African countries or Black nations around the globe.   
See Table 1. 
 
Table 1. Demographic Characteristics of Sample (BD-10) (N=194) 
                              N        %                                                                              N      % 
Race/Ethnicity (N=194)              Employment Status (N=194) 
Black (All Male) 191    98.5       Employed                                 188     96.9 
Missing                   3      1.5       Unemployed                                         6       3.1  
 
Age (N=194) 
40-45             81    41.8      Household Income (N=194)  
46-50                   40     20.7      1. Less than $10,000                           17       9.8 
51-55                    34    17.5      2. $10,000 to $19,000                  8  4.6 
50-60         16      8.1      3. $20,000 to $39,000     29     16.8 
61-65                  9      5.0      4. $40,000 to $49,000                30     17.3 







71-75           5      2.5      6. $100,000 to $199,000                 24     13.9 
76-80           2      1.0      7. $200,000 to $299,000       4       2.3 
M age=49.53, SD=8.73,       8. $300,000 to $399,000                  1  0.6 
Min=40, Max=76       9. $400,000 or more       2  1.2 
       10. I don’t know                                         7 
    11. Missing                                                    14 
    M Income= 4.21, SD=1.64, Min=1, Max=9 
 
Country of Birth (N=194)    Lives in US Currently (N=194)  
Ghana         150  77.3     Yes      152       78.4      
US            21  10.8     No                                                                 42        21.6 
Jamaica            8    4.1 
Nigeria             4    2.1       Country Lives in Now (N=194) 
Cameroon            2    1.0       United States    152 78.4 
Cote d’Ivoire            2    1.0       Ghana       30      15.5 
Other African         United Kingdom        2        1.0 
  or Black Nation        7     3.6      Jamaica          2   1.0 
         Spain         2        1.0 
         Other Countries        4        2.1 
 
Education (N=194)         Relationship Status (N=194) 
High School              61     31.4     Married                                                   147     75.8 
Associate Degree      48     24.7     Divorced                                                     18       9.3 
Bachelor’s Degree    40     20.6     Separated          5       2.6 
Master’s Degree        35    18        Widowed                                                      2       1.0 
Doctoral Degree        10      5.2     Never Married                    8       4.1 
           With Significant Other                                  2       1.0  
Skin Color (N=194)          Committed Relationship                               3       1.5 
2. Very Light            1          .5     Currently Dating                                           4       2.1 
3. Light                     11       5.7      Other                                                             5       2.6 
4. Medium to Light   27    13.9 
5. Medium to Dark    58      9.9 
6. Dark                       85    43.8 
7. Very Dark            12      6.3 
 
 
Results for Research Question #2 
 
How do the men rate their health status, and what is their Body Mass Index, 
rating of their weight status, and rating of the overall quality of care received for their 








The mean health status was 4.56 (Min=1-very poor, Max=6-excellent, SD=869), 
or between good and very good. For example, 39.7% (n=77) endorsed very good.  
The mean for Body Mass Index (BMI) was 23.31 for normal weight 
(Min=5.94-underweight, Max=44.71, SD=7.51). The mean self-rated weight status 
score was 2.20 for normal weight status (Min=1-underweight, Max=4-obese, 
SD=.450). 
For the quality of medical care they receive, the sample’s mean score was 
4.41, SD=.857, Min=2, Max=6) for good. For example, 38% (N=73) rated their quality 
of care as very good. 
See Table 2.  
Table 2. Health Status, Self-Rating of Weight, Body Mass Index (HSSBMIROW-2), 
Rating of Quality of Care (ROQOC-1) 
                                                                                                                               N              %  
Self-Rate of Health Status (N=194) 
1-Very poor                 1                .5 
2-Poor                             2              1.0 
3-Fair                                                 12              6.2 
4-Good                                                77            39.7 
5-Very good                  77            39.7 
6-Excellent               25            12.9 
Mean=4.56, SD=.869, Min=1, Max=6 
Body Mass Index (BMI) (N=194) 
1-<18.24=Underweight             47            32.5 
2-18.65-24.96=Normal Weight            45            22.5 
3-25.09-29.95=Overweight             67            33 
4->30=Obese                35            17.5 
Mean=23.31, SD=7.51, Min=5.94, Max=44.71 
Self-Rating of Weight (N=194) 
1- Underweight                3              1.5 
2- Normal weight            150            77.3 
3- Overweight               40            20.6 
4- Obese                 1        .5 









Rating of Quality of Medical Care (N=194) 
2-Poor                  4              2.1 
3-Fair                19              9.9 
4-Good               80            41.7 
5-Very good               73            38.0 
6-Excellent               16              8.3 
7 Not Applicable (I do not receive any health care)            2              1 
Mean=4.41, SD=.857, Min=2, Max=6 
 
 
Results for Research Question #3 
 
What is the men’s prevalence of a diagnosis of prostate cancer, being told they 
were at risk for prostate cancer, history of screening for prostate cancer by a Digital 
Rectal Examination (DRE) or Prostate-Specific Antigen (PSA) Test, as well as the 
prevalence in their family of prostate cancer diagnoses and deaths from prostate cancer? 
(Survey PART III: PCS-6) 
The vast majority of the study population, or 94.3% (n=183), indicated they have 
not been told by a doctor or medical professional they have prostate cancer. Of note, the 
prevalence of a diagnosis of prostate cancer in this convenience sample was 5.2% (n=10), 
while only 8.8% (n=17) have been told they are at risk for prostate cancer. Only 7.7% 
(n=15) said a family member has been diagnosed with prostate cancer.  
See Table 3. 
 
 
Table 3. History of Prostate Cancer and Screening and Prostate Cancer in Family 
Network 
                                                                                                                 N              %                                         
1-Have you ever been told by a doctor or medical professional that you have prostate  
cancer? 
1 Yes                10              5.2 
2 No                                                                                                          183           94.3 
3 Unsure                       1     .5 









1 Yes                           17              8.8 
2 No                          173           89.2 
3 Unsure                            4              2.1 
3-Have you ever had a doctor or medical professional perform a digital rectal  
examination (DRE) on you (i.e., placing their gloved finger in your anus/rectum)? 
1 Yes                            65           33.5 
2 No                                     123           63.4 
3 Unsure                            6              3.1 
4-Have you ever been told by a doctor or medical professional that you were going to  
have your PSA measured, or that you were being given a screening test for prostate  
cancer? 
1 Yes                 57 29.4 
2 No               132 68.0 
3 Unsure                  5   2.6 
5-Do you know someone in your family who has been diagnosed with prostate cancer? 
Yes                           15              7.7 
No                         166            85.6 
Unsure                                      13              6.7 
6-Do you know someone in your family who died from prostate cancer? 
1 Yes                15              7.7 
2 No              166            85.6 
3 Unsure                13  6.7 
 
 
Results for Research Question #4 
 
What is the men’s history of having a Vitamin D screening, being told they were 
Vitamin D-deficient, being advised to take a Vitamin D supplement, and taking a Vitamin 
D supplement? (Survey PART IV: VDS-4) 
Regarding their Vitamin D level, 60.85% (n=118) had never had it ordered by a 
medical provider for laboratory testing, 82.5% (n=160) were never told it was too low, 
and 83.5% (n=162) had never been advised by their doctor or medical professional to 
take a daily Vitamin D supplement. 








Table 4. History of Vitamin D Screening (HHVDSTWVDD-3) and Daily Dosing 
(TVDS-1) 
                                                                                                                 N                % 
1-Have you ever had a doctor or medical professional measure your level of Vitamin D  
by laboratory testing? 
Yes                55            28.4 
No                                               118            60.8 
Unsure                            21            10.8 
2-Have you ever been told by a doctor or medical professional that your level of  
Vitamin D was too low? 
Yes                           27            13.9 
No                                    160            82.5 
Unsure                                        7              3.6 
3-Have you ever been advised by a doctor or medical professional to take a daily  
Vitamin D supplement? 
Yes                           30            15.5 
No                                    162            83.5 
Unsure                             2              1.0 
4-Have you ever taken a Vitamin D supplement? 
Yes                           74            38.1 
No                                    109            56.2 




Results for Research Question #5 
 
What is the men’s level of knowledge for Prostate cancer and screening, and for 
Vitamin D and taking a Vitamin D supplement? (Survey PART V: PC-S-KT-39) 
The mean for PC knowledge score was 25.84 (Min=0, Max=37, SD=9.50), or 
moderately high. For example, consider the top-ranked knowledge items that the men 
indicated were “True”: (1) A benefit of prostate cancer treatment is that it can prevent 
death from prostate cancer (93.8%, n=182); (2) A benefit of prostate cancer screening is 
that the cancer could be found and prostate treatment could be started (93.8%, n=182);  
(3) Some experts recommend that prostate cancer screening start as early as age 40 for 
Black men, while the American Cancer Society recommends that men considered high 







example, as part of their annual physical examination—but only after a medical provider 
has explained the risks and benefits of prostate cancer screening (91.2%, n=177);  
(4) Some experts think Black men need to be better informed, so they can actively 
participate in a decision about screening with their doctor and decide what is best for 
them (91.2%, n=177); (5) Screening for prostate cancer is important so it can be detected 
(caught, diagnosed) and treated as early as possible—and this decreases the chances of 
death (91.2%, n=177); (6) Some experts recommend that the medical provider and the 
patient discuss screening for prostate cancer together so that a good decision is made 
about screening and the decision to screen is not left up to the individual patient (86.6%, 
n=168); and (7) During the Digital Rectal Examination (DRE), the medical provider 
inserts a gloved finger into the rectum (anus) of the man—allowing the provider to detect 
an enlarged (swollen) prostate and anything else that feels abnormal (hard nodules, 
bumps) (78.9%, n=153).  
See Table 5. 
Table 5. Level of Knowledge of Prostate Cancer and Screening (LKPCS-1) and Vitamin 
D Screening and Supplementation (VDTVDS-1) (N=194) 
 Item                                                                                                    N              %  
1-Black men around the world have the highest rates of prostate cancer, and Black 
men in America, have the highest death rates from prostate cancer in the entire world.  
1. True                         100            51.5 
2. False               15              7.7 
3. Unsure               79            40.7 
2-Black men are more likely to be diagnosed with a late stage of prostate cancer (cancer 
is caught late and more advanced)—while White men are more likely to be diagnosed 
with an early stage (caught early and less advanced). 
1. True                                    122            62.9 
2. False                     8              4.1 
3. Unsure               64            33.0 
3-Because the prostate cancer of Black men is caught (diagnosed) much later than it is 








1. True                         139            71.6 
2. False               11              5.7 
3. Unsure               44            22.7 
4-Screening for prostate cancer is important so it can be detected (caught, diagnosed) and 
treated as early as possible—and, this decreases the chances of death. 
1. True                         177            91.2 
2. False                 5              2.6 
3. Unsure               12              6.2 
5-Some experts recommend that the medical provider and the patient discuss screening 
for prostate cancer together so that a good decision is made about screening and the 
decision to screen is not left up to the individual patient. 
1. True                                                                                                      168           86.6 
2. False                             6             3.1 
3. Unsure                20           10.3 
6-Some experts think Black men need to be better informed, so they can actively 
participate in a decision about screening with their doctor and decide what is best for 
them. 
1. True                         177            91.2 
2. False                 4              2.1 
3. Unsure                          13              6.7 
7- Some experts recommend that prostate cancer screening start as early as age 40 for 
Black men, while the American Cancer Society recommends that men considered high 
risk, such as Black men, screen for prostate cancer every year, starting at age 45—
for example, as part of their annual physical examination—but only after a medical 
provider has explained the risks and benefits of prostate cancer screening. 
1 True              177            91.2 
2 False                  4              2.1 
3 Unsure               13              6.7 
8-A benefit of prostate cancer screening is that the cancer could be found and prostate 
treatment could be started. 
1 True              182            93.8 
2 False                  3              1.5 
3 Unsure                    9              4.6 
9-A benefit of prostate cancer treatment is that it can prevent death from prostate cancer. 
1 True              182            93.8 
2 False                  3              1.5 
3 Unsure                 9              4.6 
10-A benefit of some prostate cancer treatments is that the cancer will not spread 
(metastasize) to the bones, lungs, brain, or other parts of the body. 
1 True              166            85.6 
2 False                  9              4.6 
3 Unsure               19              9.8 
11-A risk of some prostate cancer treatments is impotence—meaning a man can no 









1 True              124            63.9 
2 False                17              8.8 
3 Unsure               53            27.3 
12-Another risk of some prostate cancer treatments is incontinence—meaning a man can 
no longer control when he has a bowel movement or urinates, or urine may leak out of his 
penis. 
1 True              130            67.0 
2 False                22            11.3 
3 Unsure               42            21.6 
13-Some researchers think Black men with prostate cancer are less likely to receive 
cancer treatment where the intention is to cure them—while White men are more likely 
to receive treatment where the intention is to cure them. 
1 True              127            65.5 
2 False                  7              3.6 
3 Unsure                  60            30.9 
14-Note that this item was in the original survey document, but was not 
programmed into the Qualtrics Survey. Therefore, no data for this item 
are available. 
15-Prostate cancer treatments where the intent is to cure the man of prostate cancer are 
called radical treatments—for example, a radical prostatectomy (surgery that removes the 
prostate gland and surrounding tissue). 
1 True              127            65.5 
2 False                   7              3.6 
3 Unsure                          60            30.9 
16-“Watchful waiting” is an example of what is not a cancer treatment where the 
intention is to cure the patient of prostate cancer. 
1 True                99            51.0 
2 False                                                                                                        12              6.2 
3 Unsure               83            42.8 
17- “Watchful waiting” involves just monitoring a man’s prostate cancer, or the medical 
provider just watching what is going on with the prostate cancer—with no therapy being 
given to the man diagnosed with prostate cancer, until there is a complication from the 
cancer. 
1 True              108            55.7 
2 False                24            12.4 
3 Unsure               62            32.0 
18-Some experts say “watchful waiting” is definitely not the right choice for any patient 
who is under age 65 with a prostate cancer that could be cured with a radical treatment 
(e.g., a radical prostatectomy). 
1 True              119            61.3 
2 False                  9              4.6 
3 Unsure               66            34.0 
19-Other experts say that radical treatments (e.g., a radical prostatectomy, etc.) are the 
first choice of treatment for all patients under age 70 with localized prostate cancer (it has 








1 True                97            50.0 
2 False                   27            13.9 
3 Unsure                          70            36.1 
20-If there is not good control of medical conditions such as diabetes, heart disease, high 
blood pressure, or lung problems, then a radical prostatectomy is not a good choice. 
1 True              112            57.7 
2 False                22            11.3 
3 Unsure               60            30.9 
21- The Prostate-Specific Antigen (PSA) Test and the Digital Rectal Examination 
(DRE) are two ways to screen for prostate cancer, or to try to detect or catch it. 
1 True              147            75.8 
2 False                  5              2.6 
3 Unsure               42            21.6 
22-The Prostate-Specific Antigen (PSA) Test measures levels of prostate-specific 
antigen, a protein made by cells of the prostate gland. 
1 True              144            74.2 
2 False                  4              2.1 
3 Unsure               46            23.7 
23-When a medical provider talks with a patient about testing their PSA, the goal is to 
determine the levels of the Prostate-Specific Antigen (PSA) in the patient’s blood. 
1 True              161            83.0 
2 False                           3              1.5 
3 Unsure               30            15.5 
24-It is normal for men to have low levels of PSA in their blood, and normal for PSA 
levels to increase with age, but prostate cancer can increase a man’s PSA levels. 
1 True              130            67.0 
2 False                  8              4.1 
3 Unsure               56            28.9 
25-PSA levels may be higher in men with a common, noncancerous condition called 
benign prostatic hyperplasia (BPH), or with a condition called prostatitis, an 
inflammation of the prostate gland. 
1 True              122            62.9 
2 False                   6              3.1 
3 Unsure               66            34.0 
26-If a man has a high PSA, or the PSA level is rising over time, then another medical 
procedure may be needed to diagnose prostate cancer. 
1 True              137            70.6 
2 False                    9              4.6 
3 Unsure               48            24.7 
27-A prostate biopsy is a medical procedure where tiny pieces of tissue are removed 
from the prostate and studied in a laboratory in order to diagnose cancer—and only a 
biopsy can determine the presence of cancer. 
1 True              135            69.6 
2 False                10              5.2 







28-A Digital Rectal Examination (DRE) may be performed as part of a man’s regular 
physical examination and is another way that a medical provider can determine the health 
of a man’s prostate. 
1 True              145            74.7 
2 False                   6              3.1 
3 Unsure               43            22.2 
29-During the Digital Rectal Examination (DRE), the medical provider inserts a gloved 
finger into the rectum (anus) of the man—allowing the provider to detect an enlarged 
(swollen) prostate any anything else that feels abnormal (hard nodules, bumps). 
1 True              153            78.9 
2 False                  6              3.1 
3 Unsure               35            18.0 
30-Black men are less likely to have a Digital Rectal Examination (DRE) performed 
by a medical provider, in comparison to White men who receive them more regularly. 
1 True              117             60.3 
2 False                21            10.8 
3 Unsure               56            28.9 
31-A prostate that feels abnormal during a Digital Rectal Examination (DRE) and a 
high PSA level are both possible indicators of prostate cancer, but only a prostate 
biopsy can diagnose cancer. 
1 True              128            66.0 
2 False                10              5.2 
3 Unsure               56            28.9 
32- The Digital Rectal Examination (DRE) and the Prostate-Specific Antigen (PSA) Test 
are both screening tests performed during a regular physical exam, while another 
screening test for your Vitamin D level may also be a part of that exam.   
1 True              131            67.5 
2 False                  8              4.1 
3 Unsure               55            28.4 
33-Some experts recommend that Black men, in particular, need to have their Vitamin D 
level checked as a part of their regular physical exam. 
1 True              137            70.6 
2 False                  6              3.1 
3 Unsure               51            26.3 
34-Some experts say that men with dark skin (e.g., Black men) and those who avoid the 
sun have the greatest need for Vitamin D testing because they are much more likely to 
have low levels of Vitamin D (because they need more sunlight to get Vitamin D).  
1 True              130            67.0 
2 False                10              5.2 
3 Unsure               54            27.8 
35-Some experts point to research showing a low level of Vitamin D predicts having 
prostate cancer, or having an aggressive form of prostate cancer (spreads fast), or prostate 
cancer that has spread (metastasized).  
1 True              125            64.4 
2 False                26            13.4 







36-Black men are more likely to have aggressive prostate cancer (spreads fast), and 
research has found a major link between having aggressive prostate cancer and 
having low levels of Vitamin D. 
1 True              107            55.2 
2 False                17              8.8 
3 Unsure               70            36.1 
37-When the medical provider orders a screening test for the Vitamin D level, and if 
the level of Vitamin D is too low (i.e., Vitamin D deficiency), then it is important to take 
a Vitamin D pill every day (daily supplement of high-quality Vitamin D). 
1 True              146            75.3 
2 False                  4              2.1 
3 Unsure               44            22.7 
38-Some experts believe that avoiding Vitamin D deficiency (being too low) is a part of 
good health care to prevent having health issues. 
1 True              125            64.4 
2 False                26            13.4 
3 Unsure               43            22.2 
39-Some experts believe that everyone needs to make sure they get enough Vitamin D, 
and recommend taking 5,000 i.u. of high-quality Vitamin D every day. 
1 True              125            64.4 
2 False                15              7.7 
3 Unsure               54            27.8 
Mean PC Knowledge=25.84, SD=9.50, Min=0, Max=37 
 
 
Results for Research Question #6 
 
After the men are told that the researchers created the Prostate Cancer 
Knowledge Test (PC-S-KT-39)—with all TRUE answers—(i.e., as a way to prepare 
African American men to talk with their medical providers about taking important 
screening tests that may help protect them from dying from prostate cancer at a rate 
higher than for any other men in the entire world), do the men recommend the PC-S-KT-
39 to other African American men as an online intervention (i.e. diffusion of the 
innovation)? (Survey PART VI: DOI-PCKT-1) 
The majority, or 90.2% (n=175), indicated “yes” they would recommend the 







intervention. Thus, 9 out of 10 would diffuse the innovation of teaching about prostate 
cancer and screening using a true-false test. Some 7.2% (n=14) were unsure. 
See Table 6.  
 
 
Table 6. Do the Men Recommend the PC-S-KT-39 to Other African American Men as an 
Online Intervention (Diffusion of the Innovation)? (DOI-PCKT-1) 
                                                                                                                N                % 
1-Would you recommend the Prostate Cancer Knowledge Test to other Black men? 
1 Yes              175            90.2 
2 No                  5              2.6 




Results for Research Question #7 
 
After the men are told that the researchers created the Prostate Cancer 
Knowledge Test (PC-S-KT-39)—with all TRUE answers (i.e., as a way to prepare 
African American men to talk with their medical providers about taking important 
screening tests that may help protect them from dying from prostate cancer at a rate 
higher than for any other men in the entire world), how do the men rate their self-
efficacy—or item #4 after rating for confidence to talk to a medical provider about 
prostate cancer and screening, and (plus, +) item #8 after rating confidence to talk to a 
medical provider about Vitamin D screening and taking a Vitamin D supplement? (PART 
VII: PRE-A-POST-KT-RF-K-SETMP-8) 
The mean score of the prostate cancer self-efficacy post-knowledge test was 5.17 
or 80% confident (Min=1, Max=6, SD=.942). More specifically, 33.5% (n=65) indicated 
their post-knowledge test self-efficacy for talking to a provider about prostate cancer 







The mean score for Vitamin D self-efficacy post-knowledge test was 5.14 or 80 
% confident (Min=2, Max=6, SD=.985). More specifically, 30.4% (n=59) rated their 
post-knowledge test self-efficacy for talking to a provider about Vitamin D screening and 
supplementation as 80% confident. 
See Table 7. 
Table 7. Post-Knowledge Test: Ratings of Self-Efficacy to Talk to a Medical Provider 
About Prostate Cancer and Screening, and About Vitamin D Screening and Taking 
Vitamin D Supplement (N=194) 
                                                                                                                N                   % 
After I took the Knowledge Test, I would rate my level of confidence for talking to my 
doctor about prostate cancer and screening for prostate cancer (e.g., Digital Rectal 
Examination, PSA). (N=194) 
1 0% - Not Confident                1                .5 
3 40%                11              5.7 
4 60%                      29            14.9 
5 80%                65            33.5 
6 100% - Very Confident             88            45.4 
Mean=5.17, SD=.942, min=1, max=6 
After I took the Knowledge Test. I would rate my level of confidence for talking to my 
doctor about screening for Vitamin D level and taking a Vitamin D supplement. 
(N=194) 
2 20%                  4              2.1 
3 40%                  8              4.1 
4 60%                33            17.0 
5 80%                59            30.4 
6 100% - Very Confident             88            45.4 
Missing                       2              1.0 




Results for Research Question #8 
 
After taking the Prostate Cancer Knowledge Test (PC-S-KT-39)—with all TRUE 
answers—in order to determine if taking the PC-S-KT-39 may serve as a potential online 
intervention that may significantly increase knowledge and self-efficacy levels, how do 







KT-39 for (1) what they knew about prostate cancer and screening, (2) what they knew 
about Vitamin D screening and taking a Vitamin D, (3) confidence to talk to a medical 
provider about prostate cancer and screening, and (4) confidence to talk to a medical 
provider about Vitamin D screening and taking a Vitamin D supplement—and was there 
a significant difference in mean scores from before to after taking the PC-S-KT-39?  
The four paired t-tests conducted indicated a significant increase from pre-
knowledge test to post-knowledge test (with four comparisons, or Bonferroni 
Adjustment Significance, .05/4, p=.013), suggesting the knowledge test did serve as an 
effective online brief intervention, as follows: 
• First, for self-rating of knowledge of prostate cancer and screening, the 
pre-knowledge test mean was 3.50 (N=194, SD=1.393) versus the post-
knowledge test mean of 4.34 (N=194, SD=1.100), as a difference that was 
statistically significant (t=-8.475, df=193, p=.000). 
• Second for self-efficacy for talking to doctor about prostate cancer and 
screening, the pre-knowledge test mean was 4.19 (N=194, SD=1.544) versus 
the post-knowledge test mean of 5.17 (N=194, SD=.942), as a difference that 
was statistically significant (t=-9.098, df=193, p=.000). 
• Third, for self-rating of knowledge of Vitamin D screening and 
supplementation, the pre-knowledge test mean was 3.60 (N=194, SD=1.535) 
versus the post-knowledge test mean of 4.67 (N=194, SD=1.070), as a 
difference that was statistically significant (t=-9.748, df=193, p=.000). 
• Fourth for self-efficacy for talking about Vitamin D screening and 







versus the post-knowledge test mean of 5.14 (N=192, SD=.985), as a 
difference that was statistically significant (t=-9.384, df=193, p=.000). 
See Table 8.  
 
Table 8. Changes From Before to After Taking the Knowledge Test: Paired t-Tests 
                                                            Before Versus After                   t-tests 
                                                         Taking Knowledge Test 
 
                                                           N         M          SD                 t          df      P 
Self-Rating of Knowledge of               -8.475   193   .000*** 
Prostate Cancer & Screening  
Before Knowledge Test                 194      3.50     1.393 
After Knowledge Test                    194      4.34     1.100 
 
Self-Efficacy for Talking to                                                           -9.098   193   .000*** 
Doctor about Prostate Cancer 
& Screening  
Before Knowledge Test          194   4.19     1.544 
After Knowledge Test                    194    5.17       .942 
 
Self-Rating of Knowledge of                                                          -9.748   193   .000*** 
Vitamin D Screening & 
Supplementation  
Before Knowledge Test          194      3.60     1.535 
After Knowledge Test                        194      4.67     1.070 
 
Self-Efficacy for Talking to                                                           -9.384   19     .000*** 
Doctor about Vitamin D 
Screening & Supplementation 
Before Knowledge Test          192      4.05     1.627 
After Knowledge Test                        192      5.14       .985 
*p<.05, **p<.01, ***p<.001 Bonferroni Adjustment Significance (.05/4, p=.013)  
Note: All p values above .013 are considered non-significant, and only those below 
.013 are considered statistically significant 
 
Results for Research Question #9 
Are there any significant relationships between selected demographics and 1-








Talk to a Medical Provider about prostate cancer and prostate cancer (PC) screening, 
after they took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—as 
item #4 in survey Part VII, i.e., POST PC Self-efficacy), and 2-study outcome 
variable/dependent variable #2—a higher self-rating for Self-Efficacy to Talk to a 
Medical Provider about Vitamin D (VD) screening and supplementation, after they took 
the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—as item #8 in survey 
Part VII, i.e., POST VD Self-efficacy)? 
Independent t-tests comparing groups on outcome variable #1. First, 
independent t-tests were conducted to compare dichotomous groups (e.g., if married, if 
employed, etc.) on 1-study outcome variable/dependent variable #1—a higher self-
rating for Self-Efficacy to Talk to a Medical Provider about prostate cancer and 
prostate cancer (PC) screening, after they took the Prostate Cancer and Screening 
Knowledge Test (PC-S-KT-39—as item #4 in survey Part VII, i.e., POST PC Self-
efficacy. Only one comparison was significant, as follows: Those who responded “yes,” 
that they had prior prostate cancer screening with a Digital Rectal Exam (DRE) had 
a mean self-efficacy for talking to their provider about prostate cancer and 
screening (mean=5.43, SD=.790) that was significantly higher than the mean self-
efficacy of those who never had a DRE (t=12.782, df=192, p=.003; < Bonferroni 
Adjustment Significance (0.05/10, p=0.005). 









Table 9. Independent t-Tests Comparing Dichotomous Groups on Self Efficacy  
for Talking to Provider About Prostate Cancer and Screening  
                                                      Self-Efficacy 
                                              For Talking to Provider 
                                               About Prostate Cancer                              t-tests 
                                                 N               M                  SD            t            df          p 
If currently married                                                                       .598       192       .571 
0 no                                           46              5.24             .874 
1 yes                                         148             5.15           1.017 
If currently lives in US                                                                 -1.512       192       .132 
0 no                                            42              4.98             .975   
1 yes                                         152              5.22             .929  
If full- or part-time employed                                                       -1.233       192       .219  
0 no                                            27               4.96            .898 
1 yes                                         167               5.20            .948  
If had DRE                                                                                   -2.782      192     .003*** 
0 no     129              5.04            .987 
1 yes       65          5.43     .790 
If had PSA                                                                                    -1.904      192     .058 
0 no     137          5.09     .989 
1 yes       57          5.37     .794 
If tested for Vitamin D                                                                   -.954      192     .341  
0 no     139          5.13     .977 
1 yes       55          5.27     .849 
If told Vitamin D low                                                                    -1.192      192     .235 
0 no     167           5.14     .963 
1 yes             27           5.37     .792 
If recommended take D supplement                                            -1.458      192     .147 
0 no     164           5.13     .973 
1 yes       30           5.40     .724 
If taken Vitamin D supplement             -.378      192     .706 
0 no     120           5.15     .958 
1 yes       74           5.20     .921 
If family member had prostate cancer           -1.843      192     .067 
0 no             170           5.12     .956 




*p<0.05, **p<0.01, ***p<0.001; Bonferroni Adjustment Significance (0.05/10, p=0.005)  
Note: All p values above 0.005 are considered non-significant, and only those below 0.005 are 










Independent t-tests comparing groups on outcome variable #2. Second, 
independent t-tests were conducted to compare dichotomous groups (e.g., if married, if 
employed, etc.) on 2-study outcome variable/dependent variable #2—a higher self-
rating for Self-Efficacy to Talk to a Medical Provider about Vitamin D (VD) 
screening and supplementation, after they took the Prostate Cancer and Screening 
Knowledge Test (PC-S-KT-39—as item #8 in survey Part VII, i.e., POST VD Self-
efficacy. None of the 10 comparisons were significant (Bonferroni Adjustment 
Significance (0.05/10, p=0.005). 
See Table 10. 
 
Table 10. Independent t-Tests Comparing Dichotomous Groups on Self Efficacy  
for Talking to Provider About Vitamin D Screening and Supplementation 
                                                           Self-Efficacy 
                                                For Talking to Provider 
                                               About Vitamin D Screening                   t-tests 
                                                 N            M                     SD           t             df         p 
If currently married                                                                    1.295       190       .197 
0 no                                           46            5.30               .866 
1 yes                                        146            5.09             1.017 
If currently lives in US                                                                -1.211       190       .227 
0 no                                           41            4.98                .908   
1 yes                                        151            5.19              1.003  
If full- or part-time employed                                                        -.112       190      .911  
 0 no                                           25            5.12                .833 
1 yes                                         167            5.14              1.008  
If had DRE                                                                                    -2.167      190      .031* 
0 no     127        5.03       .999 
1 yes       65        5.35       .926 
If had PSA                                                                                     -1.936 190 .054 
0 no     135        5.05     1.010 
1 yes       57        5.35       .896 
If tested for Vitamin D                                                                    -.717 190 .474  
0 no     138        5.11     1.030 
1 yes      54        5.22       .849 
If told Vitamin D low                                                                    -1.798 190 .074 
0 no     166        5.09     1.008 








If recommended take D supplement                                             -1.168 190 .244 
0 no     162        5.10     1.019 
1 yes       30        5.33       .758 
If taken Vitamin D supplement              -.412 190 .681 
0 no     119        5.11     1.035 
1 yes       73        5.18       .903 
If family member had prostate cancer           -1.925 190 .056 
0 no              168        5.09       .978 
1 yes      24        5.50       .978 
  
 
*p<0.05, **p<0.01, ***p<0.001; Bonferroni Adjustment Significance (0.05/10, p=0.005).  
Note: All p values above 0.005 are considered non-significant, and only those below 0.005 are 
considered statistically significant. 
 
 
Pearson correlations and study outcome variables #1 and #2. Third, Pearson 
correlations explored relationship between selected variables (i.e., age, household income 
etc.) and the two study outcome variables. There were 13 independent variables, so the 
Bonferroni adjustment significance (.05/13=0.004) involved the higher significance level 
of .004. 
1-The higher the self-rating for Self-Efficacy to Talk to a Medical Provider 
about prostate cancer and prostate cancer (PC) screening, after they took the Prostate 
Cancer and Screening Knowledge Test (PC-S-KT-39), then: 
• The higher their Prostate Cancer and Screening Knowledge Test (PC-S-KT-
39) Score (r=.226, p=.002; < Bonferroni Adjustment Significance of .004) 
• The higher the Amount of Change in Prostate Cancer Self-Efficacy 
(confidence to talk to a medical provider about prostate cancer and 
screening) from Pre-Knowledge Test to Post-Knowledge Test (r=.145, p=.000; 
< Bonferroni  
Adjustment Significance of .004) 
2-And, the higher self-rating for Self-Efficacy to Talk to a Medical Provider 
about Vitamin D (VD) screening and supplementation, then: 
• The higher their Prostate Cancer and Screening Knowledge Test (PC-S-KT-







• The higher the Amount of Change in Prostate Cancer Self-Efficacy 
(confidence to talk to a medical provider about prostate cancer and 
screening) from Pre-Knowledge Test to Post-Knowledge Test (r=.234, p=.001; 
< Bonferroni Adjustment Significance of .004) 
• The higher the Amount of Change in Vitamin D Self-Efficacy from Pre-
Knowledge Test to Post-Knowledge Test (r=.286, p=.000; < Bonferroni 
Adjustment Significance of .004) 
 
See Table 11. 
Table 11. Correlations Between Selected Variables and the Two Study Outcome 
Variables of Prostate Cancer Self-Efficacy and Vitamin D Self-Efficacy— 
Post-Knowledge Test 
                                                                                     Post Knowledge Test: 
                                                                      Prostate Cancer                  Vitamin D                                                                                   
                                                                         Self-Efficacy                   Self-Efficacy  
13 Selected Variables                                         R                 P          R               P           
Age   .095 .185   .095 .189 
Skin Color   .029 .689 -.005 .941 
Annual Household Income   .078 .309   .000 .996 
Education   .064 .373 -.048 .509 
Self-Rating of Health Status -.002 .974 -.050 .492 
Self-Rating of Weight Status   .017 .818 -.006 .938 
Rating of Quality of Care   .134 .064   .056 .444 
BMI (Body Mass Index)   .207 .004**   .154 .033* 
Prostate Cancer and Screening Knowledge     
   Test (PC-S-KT-39) Score 
  .226 .002**   .290 .000*** 
#Amount of Change in Prostate Cancer   
   Knowledge from Pre-Knowledge Test to  
   Post-Knowledge Test 
  .132 .066   .158 .029* 
#Amount of Change in Vitamin D  
   Knowledge from Pre-Knowledge Test  
   to Post-Knowledge Test 
  .153 .033*   .193 .007** 
#Amount of Change in Prostate Cancer   
   Self-Efficacy from Pre-Knowledge  
   Test to Post-Knowledge Test 
  .267 .000***   .234 .001** 
#Amount of Change in Vitamin D Self-    
   Efficacy from Pre-Knowledge Test to  
   Post-Knowledge Test 
  .145 .045*   .286 .000*** 
*p<.05, **p<.01, ***p<.001 Bonferroni Adjustment Significance (.05/13=.004) 
#NOTE: These 4 variables were change scores, capturing the amount of change from  
pre-knowledge test to post-knowledge test. See Appendix H, About the Option of Using 








Results of Research Question #10 
 
What are the significant predictors of 1-study outcome variable/dependent 
variable #1—a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
prostate cancer and prostate cancer (PC) screening, after they took the Prostate Cancer 
and Screening Knowledge Test (PC-S-KT-39—as item #4 in survey Part VII, i.e., POST 
PC Self-efficacy), and 2-study outcome variable/dependent variable #2—a higher self-
rating for Self-Efficacy to Talk to a Medical Provider about Vitamin D (VD) screening 
and supplementation, after they took the Prostate Cancer and Screening Knowledge Test 
(PC-S-KT-39—as item #8 in survey Part VII, i.e., POST VD Self-efficacy)? 
Backward stepwise regression. Significant predicators were sought for the two 
study outcome variables. 
1. a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
prostate cancer and prostate cancer (PC) screening, after they took the 
Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—as item 
#4 in survey Part VII, i.e., POST PC Self-efficacy). 
2. study outcome variable/dependent variable #2—a higher self-rating for Self-
Efficacy to Talk to a Medical Provider about Vitamin D (VD) screening 
and supplementation, after they took the Prostate Cancer and Screening 
Knowledge Test (PC-S-KT-39—as item #8 in survey Part VII, i.e., POST 
VD Self-efficacy). 
The independent variables. Each backward stepwise regression proceeded, 
given the following 19 independent variables as potential predictors: age; skin color; 







employed; if had a digital rectal examination (DRE); if had a PSA test; if screened for 
Vitamin D; history of low Vitamin D test results; ever advised to take Vitamin D 
supplement; ever took Vitamin D supplement; if family member had prostate cancer; 
rating of health status; rating of weight status; rating of quality of care received; Body 
Mass Index (BMI); and the amount of change in prostate cancer knowledge from pre- to 
post-knowledge test.  
Backward stepwise regression. This analysis began with the full group of  
19 predictor variables or independent variables entered into the regression model. Next, 
the backward stepwise method involved the least significant variable (one with the largest 
p value) being removed when the model was refitted. Then, a new model is built in the 
absence of that one independent variable and the evaluation process is repeated again—
removing the least significant variable. This removal process and equation-reconstruction 
process was continued until only significant independent variables (p<.05) remained—as 
the final model reported for the backward stepwise regression.  
The rationale for using this approach comes from the work of Mantel (1970), who 
explained that backward selection serves to reduce the degrees of freedom, has joint 
predictor capability, and removes noise caused by including unrelated variables or 
variables that may be highly correlated with each other.  
First, when using backward stepwise regression, it was found that the significant 
predictors of 1-a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
prostate cancer and prostate cancer screening, after they took the Prostate Cancer and 








• Had History of Screening with a Digital Rectal Exam (DRE) (b=.435, SEB= 
-.225, p=.003) 
• Higher Rating of Quality of Care (b=-.160, SEB=-.152, p=.041) 
• Greater Amount of Change in Prostate Cancer Knowledge from Pre-
Knowledge Test to Post-Knowledge Test (b=.116, SEB=.181, p=.016) 
For this model, the R 2=.095, and the Adj R 2=.079, meaning 7.9% of the 
variance was explained by this model. 
See Table 12. 
 
Table 12. Backward Stepwise Regression Predicting Study Outcome Variable #1 of 
Higher Post-Knowledge Test Prostate Cancer Self-Efficacy  
Variables                                                                      B             SEB                   P                                       
Had History of Screening with DRE                            .435          .225                  .003** 
Higher Rating of Quality of Care                                 .160          .152                  .041* 
#Greater Amount of Change in  
   Prostate Cancer Knowledge from  
   Pre-Knowledge Test to Post-Knowledge Test   .116          .181                  .016* 
 
*p<.05, **p<.01, ***p<.001, F=5.846 (p=.012; R2=(0.095), Adjusted R2=(0.079)—
meaning 7.9% of variance was explained by this model. F=5.846 
#NOTE: This was based on a change score, capturing the amount of change from pre-
knowledge test to post-knowledge test. See Appendix H, About the Option of Using 
Change Scores, and see explanation of their calculation and scoring.  
 
Second, when using backward stepwise regression, it was found that the 
significant predictors of 2-study outcome variable/dependent variable #2—a higher self-
rating for Self-Efficacy to Talk to a Medical Provider about Vitamin D (VD) 
screening and supplementation, after they took the Prostate Cancer and Screening 








• Had History of Being Told Low Vitamin D (b=.418, SEB=-.159, p=.038) 
• Greater Amount of Change in Vitamin D Knowledge from Pre-Knowledge 
Test to Post-Knowledge Test (b=.140, SEB=.231, p=.003) 
For this model, the R 2=.065, and the Adj R 2=.053, meaning 5.3% of the 
variance was explained by this model. 
See Table 13. 
 
Table 13. Backward Stepwise Regression Predicting Study Outcome Variable # 2 of 
Higher Post-Knowledge Test Vitamin D Self-Efficacy  
Variables                                                               B             SEB                   P                                       
Had History of Being Told Low Vitamin D   .418          .159                  .038* 
#Greater Amount of Change in  
   Vitamin D Knowledge from  
   Pre-Knowledge Test to Post-Knowledge Test .140           .231                  .003** 
 
*p<.05, **p<.01, ***p<.001, F=5.771 (p=.004; R2=(0.065), Adjusted R2=(0.053)—
meaning 5.3 % of variance was explained by this model. F=5.771 
#NOTE: This was based on a change score, capturing the amount of change from pre-
knowledge test to post-knowledge test. See Appendix H, About the Option of Using 




This chapter presented the results of data analysis by research question, including 
the use of tables to present summary data. Chapter V next discusses the results while also 












SUMMARY, DISCUSSION, IMPLICATIONS, RECOMMENDATIONS,  
AND CONCLUSION 
 
This chapter provides a summary of the dissertation research, as well as a 
discussion of the results, along with implications. This chapter ends with a discussion of 
the limitations of this research and offer a final conclusion.   
Summary of the Review of Literature 
The American Cancer Society’s (ACS, 2018) age‐adjusted incidence rates of 
prostate cancer among Black men remain 75% higher than those among non‐Hispanic 
White men, and mortality rates among Black men are more than double (ACS, 2018). 
Strikingly, “Black men in America have the highest death rates from prostate cancer” in 
the world (Ogunsanya et al., 2017, p. 1009). Yet, this is a global problem. Wang et al. 
(2015) reported that prostate cancer was the “second most frequently diagnosed cancer 
among men worldwide” and of all racial/ethnic groups (p. 733). Cook et al. (2015) 
indicated that “it is not just blacks in the U.S. who have a relative high prostate cancer 
incidence; blacks in Brazil are 1.7-fold (12), and in the UK are 3-fold (13) more likely 
than whites to be diagnosed with prostate cancer” (p. 5). On the other hand, Taitt (2018) 







highest for African Americans,” even though “the data is inconclusive regarding PCa 
rates in native African men, Black men residing in other countries, and men in Asia, 
Europe, and the Americas” (p. 1807). 
The ACS (2016) estimated that 1 in 6 Black men will be diagnosed with “prostate 
cancer in his lifetime, compared to 1 in 8” White men (p. 15). Richards et al. (2017) 
emphasized how African American men “not only present with PCa at a younger age, but 
they also have 50% higher incidence and twice the mortality compared with European 
American (EA) men” (p. 1). 
Ashorobi et al. (2017) emphasized how African American men not only have the 
highest incidence and mortality from prostate cancer in the United States, but also have 
held this status as a persistent trend for more than 3 decades. Moreover, it was found that 
men from “low socioeconomic backgrounds are at a higher risk” for having an increased 
prostate cancer burden, including a lower utilization of prostate cancer screening services 
(p. 82). They concluded that, in order to “address this health disparity among medically 
underserved racial and ethnic groups, there must be increased education and awareness” 
on the topic of prostate cancer (p. 82). 
Prostate cancer screening with the use of the prostate-specific antigen (PSA) test 
“is common” (Schenk et al., 2014, p. 2), while the digital rectal examination (DRE) is 
also commonly performed by physicians (Ashorobi et al., 2017, p. 82). The ACS has 
recommended that men start screening for prostate cancer at age 45, “with the interval for 
further screening based on initial and subsequent PSA levels” (Smith et al., 2018, p. 297). 
Baptista et al. (2018) indicated that “screening for prostate cancer is a 







screened should be an individual one based on conversations with the physician about the 
benefits and adverse effects of screening, in order to help men make a decision based on 
personal values and preferences” (p. 4). However, the majority of experts justify “a 
shared decision-making process involving doctor and patient, using validated decision 
aids” (p. 4).  
Further, it was reported that “many guidelines issued by medical organizations 
such as the European Association of Urology, the American Cancer Society, and the 
American College of Physicians support a shared decision-making process for prostate 
cancer screening”—including the patient and their medical provider, and with the use of 
decision aids to help ensure the quality of the decision, instead of relying solely on 
individualized decision making (Baptista et al., 2018, p. 4). Further, “the American 
Cancer Society endorses prostate cancer screening annually,” but only after the “benefits 
and limitations of prostate cancer screening have been outlined to patients” through such 
discussion with medical providers (Ogunsanya et al., 2017, p. 1010).  
According to Ogunsanya et al. (2017), for “effective decision making to take 
place, it is also important for patients to understand the risks and benefits associated with 
the decision (prostate cancer screening) to be made” (p. 1010). Consider how screening 
may also lead to treatment; while “prostate cancer treatment may be lifesaving, studies 
suggest that this benefit is not applicable in all cases” (Wang et al., 2015, p. 733). For 
example, a “large randomized study revealed that in comparison with watchful waiting, 
15 men must be treated with radical prostatectomy to save 1 life” (p. 733).  
Mahal et al. (2014) expressed doubt as to whether “African Americans (AAs) 







White patients (p. 386). For “patients with intermediate to high-risk” prostate cancer, 
“definitive treatments have been shown to decrease prostate cancer-specific mortality” 
and “improve overall survival” (p. 386). African American men with “intermediate- to 
high-risk” prostate cancer “are less likely” to receive treatment with “curative intent” 
than are White men—such that the “disparity is worse in high-risk disease and is not 
improving over time” (p. 386). Given racial disparities in the treatment of prostate cancer, 
African American men “have a significantly higher risk of dying from” prostate cancer 
than White men (p. 386).   
Hoffman (2011) urged that “experts recommend that men receive support in 
making informed decisions,” rather than the usual way where “PSA testing is often 
performed without discussion of the benefits and harms of screening” (p. 2016). It is 
crucial for “adult males to understand the impact that PSA testing has in order to treat 
prostate cancer at an early stage,” which would “prevent further harm to their bodies and 
improve their quality of life” (p. 19). 
Batai et al. (2017) found that “African American men have higher incidence rates 
of aggressive prostate cancer, where high levels of calcium and serum Vitamin D 
deficient levels play a role in the racial differences in incidence” (p. 1). Also, “AA men 
with higher Vitamin D levels see a reduced risk in high-grade disease, while results in 
Afro-Caribbean men residing in the Caribbean indicate Vitamin D insufficiency may 
contribute to increased prostate cancer risk” (p. 2). In addition, “molecular studies 
suggest deficiencies in Vitamin D over time may lead to progression from pre-clinical to 
clinically aggressive forms of prostate cancer” (p. 2). Batai et al. established that in 







aggressive cases had mean levels of serum 25(OH)D below deficient levels, as defined by 
the Institute of Medicine (IOM)” (p .6).  
Lappe (2011) indicated that an “impressive body of evidence suggests that 
Vitamin D decreases the risk of cancer,” while it has “long been recognized that there is 
an inverse association between sunlight exposure and malignancy” (p. 63). The study 
concluded that there is even “stronger evidence for the anticancer effect of Vitamin D”—
as provided by “numerous cohort and case–control studies that show an inverse 
association between serum 25(OH)D and cancer incidence/mortality” (p. 63). Lappe 
indicated how it is “very difficult to achieve and maintain optimal levels of serum 
25(OH)D by diet alone since few foods are natural sources of Vitamin D and fortified 
foods contain limited amounts” (p. 61). Thus, “Vitamin D dietary supplements, which are 
safe and inexpensive, are becoming widely available” (p. 61). The IOM had, during that 
era, “raised the tolerable upper intake level of Vitamin D from 2000 IU/day to 4000 
IU/day” (p. 62). 
Obana and O’Lawrence (2015) observed that communication “between men and 
their primary care physicians was critical in improving their awareness of PSA tests, their 
overall health, and ensuring that they received the proper screening” (p. 20).  
For this study, such considerations went beyond the importance of patient-
provider communication and discussion about screening for prostate cancer to also 









Summary of the Statement of the Problem 
The problem that this study addressed was the need to educate Black men 
globally about prostate cancer and screening—and also the potential value in screening 
for Vitamin D level—toward the goal of increasing their level of knowledge and self-
efficacy to engage in discussions about screening with their medical providers.  
Summary of the Purpose of the Study 
The purpose of the study was to identify significant predictors of the two study 
outcome variables/dependent variables, as follows: (a) study outcome variable #1—a 
higher self-rating for Self-Efficacy to Talk to a Medical Provider about prostate 
cancer and prostate cancer (PC) screening, after they took a new Prostate Cancer and 
Screening Knowledge Test (PC-S-KT-39), as a brief online intervention; and (b) study 
outcome variable/dependent variable #2—a higher self-rating for Self-Efficacy to 
Talk to a Medical Provider about Vitamin D (VD) screening and supplementation, 
also after they took the new Prostate Cancer and Screening Knowledge Test (PC-S-KT-
39). 
Summary of Research Questions, Survey Parts, and Data Analysis Plan 
Given a global online sample of Black men (n=194) who responded to a social 
media campaign (i.e., “Go to https://tinyurl.com/Black-Men-Age-40-PLUS to take the 
Prostate Cancer & Screening—& Vitamin D Survey for Black Men age 40 and above for 
a chance to win 1 of 3 $100 Amazon gift cards”) and completed the study, the following 







1-What are the men’s demographic and background characteristics (e.g., age, skin color, 
partner status, born in the United States—yes/no, living in United States or other country, 
annual household income, level of education, employment status)? 
Part I: Basic Demographics (BD-9) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
2-How do the men rate their health status, and what is their Body Mass Index, rating of 
their weight status, and rating of the overall quality of care received for their health? 
Part II: Brief Health Survey (BHS-5) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
3-What is the men’s prevalence of a diagnosis of prostate cancer, being told they were at 
risk for prostate cancer, history of screening for prostate cancer by a Digital Rectal 
Examination (DRE) or Prostate-Specific Antigen (PSA) Test, as well as the prevalence in 
their family of prostate cancer diagnoses and deaths from prostate cancer? 
Part III: Prostate Cancer Scale (PCS-6) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
4-What is the men’s history of having a Vitamin D screening, being told they were 
Vitamin D-deficient, being advised to take a Vitamin D supplement, and taking a 
Vitamin D supplement? 
Part IV: Vitamin D Scale (VDS-4) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
5- What is the men’s level of knowledge for prostate cancer and screening and for 
Vitamin D and taking a Vitamin D supplement? 
Part V: Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
6-After the men are told that the researchers created the Prostate Cancer Knowledge Test 
(PC-S-KT-39)—with all TRUE answers—(i.e., as a way to prepare African American 
men to talk with their medical providers about taking important screening tests that may 
help protect them from dying from prostate cancer at a rate higher than for any other men 
in the entire world), do the men recommend the PC-S-KT-39 to other African American 
men as an online intervention (i.e., diffusion of the innovation)? 
 
Part VI: Diffusion of the Innovation of the Prostate Cancer Knowledge Test  
(DOI-PCKT-1) 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 








7-After the men are told that the researchers created the Prostate Cancer Knowledge Test 
(PC-S-KT-39)—with all TRUE answers—(i.e., as a way to prepare African American 
men to talk with their medical providers about taking important screening tests that may 
help protect them from dying from prostate cancer at a rate higher than for any other men 
in the entire world), how do the men rate their self-efficacy—or item #4 after rating for 
confidence to talk to a medical provider about prostate cancer and screening, and item 
#8 after rating confidence to talk to a medical provider about Vitamin D screening and 
taking a Vitamin D supplement? 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
 
Part VII: Pre- and Post-Knowledge Test—Ratings for Knowledge and Self-Efficacy 
to Talk to a Medical Provider (PRE-A-POST-KT-RF-K-SETMP-8), specifically, the 
mean for the: 
After Took PC-S-KT-39 Global Self-Efficacy Subscale #4 
Data Analysis Plan: Descriptive statistics, including means, standard deviations, 
frequencies, and percentages 
NOTE: item #4 and item #8 after ratings are the two study outcome 
variables/dependent variables 
 
8-After taking the Prostate Cancer Knowledge Test (PC-S-KT-39)—with all TRUE 
answers—in order to determine if taking the PC-S-KT-39 may serve as a potential online 
intervention that may significantly increase knowledge and self-efficacy levels, how do 
the men rate themselves for before taking the PC-S-KT-39 versus after taking the 
PC-S-KT-39 for (1) what they knew about prostate cancer and screening, (2) what they 
knew about Vitamin D screening and taking a Vitamin D, (3) confidence to talk to a 
medical provider about prostate cancer and screening, and (4) confidence to talk to a 
medical provider about Vitamin D screening and taking a Vitamin D supplement—and 
was there a significant difference in mean scores from before to after taking the  
PC-S-KT-39?  
Data Analysis Plan: Paired t-tests (before v. after ratings) 
 
9-Are there any significant relationships between selected demographics and 1-study 
outcome variable/dependent variable #1—a higher self-rating for Self-Efficacy to Talk 
to a Medical Provider about prostate cancer and prostate cancer (PC) screening, 
after they took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—
as item #4 in survey Part VII, i.e., POST PC Self-efficacy), and 2-study outcome 
variable/dependent variable #2—a higher self-rating for Self-Efficacy to Talk to a 
Medical Provider about Vitamin D (VD) screening and supplementation, after they 
took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39—as item #8 
in survey Part VII, i.e., POST VD Self-efficacy)? 










10-What are the significant predictors of 1-study outcome variable/dependent variable 
#1—a higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
prostate cancer and prostate cancer (PC) screening, after they took the Prostate 
Cancer and Screening Knowledge Test (PC-S-KT-39—as item #4 in survey Part 
VII, i.e., POST PC Self-efficacy), and 2-study outcome variable/dependent variable #2—
a higher self-rating for Self-Efficacy to Talk to a Medical Provider about Vitamin D 
(VD) screening and supplementation, after they took the Prostate Cancer and 
Screening Knowledge Test (PC-S-KT-39—as item #8 in survey Part VII, i.e., POST 
VD Self-efficacy)? 
Data Analysis Plan: Backward stepwise regression 
 
Summary of the Research Sample and Procedures 
The cross-sectional study used an online survey. Qualtrics provided the platform 
and secure technology to support the online survey—as the only platform deemed 
sufficiently secure for research use by Teachers College, Columbia University. First, 
before any data collection began, this study received approval from the Teachers College, 
Columbia University Institutional Review Board (IRB) as Protocol #19-134, with an 
“exempt status.” 
This study recruited 194 Black Men between the ages of 40 and 76 who were 
potentially at risk for prostate cancer. Participants were recruited to this study via a social 
media campaign, globally, wherein the main study recruitment message, shown below, 
was disseminated via Facebook, emails, text messages, and twitter:  
Go to https://tinyurl.com/Black-Men-Age-40-PLUS to take the Prostate Cancer & 
Screening—& Vitamin D Survey for Black Men age 40 & above for a chance to 
win 1 of 3 $100 Amazon gift cards. 
 
In addition, flyers were distributed in venues frequented by African American 
men, including barber shops and churches, featuring the same message shown above. In 
addition, members of my extended social network were asked to help recruit Black males 







building, (b) by distributing the flyer to their clientele (many copies were provided to that 
effect), or (c) by sending an email out on any listserv that they may have had (not all 
entities had listservs). This flyer outlined the tasks involved in the study, including: 
taking a 20-minute online survey. The flyer may have motivated potential participants to 
join the study by having photographs of Black men and inviting interested parties to take 
part in the study for a 3 in 250 chance of winning one of three $100 Amazon gift cards by 
providing their email addresses. Finally, the Principal Investigator also texted an invite to 
potentially interested participants. 
After a period of 2 weeks, 390 participants had completed the Informed Consent 
and proceeded to start the survey. However, data analysis could only proceed with 194 
who completed the survey to the point of providing data for at least one of this study’s 
two outcome variables. Another 132 were eligible for study participation but did not 
complete the survey to the point of providing data for a study outcome variable. When 
comparing the group of survey completers (n=194) to the group of survey non-completers 
(n=132), using independent t-tests, there were no significant differences between the 
groups on dichotomous variables (i.e., if married, if lives in U.S., if employed), and not 
for continuous variables (i.e., age, skin tone, annual household income, level of 
education). 
Although the intent was to collect up to 250 responses, only 194 respondents met 
the additional study inclusion criteria of providing sufficient data as survey completers on 
at least one of the study’s outcome variables. 
Once the survey was completed (N=194), participants were routed to a “thank 







email address, thereby formally entering the lottery for a 1 in 3 chance to win one of three 
$100 gift cards for use on www.Amazon.com. As a final step, the webmaster of the 
RGDH, Dr. Rupananda Misra, had responsibility for the program to select the three 
winners. The winners received an email with the bar-coded gift certificate information. 
The Principal Investigator did not have access to the email addresses. Also, of note, study 
participants were made aware that their study information was not linked to their email 
addresses, thereby ensuring their confidentiality.   
Summary of the Research Instrumentation 
The study measure is entitled “The Prostate Cancer & Screening and Vitamin D 
Survey for African American Men.” This survey has 7 parts, as follows: 
• Part I: Basic Demographics (BD-9) 
• Part II: Brief Health Survey (BHS-5) 
• Part III: Prostate Cancer Scale (PCS-6) 
• Part IV: Vitamin D Scale (VDS-4) 
• Part V: Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) 
• Part VI: Diffusion of the Innovation of the Prostate Cancer Knowledge 
Test (DOI-PCKT-1) 
• Part VII: Pre- and Post-Knowledge Test—Ratings for Knowledge and 









Summary of the Data Management and Data Analysis Plan 
The data were transferred from the online Qualtrics platform to the latest version 
of SPSS: 25.0. Data analysis proceeded using SPSS 25.0. The data analysis plan included 
descriptive statistics (e.g. means, standard deviations, frequencies, and percentages), 
inferential statistics (Pearson correlation, independent t-tests), paired t-tests, and 
backward stepwise regression.  
Summary of Results and Data Analysis 
The study’s global convenience sample of Black males (N=194) was mostly 
married (75.85, N=147) and had a mean age of 49.53 years (min 40, max 76, SD=8.73). 
The sample was well educated with 24.7% (n=48) having an Associate Degree, 20.6% 
(n=40) having a Bachelor’s Degree, 18% (n=35) having Master’s Degree, and 5.2% 
(n=10) having a Doctoral Degree. The mean annual income was 4.21. for category 4 of 
$40,000-$49,999 (min 1, max 9, SD=1.64). Most of the participants were employed 
(n=188, 96.9%) and born in the United States (n=152, 78.4%).  
As a reflection of being a global sample, if not a sample of men born in Ghana 
(77.3%, n=194) who are now dispersed across the globe, over two-thirds (77.3%) 
were born in Ghana, including 78.4% (n=152) currently living in the United States and 
5.5% (n=30) in Ghana—followed by 5.1 (n=10) currently living in other countries.  
The mean health status was 4.56 (Min=1-very poor, Max=6-excellent, 
SD=.869), or between good and very good. The mean for Body Mass Index (BMI) 
was 23.31 for normal weight (Min=5.94-underweight, Max=44.71, SD=7.51).  







(Min=1-underweight, Max=4-obese, SD=.450). For the quality of medical care they 
received, the sample’s mean score was 4.41, SD=.857, Min=2, Max=6) for good. 
The prevalence of a diagnosis of prostate cancer in this convenience sample was 
5.2% (n=10), while only 8.8% (n=17) have been told they are at risk for prostate cancer.  
Regarding their Vitamin D level, 60.85% (n=118) had never had it ordered by a 
medical provider for laboratory testing, 82.5% (n=160) were never told it was too low, 
and 83.5% (n=162) had never been advised by their doctor or medical professional to 
take a daily Vitamin D supplement. 
With regard to the men’s level of knowledge for prostate cancer and screening, 
and for Vitamin D and taking a Vitamin D supplement, a new survey tool was created: 
i.e., the Prostate Cancer Knowledge Test (PC-S-KT-39)—with all TRUE answers—as an 
online intervention designed to prepare Black men to talk with their medical providers 
about taking important screening tests for prostate cancer and their Vitamin D level.  
First, as a measure of men’s level of knowledge for prostate cancer and screening, 
and for Vitamin D and taking a Vitamin D supplement, the mean for PC knowledge 
score was 25.84 (Min=0, Max=37, SD=9.50), or moderately high.  
Second, as an innovation for preparing Black men to engage in discussions with 
their medical providers about screening for prostate cancer and their levels of Vitamin D, 
90.2% (n=175) indicated “yes” they would recommend the PC-S-KT-39 to other Black 
men as an online intervention. 
Data supported viewing taking the PC-S-KT-39 as a brief intervention, as four 
paired t-tests indicated a significant increase from pre-knowledge test to post-knowledge 







prostate cancer and screening (t=-8.475, df=193, p=.000), 2-self-efficacy for talking 
to doctor about prostate cancer and screening (t=-9.098, df=193, p=.000),  
3-knowledge of Vitamin D screening and supplementation (t=-9.748, df=193, 
p=.000), and 4-self-efficacy for talking about Vitamin D screening and 
supplementation (t=-9.384, df=193, p=.000). 
Independent t-tests comparing groups on outcome variable #1 showed only one 
comparison was significant, with those who had prior prostate cancer screening with a 
Digital Rectal Exam (DRE) had a significantly higher mean self-efficacy for talking to 
their provider about prostate cancer and screening (mean=5.43, SD=.790) that was 
significantly higher than the mean self-efficacy of those who never had a DRE (t=12.782, 
df=192, p=.003; < Bonferroni Adjustment Significance (0.05/10, p=0.005). 
Pearson correlations demonstrated, as follows: 1-the higher the self-rating for 
Self-Efficacy to Talk to a Medical Provider about prostate cancer and prostate 
cancer (PC) screening, after they took the Prostate Cancer and Screening Knowledge 
Test (PC-S-KT-39), then the higher their Prostate Cancer and Screening Knowledge Test 
(PC-S-KT-39) Score (r=.226, p=.002; < Bonferroni Adjustment Significance of .004), 
and the higher the amount of change in Prostate Cancer Self-Efficacy (confidence to talk 
to a medical provider about prostate cancer and screening) from pre-knowledge test to 
post-knowledge test (r=.145, p=.000; < Bonferroni Adjustment Significance of .004); and 
2-the higher self-rating for Self-Efficacy to Talk to a Medical Provider about 
Vitamin D screening and supplementation, then the higher their Prostate Cancer and 
Screening Knowledge Test (PC-S-KT-39) Score (r=.290, p=.000; < Bonferroni 







self-efficacy (confidence to talk to a medical provider about prostate cancer and 
screening) from pre-knowledge test to post-knowledge test (r=.234, p=.001; < Bonferroni 
Adjustment Significance of .004), and the higher the amount of change in Vitamin D 
Self-Efficacy from pre-knowledge test to post-knowledge test (r=.286, p=.000;  
< Bonferroni Adjustment Significance of .004). 
Backward stepwise regression identified the significant predictors of study 
outcome variable #1—a higher self-rating for Self-Efficacy to Talk to a Medical 
Provider about prostate cancer and prostate cancer (PC) screening, after they took 
the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) were: having had a 
history of screening with a Digital Rectal Exam (DRE) (b=.435, SEB=-.225, p=.003), a 
higher rating of quality of care (b=-.160, SEB=-.152, p=.041), and a greater Amount of 
Change in Prostate Cancer Knowledge from Pre-Knowledge Test to Post-Knowledge 
Test (b=.116, SEB=.181, p=.016). For this model, the R 2=.095, and the Adj R 2=.079, 
meaning 7.9% of the variance was explained by this model. 
Finally, a second backward stepwise regression identified the significant 
predictors of study outcome variable #2—a higher self-rating for Self-Efficacy to Talk 
to a Medical Provider about Vitamin D (VD) screening and supplementation, after 
they took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-39) were: 
having a history of being told one had a low Vitamin D level (b=.418, SEB=-.159, 
p=.038), and a greater amount of change in Vitamin D Knowledge from Pre-Knowledge 
Test to Post-Knowledge Test (b=.140, SEB=.231, p=.003). For this model, the R 2=.065, 








Discussion of Study Results 
Discussion of Demographics 
This study had a global sample, if not a sample of men born in Ghana (77.3%, 
n=194) who are now dispersed across the globe. In contrast, within an intervention study 
using an e-health video on prostate cancer designed to increase awareness and screening 
by African American men, 80% were U.S.-born (Hall, 2018). Thus, most study findings 
are best compared to Hall (2018), who used many of the same measures as used in the 
present study, but with a smaller sample (N=41)—yet, also within an online intervention 
study. For Hall (2018), it was an online e-health video intervention on prostate cancer and 
screening.  
In this study, the mean annual income was 4.21. for category 4 of $40,000-
$49,999 (min=1, max=9, SD=1.64), whereas in Hall (2018) it was much higher 
(M=$118,048.45, Median=$74,999.50, SD=$152,626.25). Also, regarding education, in 
Hall (2018), 75.6% (n=31) had a Bachelor’s Degree to a Doctoral Degree, whereas in this 
study, 43.1% (n=85) had a Bachelor’s Degree to a Doctoral Degree. Thus, this study’s 
sample both had a lower mean income and lower involvement in higher education. Also, 
in Hall (2018), 65.8% (n=27) were employed, while a larger percentage was employed in 
the present study (n=188, 96.9%). These differences may reflect the current sample, 
including many immigrants such as those born in Ghana (n=150, 77.3%) and those living 








Discussion of Health Status 
Using the same scale, Hall (2018) found overall mean health status was 4.71 
(SD=.84) closest to very good. Similarly, this study found a mean health status was 4.56 
(Min=1-very poor, Max=6-excellent, SD=.869), or between good and very good. In this 
study, the mean for Body Mass Index (BMI) was 23.31 for normal weight (Min=5.94- 
underweight, Max=44.71, SD=7.51), while Hall (2018) reported a higher mean BMI of 
28.45 (SD=4.72). For this study, the mean self-rated weight status score was 2.20 for 
normal weight status (Min=1-underweight, Max=4-obese, SD=.450), whereas in Hall 
(2018), it was higher with a mean of 2.46 (SD=60). For the quality of medical care they 
receive, this sample’s mean score was 4.41, SD=.857, Min=2, Max=6) for good, while 
Hall (2018) reported a higher mean of 4.78 (SD=.83).  
Discussion of Knowledge Test 
First, as a measure of men’s level of knowledge for prostate cancer and screening, 
and for Vitamin D and taking a Vitamin D supplement, the mean for PC knowledge score 
was 25.84 (Min=0, Max=37, SD=9.50), or moderately high. Comparable here is a study 
by Aiyedun (2014), in which both an HIV window period knowledge test and an e-health 
video served as a brief online intervention; first, for Aiyedun (2014), the mean of 34.496 
suggested a moderate level of knowledge of the HIV window period. Second, as an 
innovation for preparing Black men to engage in discussions with their medical providers 
about screening for prostate cancer and their levels of Vitamin D using the knowledge 
test (PC-S-KT-39), 90.2% (n=175) indicated “yes” they would recommend the PC-S-KT-








Similarly, in Aiyedun (2014), the vast majority (89.6%, n=103) of the men indicated that 
they would recommend the avatar video. 
Discussion of Improvements From Pre- to Post-Intervention 
This study’s data supported viewing taking the PC-S-KT-39 as a brief 
intervention, as four paired t-tests indicated a significant increase from pre-knowledge 
test to post-knowledge test (p<.000; Bonferroni Adjustment Significance, .05/4, p=.013) 
for 1-knowledge of prostate cancer and screening (t=-8.475, df=193, p=.000), 2-self-
efficacy for talking to doctor about prostate cancer and screening (t=-9.098, df=193, 
p=.000), 3-knowledge of Vitamin D screening and supplementation (t=-9.748, df=193, 
p=.000), and 4-self-efficacy for talking about Vitamin D screening and supplementation 
(t=-9.384, df=193, p=.000). Aiyedun (2014) similarly found significant increases from 
pre- to post-intervention for stages of change for screening for HIV (p=.001), self-
efficacy for screening for HIV (p=.000), stages of change for screening for HIV after an 
episode of unprotected sex (p=.000), and self-efficacy for screening for HIV after an 
episode of unprotected sex.  
Of note, in Aiyedun (2014), it was difficult to discern impacts from the 
knowledge test alone or from watching the e-health video—whereas, by solely 
functioning on the impact of a knowledge test alone, this study adds something new. This 
study’s online knowledge test emerges as a brief online intervention, suggesting the 
power in disseminating online such learning devices as a 39-item knowledge test, i.e., the 
PC-S-KT-39. 
Hence, at the conclusion of the study, there is support for widely disseminating 







(PC-S-KT-39), in order to potentially replicate the promise that Baptista et al. (2018) 
found in Web-based decision aids. More specifically, Baptista et al. found that Internet- 
or Web-based decision aids have great value; they can “increase patient knowledge, make 
people feel clearer about their values, reduce decisional conflict, and promote an active 
patient role in decision making” about prostate cancer screening and treatment (p. 5). 
This study’s new PC-S-KT-39 may similarly be viewed as having great value.  
Relationships Among Study Variables 
Independent t-tests comparing groups on outcome variable #1 showed only one 
comparison was significant, as follows: Those who responded “yes” that they had prior 
prostate cancer screening with a Digital Rectal Exam (DRE) had a mean self-efficacy for 
talking to their provider about prostate cancer and screening (mean=5.43, SD=.790) that 
was significantly higher than the mean self-efficacy of those who never had a DRE 
(t=12.782, df=192, p=.003; < Bonferroni Adjustment Significance (0.05/10, p=0.005). As 
per the work of Reynolds (2008), this underscores the importance of DRE for men at risk 
of prostate cancer, as it presents an opportunity, potentially, for discussion with one’s 
medical provider—which may serve to increase self-efficacy for engaging in such 
discussions over time.  
Pearson correlations showed in this study that a higher self-rating for Self-
Efficacy to Talk to a Medical Provider about prostate cancer and prostate cancer 
screening, after they took the Prostate Cancer and Screening Knowledge Test (PC-S-KT-
39) was associated with a higher mean score on the PC-S-KT-39, and a greater amount of 
change in Prostate Cancer Self-Efficacy (confidence to talk to a medical provider about 







p=.000; < Bonferroni Adjustment Significance of .004). Also, a higher self-rating for 
Self-Efficacy to Talk to a Medical Provider about Vitamin D (VD) screening and 
supplementation, after they took the Prostate Cancer and Screening Knowledge Test  
(PC-S-KT-39), was also associated with a higher mean score on the PC-S-KT-39, a 
greater amount of change in prostate cancer self-efficacy (confidence to talk to a medical 
provider about prostate cancer and screening) from pre-knowledge test to post-knowledge 
test (r=.234, p=.001; < Bonferroni Adjustment Significance of .004), and a greater 
amount of change in Vitamin D Self-Efficacy from pre-knowledge test to post-
knowledge test (r=.286, p=.000; < Bonferroni Adjustment Significance of .004). A 
pattern emerges of higher knowledge on the PC-S-KT-39 being associated with a higher 
self-efficacy for talking to one’s medical provider. 
Backward stepwise regression identified the significant predictors of study 
outcome variable #1—a higher self-rating for Self-Efficacy to Talk to a Medical Provider 
about prostate cancer and prostate cancer screening, after they took the Prostate Cancer 
and Screening Knowledge Test (PC-S-KT-39) were: having had a history of screening 
with a Digital Rectal Exam (DRE), a higher rating of quality of care, and a greater 
Amount of Change in Prostate Cancer Knowledge from Pre-Knowledge Test to Post-
Knowledge Test, with 7.9% of the variance explained by this model. Second, backward 
stepwise regression identified the significant predictors of study outcome variable #2—a 
higher self-rating for Self-Efficacy to Talk to a Medical Provider about Vitamin D (VD) 
screening and supplementation, after they took the Prostate Cancer and Screening 
Knowledge Test (PC-S-KT-39) were: having a history of being told one had a low 







Knowledge Test to Post-Knowledge Test, with 5.3% of the variance explained by this 
model. Given the low amount of variance accounted for in each model, both sets of 
finding suggest that future research needs to add variables, perhaps, such as stress. For 
example, the Perceived Stress Scale is a global measure for potential use with a global 
sample (Cohen, Kamarck, & Mermelstein, 1983).  
Meanwhile, the overall body of findings suggests that such future global research 
is warranted.  
Implications and Recommendations 
The first implication of the study is that there is great value in contemporary times 
for using an online social media campaign, including the posting and distribution of 
flyers in community venues (e.g., barber shops, churches) in order to gather a global 
sample of convenience that reflects the use of snowballing. As a Ghanaian Principal 
Investigator living the United States, the study methods produced a global sample, if not 
a sample of men born in Ghana (77.3%, n=194) who are now dispersed across the globe, 
including two-thirds (77.3%) who were born in Ghana, while 78.4% (n=152) were 
currently living in the United States and another 15.5% (n=30) were currently living in 
Ghana, followed by another 5.1 (n=10) currently living in other countries.  
This methodology allows international researchers to engage in the kind of 
meaningful research that captures both what is happening “back home” as well as those 
from “back home” who are now dispersed across the globe, including living in the United 







value such an approach. Future research can replicate this methodology, whether 
studying prostate cancer or Vitamin D screening, or any other health behavior. 
A second implication of the study involves the value in designing online research 
studies that use the smart phone for data collection. The present research study 
demonstrates the power in using the smart phone in global research, as well as other 
computers participants might have for taking online surveys. Of note, no data were 
collected on whether participants used a laptop, desktop, or smart phone computer for 
gaining internet access. However, anecdotal evidence the Principal Investigator collected 
indicated that smart phone use was extremely high for completing the survey. 
Focusing on the use of the smart phone in future global research may overcome 
some aspects of the digital divide that have been documented in prior research, as this 
negatively impacts Blacks, for example (Mossey, Bromberg, & Manoharan, 2019). 
Support for the pursuit of such future research is found in the work of Mossey et al. 
(2019), who emphasized the importance of harnessing the power of smart phones as 
mobile technology for bridging the digital divide. 
As mentioned earlier, in light of the low amount of variance accounted for in the 
backward stepwise regression models, the findings suggest that future research needs to 
add variables, perhaps, such as stress. For example, the Perceived Stress Scale is a global 
measure for potential use with a global sample (Cohen et al., 1983).  
Finally, future research can use this study’s innovation of the Prostate Cancer and 
Screening Knowledge Test (PC-S-KT-39) potentially as a measure of knowledge in 
future research, or the prostate cancer items could be extracted in future investigations. 







brief intervention with varied samples of Black men around the globe, including African 
Americans and Black immigrants in the United States. 
With regard to health educators, there may also be an evaluation of using the  
PC-S-KT-39 as a tool in practice, such as for in-person use by health educators in 
working with clients. The tool might be used as a memory prompt for health educators 
and other health professionals when providing education to Black men about prostate 
cancer and screening as well as Vitamin D screening. This follows from the work of 
others who found the use of such a memory prompt was effective in significantly 
impacting patient behavior (Stanek, Renslow, & Kalliainen, 2015).   
Limitations of the Study 
Several study limitations must be kept in mind when interpreting the results of 
this study. First, the use of the smart phone for completing the online survey resulted in 
being cut off from the survey when their phones rang, and was a study limitation. Sample 
size may have been much larger if not for this issue.  
Other study limitations included the following: being an online study which 
requires access to the Internet and a computer, potentially creating a sample biased 
toward those who enjoy such access; the use of an online sample of convenience of 
volunteers who were able to devote the requisite time to complete the survey, including 
the use of snowballing; the lack of a measure of social desirability, which could have 
permitted controlling for socially desirable answers in the regression analysis, but would 
have added to the limitation of the burden of time to participate in the study; the fact that 







items, with a potential burden of time, given the length of this key test. To reduce the 
burden of time, the new PC-S-KT-39 was reduced from 50 items to 39 items, after the 
first pilot indicated it took 30 minutes to complete the entire survey; other parts of the 
survey were also reduced by 1-3 items, where possible (e.g., eliminating questions about 
the prevalence of prostate cancer among friends and associates). The result of the attempt 
to reduce the burden of time on study participants was a survey that took about 20-30 
minutes to complete.  
Also, another study limitation involved the use of a study methodology where the 
study men were asked at the same time (i.e., after taking the new PC-S-KT-39 to rate 
both their before taking the PC-S-KT-39 and their after taking the PC-S-KT-39 levels of 
knowledge on prostate cancer and screening, and on Vitamin D screening and 
supplementation) and self-efficacy (for talking to a medical provider about prostate 
cancer and screening, and about Vitamin D screening and supplementation).  
An alternative methodology that might be perceived as more desirable would be 
to assess knowledge and self-efficacy before taking the PC-S-KT-39, then again after 
taking the PC-S-KT-39; however, the method chosen was also deemed a way to shorten 
the length of the survey and reduce the burden of time on subjects. Moreover, after 
reading 39 true facts within the PC-S-KT-39, it was likely that the men could more 
accurately rate both their before taking the PC-S-KT-39 and their after taking the  
PC-S-KT-39 levels of knowledge (on prostate cancer and screening, and on Vitamin D 
screening and supplementation) and self-efficacy (for talking to a medical provider about 
prostate cancer and screening, and about Vitamin D screening and supplementation). 








Given a global online sample of Black men (n=194) who responded to a social 
media campaign and completed the study, the convenience sample of Black males 
(N=194) was mostly married (75.85, N=147) and had a mean age of 49.53 years (min 40, 
max 76, SD=8.73). The Black men were well educated with 24.7% (n=48) having an 
Associate Degree, 20.6% (n=40) having a Bachelor’s Degree, 18% (n=35) having 
Master’s Degree, and 5.2% (n=10) having a Doctoral Degree. The mean annual income 
was 4.21. for category 4 of $40,000-$49,999 (min 1, max 9, SD=1.64). Most of the 
participants were employed (n=188, 96.9%) and born in the United States (n=152, 
78.4%).  
As a reflection of being a global sample, if not a sample of men born in Ghana 
(77.3%, n=194) who are now dispersed across the globe, over two-thirds (77.3%) were 
born in Ghana, while 78.4% (n=152) were currently living in the United States and 
15.5% (n=30) were currently living in Ghana, followed by another 5.1 (n=10) currently 
living in other countries.  
Key findings showed that, as a brief intervention of taking the PC-S-KT-39, as 
per results of four paired t-tests (Bonferroni Adjustment Significance, .05/4, p=.013), this 
was associated with a significant increase from pre-knowledge test to post-knowledge 
test (p<.000; Bonferroni Adjustment Significance, .05/4, p=.013) for (a) knowledge of 
prostate cancer and screening (t=-8.475, df=193, p=.000), (b) self-efficacy for talking to 
doctor about prostate cancer and screening (t=-9.098, df=193, p=.000), (c) knowledge of 







efficacy for talking about Vitamin D screening and supplementation (t=-9.384, df=193, 
p=.000). 
The study demonstrated how there is great value in contemporary times in  
(a) using an online social media campaign, including the posting and distribution of flyers 
in community venues (e.g., barber shops, churches), in order to gather a global sample of 
convenience that reflects the use of snowballing; and (b) including the use of smart 
phones to conduct global online research.  
In addition to the pursuit of future research using the PC-S-KT-39 and smart 
phone mobile technology, what is justified is wide dissemination via the Internet of a link 
to the new Prostate Cancer and Screening Knowledge Test (PC-S-KT-39). If men such as 
those in the present study decide to disseminate this link, the impact has the potential to 
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Recruiting Email Message 
INVITING ALL BLACK MEN AGE 40 OR ABOVE 
 ******TO TAKE A CONFIDENTIAL SURVEY********  
 
IRB Protocol Number 19-134 
 
The Research Group on Disparities in Health within the Department of Health 
and Behavior Studies at Teachers College, Columbia University, in New York, 
New York is conducting an online study to learn what Black men know about 
prostate cancer, screening for prostate cancer, and the importance of talking 
to their medical provider about screening. We also want to know if men have 
been screened by their medical providers for prostate cancer, as well as for 
their Vitamin D level. In addition, we are also asking study participants to help 
us evaluate a new online tool we designed to increase men’s knowledge on the 
topic of screening for prostate cancer and Vitamin D level.  
 
 Participation in this study is limited to the first 250 BLACK MEN AGE 40 OR 
OVER who are able to read and understand English on a 12th grade level who 
volunteer 
 Completing the online survey takes about 20 minutes 
 Those who complete the survey will have a 3 in 250 chance of winning 1 of 3 
$100 bar-coded Amazon gift certificates  
 Please click on the link below so you can view the informed consent, learn about 
your rights as a participant and proceed to the survey 
 We also invite you to forward this email to other BLACK MEN—or text message, 
or tweet the message, below: 
 
GO TO https://tinyurl.com/Survey-For-BLACK-MEN-Age 40+ & take 
survey on screening for Prostate Cancer & Vitamin D level for chance to win 
1 of 3 $100 Amazon gift cards 
 
THANK YOU FOR YOUR PARTICIPATION! HAVE QUESTIONS?  
If you have any questions or would like to have additional information about the study, 
please contact:       
Peter Afram, MS, Doctoral Candidate, Department of Health and Behavior Studies, Teachers 
College, Columbia University, Box 114, 525 W. 120th Street, New York, NY 10027; 
psa2116@tc.columbia.edu - OR –  
Barbara C. Wallace, Ph.D., Director, Research Group on Disparities in Health, Professor of 
Health Education, Clinical Psychologist, Department of Health and Behavior Studies, 
Teachers College, Columbia University, Box 114, 525 W. 120th Street, New York, NY 









Recruiting Text Message 
 
GO TO https://tinyurl.com/Survey-For-BLACK-MEN-Age 40+ & 
take survey on screening for Prostate Cancer & Vitamin D level for 
chance to win 1 of 3 $100 Amazon gift cards 
 
 
Click https://tinyurl.com/Survey-For-BLACK-MEN-Age 40+ & 
take survey on screening for Prostate Cancer & Vitamin D level for 











INVITING ALL BLACK MEN AGE 40 OR ABOVE 
 ******TO TAKE A CONFIDENTIAL SURVEY********  
 
 IRB Protocol Number 19-134 
 
The Research Group on Disparities in Health within the Department of 
Health and Behavior Studies at Teachers College, Columbia University, 
in New York, New York is conducting an online study to learn what Black 
men know about prostate cancer, screening for prostate cancer, and the 
importance of talking to their medical provider about screening. We also 
want to know if men have been screened by their medical providers for 
prostate cancer, as well as for their Vitamin D level. In addition, we are 
also asking study participants to help us evaluate a new online tool we 
designed to increase men’s knowledge on the topic of screening for 
prostate cancer and Vitamin D level.  
 
 Participation in this study is limited to the first 250 BLACK MEN 
AGE 40 OR OVER who are able to read and understand English on a 
12th grade level who volunteer 
 Completing the online survey takes about 20 minutes 
 Those who complete the survey will have a 3 in 250 chance of winning 
1 of 3 $100 bar-coded Amazon gift certificates 
 Please click on the link below, or tear-off a tab below and use the link, 
so you can view the informed consent, learn about your rights as a 
participant and proceed to the survey 
 We also invite you to text message, or tweet other Black men, as follows: 
 
GO TO https://tinyurl.com/Survey-For-BLACK-MEN-Age 40+ & take survey 
on screening for Prostate Cancer & Vitamin D level for chance to win 1 of 3 
$100 Amazon gift cards 
 
THANK YOU FOR YOUR PARTICIPATION! HAVE QUESTIONS?  
If you have any questions or would like to have additional information about the study, please contact:       
Peter	Afram, MS, Doctoral Candidate, Department of Health and Behavior Studies, Teachers College, Columbia University, Box 114, 
525 W. 120th Street, New York, NY 10027; psa2116@tc.columbia.edu	- OR –  
Barbara C. Wallace, Ph.D., Director, Research Group on Disparities in Health, Professor of Health Education, Clinical Psychologist, 
Department of Health and Behavior Studies, Teachers College, Columbia University, Box 114, 525 W. 120th Street, New York, NY 
10027; bcw3@tc.columbia.edu; Study Contact Number:  267-269-7411 
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IRB Protocol Number 19-134 
 
 
Protocol Title: Black Men’s Knowledge of Prostate Cancer and Screening—And 
Vitamin D Screening and Supplementation: Predictors of High Self-Efficacy to Talk to 
Medical Providers About Screening 
 




INTRODUCTION.  You are being invited to participate in this research study called 
“Black Men’s Knowledge of Prostate Cancer and Screening—And Vitamin D Screening 
and Supplementation: Predictors of High Self-Efficacy to Talk to Medical Providers 
About Screening.” You may qualify to take part in this research study if you: are a Black 
man age 40 or older. Approximately 250 people will participate in this study, and it will 
take approximately 20 minutes of your time to complete. 
 
WHY IS THIS STUDY BEING DONE?  This study is being done to to learn what 
Black men know about prostate cancer, screening for prostate cancer, and the importance 
of talking to their medical provider about screening. We also want to know if men have 
been screened by their medical providers for prostate cancer, as well as for their Vitamin 
D level. In addition, we are also asking study participants to help us evaluate a new tool 
we designed to increase men’s knowledge on the topic of screening for prostate cancer 
and Vitamin D level.  
 
WHAT WILL I BE ASKED TO DO IF I AGREE TO TAKE PART IN THIS 
STUDY?  If you decide to participate in the study, you will answer a series of questions 
for an online survey on the following topics: your personal background (age, education, 
etc.); ratings of your health status and medical care; if you or your family members have 
ever been diagnosed with prostate cancer; your history of screening for prostate cancer 
and your Vitamin D level; and, what you know about prostate cancer, prostate cancer 








WHAT POSSIBLE RISKS OR DISCOMFORTS CAN I EXPECT FROM TAKING 
PART IN THIS STUDY?   This is a minimal risk study, which means the harms or 
discomforts that you may experience are not greater than those you would ordinarily 
encounter if you were completing a test or paperwork in a school, college, or work 
setting. However, a participant may find questions about prostate cancer or about 
knowing anyone who died from prostate cancer to be uncomfortable, or stressful. Or, you 
may find the time it takes to answer questions to be a burden. You do not have to answer 
any questions or share anything you do not want to share. Participation in this study is 
completely voluntary. You can discontinue participation in this study at any time. Simply 
exit the study and delete the link to the study.  
 
WHAT POSSIBLE BENEFITS CAN I EXPECT FROM TAKING PART IN THIS 
STUDY?  There is no direct benefit to you for participating in this study.  
 
WILL I BE PAID FOR BEING IN THIS STUDY?  You will not be paid to 
participate. However, when you complete the survey you will be invited to enter your 
email address and to hit a “submit” button—so that you are officially entered into a 
drawing for a chance to receive a prize (i.e., there will be 3 bar coded Amazon gift 
certificates for $100 each). You do not have to enter the lottery drawing to complete the 
survey. Once you submit your email address, then it will automatically be entered into a 
private and secure data base that even the principal investigator cannot access. Once 250 
people have completed the entire survey, you will have a 3 in 250 chance of winning one 
of the 3 bar coded Amazon gift certificates for $100 each. The www.Amazon.com gift 
certificates will be sent to three randomly chosen e-mail accounts using a secure online 
program. This occurs without in any way linking your identity to the survey results. The 
principal investigator is not able to view any of the e-mail addresses to which the gift 
certificates are sent. Only the 3 winners will be contacted. 
 
WHEN IS THE STUDY OVER? CAN I LEAVE THE STUDY BEFORE IT ENDS?  
The study is over when you have completed the online survey. However, you can 
discontinue answering the survey questions at any time. You can exit the study at any 
time and delete the link to the study.  
 
PROTECTION OF YOUR CONFIDENTIALITY The study does not involve 
collecting any of your personal identifying information, such as your name or address, 
allowing you to remain anonymous. Teachers College, Columbia University has 
determined that www.Qualtrics.com provides a secure platform for the online survey you 
will take. The survey data files will also be saved on the primary researcher’s password 
protected computer. Regulations require that research data be kept for at least three years. 
 
For quality assurance, the study team, and/or members of the Teachers College 
Institutional Review Board (IRB) may review the data collected from you as part of this 
study. Otherwise, all information obtained from your participation in this study will be 
held strictly confidential and will be disclosed only with your permission or as required 








HOW WILL THE RESULTS BE USED?  The results of this study will be published in 
journals and presented at academic conferences. This study is being conducted as part of 
the doctoral dissertation of the principal investigator.  
 
WHO CAN ANSWER MY QUESTIONS ABOUT THIS STUDY? 
If you have any questions about taking part in this research study, you should contact the 
principal investigator, Peter S. Afram, MS, at psa2116@tc.columbia.edu or at 347-525-
4241. You can also contact the sponsor/ supervisor of this research study, Dr. Barbara 
Wallace, at bcw3@tc.columbia.edu or 267-269-7411. 
 
If you have questions or concerns about your rights as a research subject, you 
should contact the Institutional Review Board (IRB) (the human research ethics 
committee) at 212-678-4105 or email IRB@tc.edu. Or you can write to the IRB at 
Teachers College, Columbia University, 525 W. 120th Street, New York, NY 10027.  
Box 151. The IRB is the committee that oversees human research protection for 
Teachers College, Columbia University.  
 
PARTICIPANT’S RIGHTS 
• I have read the Informed Consent Form and have been offered the opportunity 
to discuss the form with the researcher.  
• I have had ample opportunity to ask questions about the purposes, procedures, 
risks and benefits regarding this research study.  
• I understand that my participation is voluntary. I may refuse to participate or 
withdraw participation at any time without penalty.  
• The researcher may withdraw me from the research at his or her professional 
discretion.  I understand that if I take the survey more than once I will be 
eliminated from the study.    
• If, during the course of the study, significant new information that has been 
developed becomes available which may relate to my willingness to continue 
my participation, the researcher will provide this information to me.  
• Any information derived from the research study that personally identifies me 
will not be voluntarily released or disclosed without my separate consent, 
except as specifically required by law.  
• I should receive a copy of the Informed Consent Form document. (I 
understand that I can download it.) 
 
By checking the box below, I agree to participate in the study and I am confirming 
that I am a Black man age 40 or above, and I am able to read and understand 
English on a high school level,  
 

















Teachers College, Columbia University 




1) Are you a Black man who is age 40 or older? 
Yes ___ No___ 
 
2) Are you able to read and understand English on a high school level? 
Yes ___ No___ 
 
3) Are you able to spend about 20 minutes answering a survey—for a chance to win one 














THE PROSTATE CANCER & SCREENING – & 
VITAMIN D STUDY FOR BLACK MEN AGE 40 + 
 
STUDY SURVEY 
Teachers College, Columbia University 
Institutional Review Board (IRB) Protocol # 19-134 
 
 
Instructions:  Please answer the following questions in each section by clicking the box 
next to the item of your choice,  or typing your answer in the blank box. 
 
------------------------------------------------------------------------------------------------ 
PART I: BASIC DEMOGRAPHICS (BD-10) 
1)   I am:         A.  Female        B.   Male       
2)  My age is:  _________ (USE DROP DOWN MENU OF AGES 18-85) 
3)  I am currently:  A.  Married    B.   Divorced   C.   Separated    
 D.  Widowed         E.   Never Married    F.  In Domestic Partnership           
 G.   Living with Significant Other H. In a Committed Relationship 
I. Currently Dating  Other ___________________ 
 
4) My race/ethnicity is as follows: (Please mark all that apply) 
Black (African American, of other African Descent) 
Hispanic / Latino (including Puerto Rican, Mexican, Mexican American, Chicano, 
Cuban, other Spanish) 
Asian (Asian Indian, Chinese, Filipino, Japanese, Korean, Vietnamese, or other Asian)  
White / Caucasian / European American 
Native American/American Indian / Alaska Native 
Native Hawaiian / Pacific Islander 
Arab American / Middle Eastern 
Other group(s) (specify)  
 
5) My skin color is 
a. ___Very Dark                 b. ___Dark            c. ____Medium to Dark 
d. ___Medium to Light      e. ___Light           f. ____Very Light            g.___ White 
  
6)  Please indicate the country that you live in NOW: 
[DROP DOWN MENU WITH COUNTRIES] 
 
7) Please indicate the country of your birth: 








8) My yearly household income is: 
__Less than $10,000 
__$10,000 to $19,000  
__$20,000 to $39,000 
__$40,000 to $49,000 
__$50,000 to $99,999 
__$100,000 to $199,999 
__$200,000 to $299,000 
__$300,000 to $399,000 
__$400,000 or More 
__I do not know 
__Other – indicate the your annual household income in your country’s money______ 
 
9) My highest education level is: 
                   1-Grade School (please indicate your grade completed) _____________ 
                   2-High School 
                   3-Associate Degree or Certificate Program 
                   4-Bachelor’s Degree  
                   5-Master’s Degree  
                   6-Doctoral Degree 
                   Other Degree (please explain) ______________________________ 
 
10) I am currently (check all that apply) 
__ part-time undergraduate student 
__ full-time undergraduate student 
__part-time graduate student 
__full-time graduate student 
__unemployed  
__on Welfare/government assistance 
__Employed Part-time 
__Employed Full-time 
____receiving Social Security Income 
____receiving Social Security Disability Income 
__Other (please explain________________________) 
------------------------------------------------------------------------------------------------ 
PART II: BRIEF HEALTH SURVEY (BHS-5) 
1). I rate my overall health status as 
a.___Excellent         b.___Very Good        c.__Good         d.__Fair          
e.__Poor        f.__Very Poor 
 
2).  My height is _________ feet _______ inches 
 









4). I consider myself to be 
 
a). ___underweight b)___normal weight     c)___overweight         d)____obese     
 
5) I rate the overall quality of care I receive for my health (and any medical 
condition I have) as 
a.___Excellent         b.___Very Good        c.__Good         d.__Fair         




PART III: PROSTATE CANCER SCALE (PCS-6) 
1-Have you ever been told by a doctor or medical professional that you have prostate 
cancer? 
__No     __Yes    __Unsure 
 
2-Have you ever been told by a doctor or medical professional that you are at risk for 
prostate cancer? 
__No     __Yes    __Unsure 
 
3-Have you ever had a doctor or medical professional perform a digital rectal 
examination (DRE) on you (i.e. placing their gloved finger in your anus/rectum)? 
__No     __Yes    __Unsure 
 
4-Have you ever been told by a doctor or medical professional that you were going to 
have your PSA measured, or that you were being given a screening test for prostate 
cancer? 
 
__No     __Yes    __Unsure 
 
5-Do you know someone in YOUR FAMILY who has been diagnosed with prostate 
cancer? 
__No     __Yes    __Unsure 
If “Yes”  Please indicate the number of people you know who have been diagnosed 
with prostate cancer: 
____0 ____1     ___2   ____3   ____4   ____5  ____6  ____7  ____8 ____9 ___10 
 
6-Do you know someone in YOUR FAMILY who DIED from prostate cancer? 
__No     __Yes    __Unsure 
If “Yes”  Please indicate the number of people you know who have died from prostate 
cancer: 










PART IV: VITAMIN D SCALE (VDS-4) 
1-Have you ever had a doctor or medical professional measure your level of Vitamin D 
by laboratory testing? 
__No     __Yes    __Unsure 
 
2-Have you ever been told by a doctor or medical professional that your level of Vitamin 
D was too low? 
__No     __Yes    __Unsure 
 
3-Have you ever been advised by a doctor or medical professional to take a daily Vitamin 
D supplement? 
__No     __Yes    __Unsure 
 
4-Have you ever taken a Vitamin D supplement? 
__No     __Yes    __Unsure 
 
------------------------------------------------------------------------------------------------ 
PART V: PROSTATE CANCER AND SCREENING KNOWLEDGE 
TEST (PC-S-KT-39) 
This section asks you questions about prostate cancer and screening tests your medical 
provider should perform. Please answer True, False, or you are Unsure.  
 
Please be honest. Your answers are confidential and you are not being judged. What is 
important is that you read every question and provide an answer to every question.  
 
1-Black men around the world have the highest rates of prostate cancer, and Black 
men in America, have the highest death rates from prostate cancer in the entire world  
__True   __False __Unsure 
 
2-Black men are more likely to be diagnosed with a late stage of prostate cancer (cancer 
is caught late and more advanced)—while White men are more likely to be diagnosed 
with an early stage (caught early and less advanced) 
__True   __False __Unsure 
 
3-Because the prostate cancer of Black men is caught (diagnosed) much later than it is 
in White/Caucasian men, Black American men are more likely to die from their prostate 
cancer  
__True   __False __Unsure 
 
4-Screening for prostate cancer is important so it can be detected (caught, diagnosed) and 
treated as early as possible—and, this decreases the chances of death  








5-Some experts recommend that the medical provider and the patient discuss screening 
for prostate cancer, together, so that a good decision is made about screening; and, the 
decision to screen is not left up to the individual patient 
__True   __False __Unsure 
 
6-Some experts think Black men need to be better informed, so they can actively 
participate in a decision about screening with their doctor, and decide what is best for 
them 
__True   __False __Unsure 
 
7-The American Cancer Society recommends that all men undergo a screening for 
prostate cancer every year—for example, as part of their annual physical examination—
but only after a medical provider has explained the risks and benefits of prostate cancer 
screening  
__True   __False __Unsure 
 
8-A benefit of prostate cancer screening is that the cancer could be found and prostate 
treatment could be started 
__True   __False __Unsure 
 
9-A benefit of prostate cancer treatment is that it can prevent death from prostate cancer 
__True   __False __Unsure 
 
10-A benefit of some prostate cancer treatments is that the cancer will not spread 
(metastasize) to the bones, lungs, brain, or other parts of the body 
__True   __False __Unsure 
 
11-A risk of some prostate cancer treatments is impotence—meaning a man can no 
longer have or keep an erection, or his penis will not stay hard or firm enough to have sex 
__True   __False __Unsure 
 
12-Another risk of some prostate cancer treatments is incontinence—meaning a man can 
no longer control when he has a bowel movement or urinates, or urine may leak out of his 
penis 
__True   __False __Unsure 
 
13-Some researchers think Black men with prostate cancer are less likely to receive 
cancer treatment where the intention is to cure them—while White men are more likely 
to receive treatment where the intention is to cure them 
__True   __False __Unsure 
 
14-African American men have a significantly higher risk of dying from prostate 
cancer than White men—because Black men are less likely to receive cancer treatment 
where the intention is to cure them 








15-Prostate cancer treatments where the intent is to cure the man of prostate cancer are 
called radical treatments—for example, a radical prostatectomy (surgery that removes the 
prostate gland and surrounding tissue) 
__True   __False __Unsure 
  
16-“Watchful waiting” is an example of what is not a cancer treatment where the 
intention is to cure the patient of prostate cancer 
__True   __False __Unsure 
 
17-“Watchful waiting” involves just monitoring a man’s prostate cancer, or the medical 
provider just watching what is going on with the prostate cancer—with no therapy being 
given to the man diagnosed with prostate cancer, until there is a complication from the 
cancer 
__True   __False __Unsure 
 
18-Some experts say “watchful waiting” is definitely not the right choice for any patient 
who is under age 65 with a prostate cancer that could be cured with a radical treatment 
(e.g., a radical prostatectomy) 
__True   __False __Unsure 
 
19-Other experts say that radical treatments (e.g. a radical prostatectomy, etc.) are the 
first choice of treatment for all patients under age 70 with localized prostate cancer (it has 
not spread or metastasized)  
__True   __False __Unsure 
 
20-If there is not good control of medical conditions such as diabetes, heart disease, high 
blood pressure, or lung problems, then a radical prostatectomy is not a good choice 
__True   __False __Unsure 
 
21- The Prostate-Specific Antigen (PSA) Test and the Digital Rectal Examination 
(DRE) are two ways to screen for prostate cancer, or to try to detect or catch it 
__True   __False __Unsure 
 
22-The Prostate-Specific Antigen (PSA) Test measures levels of prostate-specific 
antigen, a protein made by cells of the prostate gland. 
 __True   __False __Unsure 
 
23-When a medical provider talks with a patient about testing their PSA, the goal is to 
determine the levels of the Prostate-Specific Antigen (PSA) in the patient’s blood 
__True   __False __Unsure 
 
24-It is normal for men to have low levels of PSA in their blood, and normal for PSA 
levels to increase with age—but, prostate cancer can increase a man’s PSA levels  









25-PSA levels may be higher in men with a common, noncancerous condition called 
benign prostatic hyperplasia (BPH), or with a condition called prostatitis, an 
inflammation of the prostate gland. 
__True   __False __Unsure 
 
26-If a man has a high PSA, or the PSA level is rising over time, then another medical 
procedure may be needed to diagnose prostate cancer 
__True   __False __Unsure 
 
27-A prostate biopsy is a medical procedure where tiny pieces of tissue are removed 
from the prostate and studied in a laboratory in order to diagnose cancer—and only a 
biopsy can determine the presence of cancer 
__True   __False __Unsure 
 
28-A Digital Rectal Examination (DRE) may be performed as part of a man’s regular 
physical examination—and, is another way that a medical provider can determine the 
health of a man’s prostate 
__True   __False __Unsure 
 
29-During the Digital Rectal Examination (DRE), the medical provider inserts a gloved 
finger into the rectum (anus) of the man—allowing the provider to detect an enlarged 
(swollen) prostate any anything else that feels abnormal (hard nodules, bumps) 
__True   __False __Unsure 
 
30-Black men are less likely to have a Digital Rectal Examination (DRE) performed 
by a medical provider, in comparison to White men who receive them more regularly 
__True   __False __Unsure 
 
31-A prostate that feels abnormal during a Digital Rectal Examination (DRE) and a 
high PSA level are both possible indicators of prostate cancer, but only a prostate 
biopsy can diagnose cancer 
__True   __False __Unsure 
 
32- The Digital Rectal Examination (DRE) and the Prostate-Specific Antigen (PSA) Test 
are both screening tests performed during a regular physical exam—while, another 
screening test for your Vitamin D level may also be a part of that exam  
__True   __False __Unsure 
 
33-Some experts recommend that Black men, in particular, need to have their Vitamin D 
level checked as a part of their regular physical exam 
__True   __False __Unsure 
 
34-Some experts say that men with dark skin (e.g. Black men) and those who avoid the 
sun have the greatest need for Vitamin D testing—because they are much more likely to 
have low levels of Vitamin D (because they need more sunlight to get Vitamin D)  








35-Some experts point to research showing a low level of Vitamin D predicts having 
prostate cancer, or having an aggressive form of prostate cancer (spreads fast),  or 
prostate cancer that has spread (metastasized)  
__True   __False __Unsure 
 
36-Black men are more likely to have aggressive prostate cancer (spreads fast)—and, 
research has found a major link between having aggressive prostate cancer and 
having low levels of Vitamin D 
__True   __False __Unsure 
 
37-When the medical provider orders a screening test for the Vitamin D level, and if 
the level of Vitamin D is too low (i.e. Vitamin D deficiency)—then it is important to 
take a Vitamin D pill every day (daily supplement of high quality Vitamin D) 
__True   __False __Unsure 
 
38-Some experts believe that avoiding Vitamin D deficiency (being too low) is a part of 
good health care to prevent having health issues 
__True   __False __Unsure 
 
39-Some experts believe that everyone needs to make sure they get enough Vitamin D, 
and recommend taking 5,000 i.u. of high quality Vitamin D every day 
__True   __False __Unsure 
 
Thank you for completing all these questions.  
------------------------------------------------------------------------------------------------ 
PART VI: DIFFUSION OF THE INNOVATION OF THE PROSTATE 
CANCER KNOWLEDGE TEST (DOI-PCKT-1) 
We created the Prostate Cancer Knowledge Test—with all TRUE answers—as a way to 
prepare Black men to talk with their medical providers about taking important screening 
tests that may help protect them from dying from prostate cancer at a rate higher than for 
any other men in the entire world.  
 
1-Would you recommend the Prostate Cancer Knowledge Test to other Black men? 
(For example, after this study, we will widely circulate on the internet a link to the 
Prostate Cancer Knowledge Test, while promoting it as a new way to educate Black men, 
in particular, so they are better prepared to talk to their medical providers about screening 
tests.) 










PART VII: PRE- AND POST-KNOWLEDGE TEST—RATINGS FOR 
KOWLEDGE AND SELF-EFFICACY TO TALK TO A MEDICAL 
PROVIDER (PRE-A-POST-KT-RF-K-SETMP-8) 
Please answer these 4 questions… 
ABOUT YOU—AND PROSTATE CANCER AND SCREENING 
 
1-BEFORE I answered the above questions, I would rate what I knew about prostate 
cancer and screening for prostate cancer (e.g. Digital Rectal Examination, PSA) as 
follows: 
 
Very Poor Poor Fair Good Very 
Good 
Excellent 
1 2 3 4 5 6 
 
2-AFTER I answered the above questions, I would rate what I knew about prostate 
cancer and screening for prostate cancer (e.g. Digital Rectal Examination, PSA) as 
follows: 
 
Very Poor Poor Fair Good Very 
Good 
Excellent 
1 2 3 4 5 6 
 
3-BEFORE I answered the above questions, I would rate my level of confidence for 
talking to my doctor about prostate cancer and screening for prostate cancer (e.g. 




    Extremely 
confident 
0% 20% 40% 60% 80% 100% 
 
4-AFTER I answered the above questions, I would rate my level of confidence for 
talking to my doctor about prostate cancer and screening for prostate cancer (e.g. 




    Extremely 
confident 









Please answer these 4 questions… 
ABOUT YOU—AND VITAMIN D AND SCREENING 
 
5-BEFORE I answered the above questions, I would rate what I knew about screening 
for Vitamin D level and taking a Vitamin D supplement, as follows: 
 
Very Poor Poor Fair Good Very 
Good 
Excellent 
1 2 3 4 5 6 
 
6-AFTER I answered the above questions, I would rate what I knew about screening 
for Vitamin D level and taking a Vitamin D supplement, as follows: 
 
Very Poor Poor Fair Good Very 
Good 
Excellent 
1 2 3 4 5 6 
 
7-BEFORE I answered the above questions, I would rate my level of confidence for 
talking to my doctor about screening for Vitamin D level and taking a Vitamin D 




    Extremely 
confident 
0% 20% 40% 60% 80% 100% 
 
8-AFTER I answered the above questions, I would rate my level of confidence for 
talking to my doctor about screening for Vitamin D level and taking a Vitamin D 




    Extremely 
confident 












About the Option of Using Change Scores 
 
 
While the evaluation of the online knowledge test as a brief intervention may best 
be evaluated using paired t-tests, there is an alternative way of evaluating improvement 
from pre- to post-intervention. This involves the calculation of four “change scores.” The 
change scores are created by calculating the after scores minus (-) the before scores—
with the change score represented as means. A positive mean suggests improvement from 
before to after; and, a negative mean suggests deterioration or a decrease from before to 
after. The following four change scores may also be calculated: 
1-Change Score for Knowledge About Prostate Cancer and Screening = after 
knowledge about prostate cancer and screening (item # 2) minus (-) before knowledge 
about prostate cancer and screening (item #1) [or, after score # 2 – before score # 1 = 
change score] 
2-Change Score for Knowledge About Vitamin D and Taking Vitamin D 
Supplement = after knowledge about Vitamin D screening and taking a Vitamin D 
supplement (item # 6) minus (-) before knowledge about Vitamin D screening and taking 
a Vitamin D supplement (item #5) [or, after score # 6 – before score # 5 = change score] 
3-Change Score for Self-Efficacy to Talk to a Medical Provider About Prostate 
Cancer and Screening = after confidence to talk to a medical provider about prostate 
cancer and screening (item # 4) minus (-) before confidence to talk to a medical provider 








4-Change Score for Self-Efficacy to Talk to a Medical Provider About Vitamin D 
and Taking Vitamin D Supplement = after confidence to talk to a medical provider 
about Vitamin D screening and taking a Vitamin D supplement (item # 8) minus (-) 
before confidence to talk to a medical provider about Vitamin D screening and taking a 
Vitamin D supplement (item #7) [or, after score # 7 – before score # 8 = change score] 
 
